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Abstract 
HIV-1 infection in paediatric patients is a major public health issue with an estimated 
740 000 children living with HIV-1 globally, and South Africa accounting for almost half 
of these infections. In South Africa, children <3 years of age are initiated on a protease 
inhibitor (PI)-based regimen on diagnosis. For those who fail therapy, there are limited 
second-line treatment options available. While virological failure is often associated with 
HIV-1 drug resistance, a number of studies have shown infrequent selection of protease 
mutations in adults and children. The protease enzyme recognises and cleaves the gag 
substrate at specific sites to release structural components and enzymes essential for viral 
replication. Thus, changes occurring at the gag cleavage sites (CS) represent an alternate 
route of PI resistance. We therefore investigated the genotypic changes in the gag 
substrate in paediatric patients failing PI-based therapy to determine if changes in gag 
could contribute to PI failure. The phenotypic effects of these changes on PI susceptibility 
both in the presence and absence of PI mutations were also examined. In addition, the 
impact of key protease and gag mutations were assessed by site-directed mutagenesis on 
phenotypic resistance. Furthermore, cross-resistance to other PIs were tested to identify 
PIs suitable for subsequent use. 
 
Plasma samples from 20 HIV-1 subtype C-infected children <2 years of age at 
pre-treatment and failing PI-based therapy were genotyped to identify changes in gag and 
protease associated with regimen failure. Fourteen patients received RTV as a single PI 
of which 7 were later switched to LPV/r. Six patients received LPV/r only. Following 
laboratory confirmed virologic failure, genotyping was performed on the first available 
sample (mean time to failure of 285 days). Major PI mutations (M46I, I54V and V82A) 
were found in 8 (40%) patients, all of whom had received RTV as a single PI at some 
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point. Gag CS mutations were observed in 5 of these 8 patients (at codons 374, 378, 428, 
431 and 451). In addition, amino acid changes at gag non-CS were noted, some of which 
were predicted to be under HLA/KIR immune-mediated pressure and/or drug selection 
pressure. These changes in gag following PI therapy failure were further explored by 
phenotypic analysis to assess whether they contributed to resistance. 
 
The gag-protease genes from pre-treatment and post-failure specimens from all 20 
patients were cloned into an HIV-1 expression vector and tested for their PI susceptibility 
using an in vitro single-cycle phenotypic assay. Phenotypic resistance to LPV and RTV 
(up to >100-fold) was seen in 7 of the 8 patients with major PI mutations. Of the 12 
patients with genotypically wild-type protease, 3 showed reduced susceptibility to RTV, 
1 of which also had reduced susceptibility to LPV. These patients had changes in gag CS 
(L449P and P453L) or non-CS (codons 62 and 69 also under positive selection pressure) 
causing up to a 7-fold increase in resistance. Investigation of cross-resistance to other PIs, 
revealed that of the 8 patients with PI major mutations, 6 showed reduced susceptibility to 
atazanavir (ATV), 4 to amprenavir (APV), 1 to darunavir (DRV) and 4 to saquinavir 
(SQV). In addition, 3 patients with genotypically wild-type protease who showed reduced 
susceptibility to ATV (up to 11-fold) and in one case also to DRV (5-fold), had gag CS 
(S373A, L449P and P453L) and/or gag non-CS mutations (T62A and K69R). 
 
To investigate the effects of individual gag and protease mutations on PI 
susceptibility, single and multiple mutants were created in a subtype C reference vector 
by site-directed mutagenesis and tested in the single-cycle phenotypic assay. Analysis of 
single and multiple gag and protease site-directed mutants showed that individual 
changes were not sufficient to cause resistance in this assay system. However, in 
combination with major protease mutations, gag mutations were shown to contribute to 
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PI resistance by reducing susceptibility to PIs by up to 4-fold. This suggests a minimal 
but significant impact and is consistent with findings using clinical samples. 
Overall, these results show that RTV therapy selects for genotypic and phenotypic 
resistance that caused cross-resistance to other PIs. This rarely occurred following LPV/r-
based therapy which is the standard first-line treatment for infants. PI resistance was 
predominantly explained by the presence of major protease mutations. In some patients, 
gag mutations reduced PI susceptibility but their effect was more pronounced when they 
were present in combination with major protease mutations. Thus, incorporating gag in 
drug resistance algorithms could improve interpretation of genotyping data and drug 
resistance prediction. Furthermore, these results support the use of genotypic testing of 
children failing first-line treatment to guide future PI therapy options. However, eight 
children failed PI therapy in the absence of gag and protease mutations, highlighting the 
importance of further investigation into the reasons for paediatric failure, including 
reliable measures of adherence.  
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Chapter 1 
Introduction 
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1.1. The Epidemiology of HIV 
In 1981, acquired immunodeficiency syndrome (AIDS) was first identified in a group of 
homosexual men presenting with symptoms of rare opportunistic infections (Gottlieb et 
al., 1981). The causative agent of AIDS was discovered in 1983 to be the human 
immunodeficiency virus (HIV) (Barre-Sinoussi et al., 1983, Gallo et al., 1984). HIV is a 
member of the family of Retroviruses, in the genus Lentiviruses and was initially known 
as human T-lymphotropic virus type III (HTLV-III) (Sharp, 2011). 
 
There are two types of human immunodeficiency virus (HIV) which cause infection in 
humans i.e. HIV type-1 (HIV-1) and HIV type-2 (HIV-2) (Cohen et al., 2008). HIV-1 is 
believed to have originated from the cross-species transmission of simian 
immunodeficiency virus (SIV) infecting chimpanzees to humans in West-central Africa 
and HIV-2 from a cross-species transmission of the Sooty mangabey virus (Lihana RW, 
2012, Cohen et al., 2008). HIV-1 and HIV-2 differ by up to 40% at the sequence level 
(Cohen et al., 2008). Globally, HIV-1 is more prevalent and is associated with a faster 
progression to immune deficiency (Cohen et al., 2008). Both viruses are transmitted 
through contaminated blood, sexual intercourse and from an infected mother to her baby 
(Cohen et al., 2008). 
 
There was an estimated 35 million individuals living with HIV/AIDS globally by the end 
of 2013 (UNAIDS, 2014). Regionally, Africa accounts for the greatest burden of HIV 
infections (Figure 1.1.), with an estimated 5.6 million infected adults and 360 000 
infected children, in South Africa (UNAIDS, 2013).  
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Figure 1.1. The global prevalence of HIV-1 
An estimated 0.8% of adults aged between 15–49 years worldwide are living with HIV, although 
the burden of the epidemic continues to vary considerably between countries and regions. South 
Africa remains most severely affected with a prevalence of 17.9%. Picture taken from the World 
Health Organisation (WHO) Map production: Health Statistics and Information Systems 2012, 
WHO (2014) 
 
1.2. The Classification of HIV-1  
HIV-1 is characterised by extensive genetic diversity and comprises of four distinct 
lineages, groups M (Major), N (non-M and non-O), O (Outlier) and P (pending the 
identification of further human cases), of which group M is responsible for the HIV-1 
pandemic (Sharp, 2011). Group M can be further subdivided into nine different subtypes, 
namely A-D, F-H, J and K, which differ in their protein sequence of the major structural 
proteins Gag, Pol and Env by 15%, 10% and 24%, respectively (Sampathkumar et al., 
2012, Lihana RW, 2012). The HIV-1 subtypes show distinct regional prevalence of 
variants around the world (Santos and Soares, 2010) with subtype C predominating in 
sub-Saharan Africa and accounting for 48% of HIV-1 infections worldwide (Lihana RW, 
2012). Subtype A is prevalent in Central Africa, Iran and Eastern Europe, and in Central 
Asia while subtype B predominates in developed countries, such as the United States, 
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countries of Western Europe, Japan and Australia (Santos and Soares, 2010). The 
remaining six HIV-1 subtypes (D, F, G, H, J and K) together represent a small percentage 
of infections (Hemelaar et al., 2006). Circulating recombinant forms (CRFs) are 
recombinant viruses from different subtypes of HIV-1 that became established within the 
pandemic, with A/G recombinant strains predominating in West Africa and B/C 
recombinant strains predominating in China (Cohen et al., 2008).  
 
1.3. The HIV-1 Genome 
The HIV-1 genome is 9.8 kb in size and consists of nine genes which are classified into 
three groups: structural genes, regulatory genes, and accessory genes (Costin, 2007) 
(Figure 1.2). The group-specific antigen (Gag) and gag-pol (Polymerase) polyproteins 
from the structural group are cleaved by the viral protease to release matrix (MA), capsid 
(CA), p2, nucleocapsid (NC), p1 and p6, protease (PR), reverse transcriptase (RT which 
contains RNAse H) and integrase (IN) (Peterlin and Trono, 2003). The structural protein 
envelope (Env) is cleaved by cellular proteins into surface glycoprotein-120 (gp120) and 
transmembrane glycoprotein-41 (gp41). The viral regulatory proteins comprise of 
transcriptional transactivator (Tat) and regulator of virion gene expression (Rev) which 
are localised in the nucleus. Tat is the main transcriptional regulator of the long term 
repeat (LTR) and acts by binding to the transactivation response (TAR) element and 
activating transcription and elongation from the 5’ LTR promoter (Rhee et al., 2003). The 
main nuclear-export protein, Rev, is responsible for regulating early and late viral gene 
expression (Peterlin and Trono, 2003). The accessory proteins consist of the viral-
infectivity factor (Vif), viral protein r (Vpr), viral protein u (Vpu) and negative effector 
(Nef). Vif promotes the infectivity of viruses, while Vpr is involved in the nuclear import 
of pre-integration complexes, cell growth arrest and induction of cellular differentiation 
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(Rhee et al., 2003). Vpu which is unique to HIV-1 is responsible for the degradation of 
CD4 in the endoplasmic reticulum and the release of virions from infected cells (Rhee et 
al., 2003). The Nef protein is the most immunogenic of the accessory proteins and is 
responsible for downregulating CD4 (the primary viral receptor) and the major 
histocompatibility (MHC) class I molecules (Rhee et al., 2003). 
 
 
Figure 1.2. Landmarks of the HIV-1 genome 
The HIV-1 genome consists of three main genes i.e. gag, pol and env. These genes code for 
structural proteins and essential enzymes. The HIV genome also encodes regulatory proteins (tat 
and rev) and accessory proteins (vif, vpr and nef). Picture taken from Rhee et al. (2003). 
 
1.4. The Structure of HIV-1 
The HIV-1 virion is made up of a viral envelope comprising of a surface envelope protein 
(gp120, SU) and a transmembrane envelope protein (gp41, TM) (Figure 1.3) embedded in 
a lipid bilayer membrane. These two proteins are responsible for attachment of the virus 
to the host cell. The matrix (p17/MA) is associated with the inner compartment of the 
membrane while the capsid (p24/CA) forms a shell around the viral RNA/NC complex 
(Freed, 1998). Contained within the capsid is the virus’s genetic material which is made 
up of two identical strands of single stranded RNA.  
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Figure 1.3. An illustration of the HIV-1 virion 
The location of the gag proteins, envelope glycoproteins and the pol enzymes are shown. Picture 
taken and modified from Robinson (2002). 
 
 
1.5. The Pathogenesis of HIV-1 Infection 
 
Infection with HIV-1 is characterised by 3 stages which consist of initial infection, 
latency and clinical AIDS (Figure 1.4). During the acute stage of infection, the virus 
proliferates in the patient’s periphery, until approximately after the first 4 weeks. HIV-1 
specific antibody-mediated immune response begins (Cohen et al., 2008). During the 
latency phase the CD4 T cell count starts to decline and the viral load steadily increases 
over time (Costin, 2007). The onset of AIDS is defined as a CD4 T cell count of <200 
cells/mm3 and/or the presence of an opportunistic infection (Costin, 2007). 
 
After HIV-1 transmission, the interaction between the virus and the host determines the 
natural history of infection in that specific individual (Cohen et al., 2008). A small 
proportion of HIV-1 infected patients (known as long term non-progressors (LTNPs) can 
remain asymptomatic for a prolonged period in the absence of antiretroviral therapy, with 
7 
 
a high CD4 cell count and detectable viral load (Sabin and Lundgren, 2013). Elite 
controllers are a subset of LTNP and can further suppress viral load levels to remain 
undetectable in the absence of antiretroviral therapy (Sabin and Lundgren, 2013). Studies 
on these unique individuals are ongoing to understand how the host immune response is 
able to control HIV infection providing insight for the development of vaccines and new 
antiretroviral agents (Sabin and Lundgren, 2013). 
 
Figure 1.4. Time course of HIV-1 infection 
The three stages of HIV-1 infection are shown i.e. initial infection, latency phase and clinical 
AIDS. The initial infection is characterised by a rapid increase in viral load and decline in CD4 T 
cell count till four weeks. During the clinical latency phase, the viral load remains low and stable. 
Over time the clinical AIDS phase develops and is characterised by a continuous decline of CD4 
T cells and increase in viral load. Picture modified from Costin (2007). 
 
 
1.6. The HIV-1 Life Cycle 
 
The HIV-1 life cycle comprises a series of steps to allow the virus to enter the host cell, 
efficiently replicate its DNA and release mature infectious virions to infect more target 
cells (Figure 1.5) (Arts and Hazuda, 2012, Pomerantz and Horn, 2003). Virus entry is 
mediated by binding of the gp120 envelope protein to a CD4 receptor and co-receptor 
(either CXCR4 or CCR5) found on the surface of immune cells. This results in gp41 
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inducing a membrane fusion reaction between the lipid bilayer of the virion and the 
plasma membrane of the host cell and consequently causing the release of the viral core 
into the cytoplasm (Freed, 1998).  Once the virus contents enter the cell, the nucleocapsid 
undergoes a process of uncoating where its capsid is lost and through the process of 
reverse transcription, mediated by the reverse transcriptase (RT) enzyme, the two single 
stranded viral RNAs are converted to double stranded DNA (Campbell and Hope).  
 
The viral DNA is transported into the nucleus where it is integrated with the host cell’s 
DNA by the enzyme integrase (IN). When the cells become activated, the integrated DNA 
which is known as the provirus serves as a template for the synthesis of viral RNA using 
host cell’s machinery (Freed, 1998). The Env glycoproteins, Gag and Gag-Pol 
polyproteins are expressed and transported to the plasma membrane where the Gag 
precursor deploys two copies of single stranded RNA and assembles close to the inner 
plasma membrane (Freed, 1998).  As the immature viruses bud from the cell, the viral 
Env glycoproteins are incorporated into the virus membrane. After budding, the Gag and 
Gag-Pol polypeptide chains are cleaved by HIV-1 Protease into smaller proteins resulting 
in the formation of a mature infectious virus which can now initiate a new round of 
infection (Arts and Hazuda, 2012). HIV-1 protease is initially processed as part of the 
Gag-Pol polyprotein, however due to the regulated cleavage reactions it undergoes a 
process called auto-processing whereby it is released (Lee et al., 2012).  
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Figure 1.5. The life cycle of HIV-1 
The different stages of the viral life cycle are shown. After the virus binds to the CD4 T cell, it 
enters the cell and undergoes uncoating to release its contents into the cell. The viral single-
stranded DNA is reverse transcribed to double-stranded DNA which is integrated with the host 
cell DNA forming a provirus. The viral proteins are expressed and assembled close to the viral 
membrane. An immature virion buds off. The poly-proteins are cleaved to release a mature and 
infectious virus. Picture taken from Rambaut et al. (2004). 
 
 
 
1.7. Intrinsic Factors Influencing HIV-1 Evolution of gag and protease 
 
HIV is subjected to selection pressures from the host immune system which results in 
viral evolutionary measures to adapt to these pressures (Sampathkumar et al., 2012). The 
rapid evolution of HIV-1 is primarily as a result of the highly error prone RT enzyme, 
resulting in extensive genetic variability. The RT enzyme lacks a 3’ – 5’ proof-reading 
function with rates of misincorporation estimated to be 1 in 6900 and 1 in 5900 
nucleotides on the RNA and DNA templates, respectively (Sampathkumar et al., 2012). 
This results in the generation of multiple variants or quasiespecies, some of which render 
the virus resistant to ARVs or afford an evolutionary advantage. In addition to 
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antiretroviral drug pressure, cell-mediated immune responses can exert significant 
pressure on the virus thereby selecting for changes in the viral genome.  
 
1.7.1. Cyclophilin A  
Cyclophilin A (CypA) is a host factor responsible for regulating protein folding and 
trafficking (Nigro et al., 2013). It is recruited by the Gag polyprotein during infection, and 
is essential for viral infectivity (Lama and Planelles, 2007). Many single nucleotide 
polymorphisms (SNPs) have been identified in the CypA gene (PP1A). One SNP 
(1650A/G) was found to be associated with lower ex vivo virus replication in cells derived 
from PP1A homozygous individuals (AA), and slower disease progression in vivo 
(Bleiber et al., 2005).  
 
1.7.2. Tripartite Interaction Motif 5α (TRIM5α) 
TRIM5α is an intrinsic immune factor important for the innate immune defence in 
humans. It is involved in the early steps of viral replication and acts by restricting the 
replication of HIV-1 through its interaction with the viral capsid leading to unsuccessful 
infection (Restrepo et al., 2011). To avoid restriction by TRIM5α, escape mutations may 
arise in the capsid region of the virus as proof of the existence of selective pressure on the 
virus (Lama and Planelles, 2007). Studies have shown that genetic changes in the 
TRIM5α gene may influence susceptibility to HIV-1 infection as was shown with the 
R136Q SNP which occurs at a higher frequency in HIV-1 infected individuals (Lama and 
Planelles, 2007). 
 
1.7.3. Apolipoprotein B (APOBEC3G) 
APOBEC3G is a protein that plays a role in innate anti-viral immunity (Restrepo et al., 
2011). During reverse transcription, APOPBEC3G deaminates cytosine (C) to guanine 
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(G) in one DNA strand causing a G→A hypermutation in the complementary strand 
(Restrepo et al., 2011). Integration of the cDNA carrying hypermutations with the host 
DNA leads to the formation of aberrant viruses (Lama and Planelles, 2007). High 
expression of the APOBEC3G gene has been associated with reduced in vitro 
susceptibility to HIV-1 (Biasin et al., 2007). The HIV-1 Vif protein targets APOBEC3G 
for degradation thereby preventing its incorporation into the virions (Lama and Planelles, 
2007). In the absence of HIV-1 Vif, APOBEC3G is incorporated into the HIV-1 particles. 
 
1.7.4. The Human Leukocyte Antigen (HLA) System 
The HLA system, which is located within the major histocompatibility complex (MHC) 
on chromosome 6, is highly polymorphic due to its exposure to millions of pathogens 
throughout the existence of the human species (Klein and Sato, 2000). The HLA class I 
and class II molecules function by recognising and presenting specific antigenic peptides 
to CD8 and CD4 T cells respectively to trigger an adaptive immune response. HLA class 
I consists of HLA-A, B and C which are expressed by all nucleated cells, while HLA 
class II consists of HLA-DP, DQ and DR, which are expressed on the surface of antigen 
presenting cells and memory cells (Bashirova et al., 2011). During HIV-1 infection, 
pressure from the HLA system leads to the selection of immune escape mutations most of 
which are well described in the Gag, Pol and Nef proteins (Sampathkumar et al., 2012, 
Bashirova et al., 2011, Brumme et al., 2009). Immune escape mutations disrupt binding of 
the viral peptide to HLA alleles and allow the virus to escape immune recognition 
(Brumme et al., 2009).  The different HLA alleles have varied effects on the rates of HIV-
1 progression with some alleles associated with a low viral load and slow progression to 
AIDS and some associated with a more rapid progression to AIDS (Bashirova et al., 
2011).  
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1.7.5. Killer-cell Immunoglobulin-like Receptors (KIRs) 
Natural killer (NK) cells are important cells of the innate immune system and function by 
interacting directly with infectious agents or infected cells (Jamil and Khakoo, 2011). 
This interaction is facilitated by the direct binding of the surface protein killer-cell 
immunoglobulin-like receptors (KIRs) to MHC class I molecules, expressed on all cell 
types (Jamil and Khakoo, 2011). The highly polymorphic KIR genes are located on 
chromosome 19, and function by activating or inhibiting NK cell activity (Sampathkumar 
et al., 2012). A minimum of 17 highly diverse KIR genes exist and their diversity is 
thought to be driven by selective pressure from exposure to pathogens (Parham et al., 
2010). A study by Alter et al. (2011) identified polymorphisms in HIV-1 located in Vpu, 
Env, Gag and Nef that enhanced the binding of inhibitory KIRs to infected cells, resulting 
in inhibition of NK cell function and thus allowing HIV-1 to escape the immune response.  
 
1.8. Antiretroviral Therapy  
 
Figure 1.6. Antiretroviral drugs targeting specific steps in the viral life cycle 
Entry inhibitors target entry of the virus into the infected thereby preventing attachment and 
fusion. Reverse transcription of the single stranded RNA is inhibited by reverse transcripase 
inhibitors and integration of viral DNA with the host cell’s DNA is inhibited by integrase 
inhibitors. Protease inhibitors prevent cleavage of the Gag and Gag-Pol polyproteins. The 
maturation of the immature virus is inhibited by maturation inhibitors. Picture taken from Smith et 
al. (2013). 
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In March 1987, the first drug (Zidovudine) was approved for antiretroviral treatment 
(ART) of HIV-1 by the U.S. Food and Drug Administration (FDA) (Santos and Soares, 
2010). Since then, 26 drugs have been developed, targeting different stages of the virus 
life cycle, including viral entry, reverse transcription, integration, polyprotein cleavage 
and maturation (Figure 1.6). Newer ARVs, with improved pharmacological properties 
and potency, and a higher barrier to resistance, are continually being developed. To date, 
the US FDA have approved seven nucleotide reverse transcriptase inhibitors (NRTIs), 
five non-nucleotide reverse transcriptase inhibitors (NNRTIs), nine protease inhibitors 
(PIs), a fusion and an entry inhibitor, and three integrase inhibitors (INs) (Table 1.1) 
(National Institutes of Health, 2014).  
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Table 1.1. FDA approved antiretroviral drugs (National Institutes of Health, 2014) 
Drug Class Drug Name FDA Approval Date 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
 Abacavir (ABC) December 17, 1998 
 Didanosine (ddI) October 9, 1991  
 Emtricitabine (FTC) July 2, 2003 
 Lamivudine (3TC) November 17, 1995 
 Stavudine (d4T) June 24, 1994 
 Tenofovir (TDF) October 26, 2001 
 Zidovudine (AZT) March 19, 1987 
Non-nucleoside Reverse Transcriptase Inhiitors 
 Delavirdine (DLV) April 4, 1997 
 Efavirenz (EFV) September 17, 1998 
 Etravirine (ETR) January 18, 2008 
 Nevirapine (NVP) June 21, 1996 
 Rilpivirine (RPV) May 20, 2011 
Protease Inhibitors 
 Atazanavir (ATV) June 20, 2003 
 Darunavir (DRV) June 23, 2006 
 Fosamprenavir (FPV) October 20, 2003 
 
 
 
 
 
 
 
 
Indinavir (IDV) March 13, 1996 
 Lopinavir (LPV) September 15, 2000 
 Nelfinavir (NFV) March 14, 1997 
 Ritonavir (RTV) March 1, 1996 
 Saquinavir (SQV) December 6, 1995 
 Tipranavir (TPV) June 22, 2005 
Fusion Inhibitors 
 Enfuvirtide (T-20) 
(T-20) 
March 13, 2003 
Entry Inhibitors 
 Maraviroc (MVC) August 6, 2007 
Integrase Inhibitors 
 Dolutegravir (DTG) August 13, 2013  
 Elvitegravir (EVG) August 27, 2012 
 Raltegravir (RAL) October 12, 2007 
 
1.8.1. Mechanism of Action of the Different Drug Classes 
1.8.1.1. Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
NRTIs target the reverse transcriptase enzyme and have been instrumental in the 
treatment of HIV-1 (Iyidogan and Anderson, 2014). NRTIs are competitive inhibitors 
which are structurally similar to the deoxy-nucleotide triphosphates (dNTPs) but lack the 
3’-hydroxyl group needed for DNA elongation (Ammaranond and Sanguansittianan, 
2012). NRTIs are administered as prodrugs and are converted to the triphosphate form by 
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host cellular enzymes (Tang and Shafer, 2012). By out-competing endogenous dNTPs for 
incorporation into the growing DNA chain, NRTIs cause chain termination and viral 
replication is unable to proceed (Tang and Shafer, 2012). 
 
1.8.1.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
The NNRTIs are non-competitive inhibitors that act by binding to a hydrophobic pocket 
close to the polymerase active site unique to the HIV-1 reverse transcriptase enzyme 
(Iyidogan and Anderson, 2014). Once bound to the hydrophobic pocket, NNRTIs inhibit 
dNTP binding by inducing a conformational change in the dNTP-binding pocket p66 
(Ammaranond and Sanguansittianan, 2012). This change blocks the required alignment of 
substrates for the phosphodiester bond formation and prevents further replication 
(Iyidogan and Anderson, 2014) 
 
1.8.1.3. Protease Inhibitors (PIs) 
HIV-1 Protease is responsible for recognising and cleaving 10 sites in the Gag and Gag-
Pol polyproteins to form infectious virions (Huang et al., 2011). HIV-1 Protease is a 
homodimer consisting of 2 identical proteins each with 99 amino acids in length (Figure 
1.7) (Yang et al., 2012). The two flaps contain flexible ß-hairpins that allow access to the 
active site (Huang et al., 2014). PIs are competitive active site inhibitors of HIV-1 
protease (Tang and Shafer, 2012), and prevent cleavage of the Gag and Gag-Pol 
polyproteins into mature infectious viruses (Arts and Hazuda, 2012). 
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Figure 1.7. Structure of HIV-1 Protease 
Ribbon representation of the homodimeric structure of HIV-1 Protease, indicating the flap and 
active site regions. The numbers within the spheres represent amino acid positions associated with 
drug resistance. Picture taken from Louis et al. (2011). 
 
1.8.1.4. Integrase Inhibitors (INs) 
The HIV-1 integrase enzyme is required to catalyse the integration of viral DNA into the 
host cell chromosomal DNA during viral replication (Ammaranond and Sanguansittianan, 
2012). It consists of three domains i.e. the N- and C-terminal domains and a catalytic core 
(Iyidogan and Anderson, 2014). Two main residues in the active site, Asp64 and Asp116 
are critical for viral integration, such that mutations arising at these residues result in 
complete inhibition of viral integration (Ammaranond and Sanguansittianan, 2012). INs 
binds to the specific complex between integrase and the viral DNA and interact with the 
magnesium metal ion cofactors in the integrase active site and the DNA thereby 
interfering with the integration process during strand transfer (Arts and Hazuda, 2012). 
 
1.8.1.5. Fusion Inhibitors (FIs) 
HIV-1 gp41 is responsible for anchoring the envelope complex within the cell membrane. 
After binding of gp120 to CD4+ coreceptors, the heptad repeat regions of gp41 fold 
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shortening the protein and bringing the viral and host cells membranes into contact 
(Iyidogan and Anderson, 2014). The FI Enfuvirtide acts by binding to the first heptad 
repeat region of gp41, thereby preventing the virus from infecting the host cell (Iyidogan 
and Anderson, 2014). 
 
1.8.1.6. Entry Inhibitors 
Maraviroc (MVC) inhibits the binding of HIV-1 gp120 to the host CCR5 co-receptor 
(Tang and Shafer, 2012), by binding to a hydrophobic transmembrane pocket of CCR5, 
altering the conformation of the extracellular loop of the receptor, and preventing 
interaction with the V3 stem loop of gp120 (Iyidogan and Anderson, 2014). Prior to 
initiation of MVC treatment, a tropism assay is required to identify the co-receptor of the 
virus that the patient is infected with. The Trofile test (Monogram) assesses the tropism of 
envelope genes from patient samples using reporter cell lines expressing CCR5 or 
CXCR4 (Tang and Shafer, 2012) 
 
1.8.2. Highly Active Antiretroviral Therapy (HAART) and Treatment 
Regimens 
Currently, the standard of care for treatment of HIV-1 patients is combined antiretroviral 
therapy (cART) consisting of at least three different drugs, from 2 or more drug classes 
(Pomerantz and Horn, 2003). The use of cART ensures targeting of more than one viral 
replication step thereby maximising the ability to inhibit HIV-1 replication. The South 
African treatment guidelines follow the WHO guidelines and recommend the use of 
ritonavir (RTV)-boosted lopinavir (LPV/r) as a second-line regimen for adults and 
children over 3 years of age, and a first-line regimen for paediatric patients <3 years of 
age (Department of Health, 2013). A summary of the national ART regimen for adults 
and children are shown in Table 1.2 and 1.3 respectively. 
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Table 1.2. Standardised South African national treatment regimens for adults and 
adolescents (Department of Health, 2013) 
First Line 
All new patients initiating treatment TDF+FTC (or 3TC) +EFV 
Adolescents ABC+3TC+EFV 
Contraindications to EFV TDF+(FTC or 3TC)+NVP 
Contraindications to TDF AZT+3TC+EFV (or NVP) 
Contraindication to TDF and AZT d4T+3TC+EFV (or NVP) 
Contraindication to TDF, AZT and D4T ABC+3TC+EFV (or NVP) 
Second Line 
Failing on a TDF-based 1st line regimen AZT+3TC+LPV/r 
Failing on a d4T-based 1st line regimen TDF+3TC (or FTC) and LPV/r 
Third Line 
Failing 2nd line regimen Specialist referral- Most likely regimen would 
be RAL/DRV/ETR (according to genotype) 
 
Table 1.3. Standardised South African national treatment regimens for infants and 
children (Department of Health, 2013) 
First Line 
< 3 years (or < 10kg) ABC+3TC+LPV/r 
> 3 years (and > 10 kg) ABC+3TC+EFV 
Second Line 
Failed first line PI-based regimen: 
ABC+3TC+LPV/r 
d4T+3TC+LPV/r 
Under expert advice: 
AZT+3TC+EFV+LPV/r  
AZT+ABC+EFV+LPV/r 
Failed first line NNRTI-based regimen 
ABC+3TC+EFV (or NVP) 
d4T+3TC+EFV (or NVP) 
 
AZT+3TC+LPV/r 
AZT+ABC+LPV/r 
Third Line 
Failing 2nd line regimen Specialist referral- Based on genotype. 
 
Although antiretroviral therapy has significantly reduced morbidity and mortality, the 
emergence of drug resistance complicates life-long effective therapy (Ammaranond and 
Sanguansittianan, 2012). Drug resistance has been associated with each class of drugs, 
with some patients even showing multi-class drug resistance.  
 
1.8.3. Antiretroviral Therapy in Paediatric Patients 
Earlier prevention of mother-to-child transmission (PMTCT) programs were 
predominantly NNRTI-based (Zanoni et al., 2012) rapidly selecting for high rates of 
NNRTI drug resistance in infants and young children infected with HIV-1 and 
compromising the effectiveness of NNRTIs in these children (Coovadia et al., 2009). 
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Therefore, PI-based therapy is preferred as a first-line regimen for infants. Results from 
the Children with HIV Early Antiretroviral Therapy (CHER) trial showed that early 
diagnosis and treatment reduced early infant mortality and HIV progression (Palumbo et 
al., 2010, Chadwick et al., 2009). The recommendations from the trial have been adopted 
by the South African government and children now start therapy at diagnosis regardless 
of CD4 percentage. South Africa has an estimated 410 000 children infected with HIV, of 
whom just over half are eligible and receiving antiretroviral treatment (UNAIDS, 2013). 
The continued use of LPV/r in paediatric patients is limited by its poor palatability, drug-
drug interactions and development of resistance (Gupta et al., 2009). In patients with 
concomitant tuberculosis, therapy with LPV/r and rifampicin can drastically result in sub-
therapeutic levels of LPV/r (McIlleron et al., 2011). Currently children co-infected with 
HIV-1 and TB are given double doses of lopinavir/ritonavir during rifampicin-based 
therapy (McIlleron et al., 2011). However, further studies are required to determine the 
optimal dose to be used. Most PIs have not yet been approved for use in children, since 
adequate formulation and pharmacokinetic studies are still required (Hazra et al., 2010). 
Therefore it is necessary to identify more ARVs which are effective and easily accessible 
in children failing PI-based therapy. 
 
Prior to 2008, RTV monotherapy was used to treat paediatric patients receiving 
concomitant treatment for tuberculosis (TB) and/or patients <6 months of age due to 
drug-drug interactions with LPV/r (van Zyl et al., 2011, Reitz et al., 2010). HAART has 
significantly reduced disease progression and mortality in children (Ramos et al., 2011). 
However, due to their high viral loads and challenges to accurate dosing, those under 2 
years have poorer virological outcomes and greater chances of developing drug resistance 
compared to older children and adults (Hazra et al., 2010, Gupta et al., 2009).  
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1.9. Antiretroviral Drug Resistance 
 
1.9.1. Drug Resistance to the Different Classes of Drugs 
1.9.1.1. Nucleoside reverse transcriptase inhibitors  
Two biochemical mechanisms of NRTI resistance can occur. The first mechanism 
involves selecting for single mutations which allow the reverse transcriptase enzyme to 
discriminate between dideoxy-NRTI chain terminators and the cells natural dNTPs 
thereby disrupting incorporation of the NRTIs into the growing DNA chain (Tang and 
Shafer, 2012). The K65R, L74V, Q151M and M184V mutations cause resistance to 
NRTIs in this manner, and are also known as discriminatory mutations. The second 
mechanism is mediated by mutations (known as excision mutations) that facilitate the 
phosphorylytic excision of the chain terminating NRTI residue from the 3’ end of the 
growing viral DNA chain, which in turn permits continued DNA synthesis (Ammaranond 
and Sanguansittianan, 2012). These mutations are also referred to as thymidine analogue 
mutations (TAMs) since they are selected by thymidine analogue drugs (Tang and Shafer, 
2012), and include the M41L, D67N, K70R, L210W, T215YF and K219QE mutations. 
TAMs can cause broad cross-resistance to NRTIs (Rhee et al., 2003). The T69 insertion 
complex is also associated with other NRTI mutations that can cause multi-NRTI 
resistance (Iyidogan and Anderson, 2014). Therefore, with the development of TAMs, 
genotypic resistance testing should be performed prior to the use of another thymidine 
analogue.  
 
1.9.1.2. Non-nucleoside reverse transcriptase inhibitors 
NNRTIs, such as EFV and NVP, have a low genetic barrier to resistance, in that a single 
mutation may cause high-level resistance and even cross-resistance among the NNRTI 
drug classes (Ammaranond and Sanguansittianan, 2012). The mutations responsible for 
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NNRTI resistance are located close to the hydrophobic pocket of reverse transcriptase and 
these the binding affinity of the inhibitors (Ammaranond and Sanguansittianan, 2012). 
Mutations K103N, V106M, Y181C and G190A are the most common single mutations 
which confer cross-resistance to NVP and EFV (Iyidogan and Anderson, 2014). The 
second-generation NNRTIs ETR and RVP show promise following use of NVP or EFV 
since most of the mutations acquired with NVP or EFV use do not cause cross-resistance 
to the newer NNRTIs (Basson et al., 2014).  
 
1.9.1.3. Protease Inhibitors 
Resistance to PIs is mediated by the development and accumulation of patterns of 
mutations primarily located in the active site of the protease gene (Figure 1.7) 
(Ammaranond and Sanguansittianan, 2012, Molla et al., 1996). Of the 99 amino acids in 
protease, 46 have been shown to be associated with selection by PIs, with 26 positions 
identified as those commonly involved in PI resistance (Rhee et al., 2010).  Protease 
mutations are classified as either major or minor mutations: major protease mutations are 
those which by themselves cause reduced susceptibility to one or more PIs, whereas 
minor mutations are those which have little or no effect on PI susceptibility on their own 
but may further reduce susceptibility in combination with major mutations (Rhee et al., 
2003). In the presence of a mutant Protease, the natural substrate (i.e gag and gag-pol) can 
still bind to the enzyme and be cleaved while the inhibitor is no longer effective against 
the enzyme (Figure 1.8).  
 
Cross-resistance refers to the ability of PI-selected mutations to cause resistance to other 
PIs. This presents a predicament when choosing new PI-based regimens in PI-
experienced individuals. Major mutations arising due to LPV/r-based therapy include: 
I47V/A, I50V, I54V/T/A/L/M, L76V, V82A/F/T/S and I84V. Some of which cause high 
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level resistance to other PIs such as I47A (to FPV/r), L76V (to FPV/r and IDV/r), V82A 
(to IDV/r and NFV), I84V (to ATV/r, FPV/r, IDV/r, NFV and SQV/r) and L90M (to NFV 
and SQV/r) (Rhee et al., 2003).  
 
Figure 1.8. Mechanism of action of protease inhibitors 
The natural substrate (Gag) binds to the active site of Protease, thereby allowing Protease to 
cleave Gag into smaller polypeptides rendering the virus mature and infectious. The scissor is an 
analogy used to show the function of the flap region of Protease. Protease inhibitors act by 
recognising and binding to the active site of the enzyme and preventing substrate cleavage. In the 
presence of drug resistant protease inhibitors do not bind to the active site, but the substrate still 
has the ability to recognise and bind to mutant protease. Picture taken from Immunopaedia 
(2010). 
 
Although the presence of PI mutations predicts failure on a PI-based regimen, a number 
of studies have reported a low frequency of protease mutations in adult and paediatric 
patients failing PI-based therapy (Wallis et al., 2011, van Zyl et al., 2009, Levison et al., 
2012). Although the lack of PI mutations is often associated with non-adherence, some 
patients still show resistance to other classes of drugs in the regimen suggesting that 
patients are being exposed to drug levels (Siliciano and Siliciano, 2013). These findings 
suggest that there may be alternate pathways of PI resistance (Bartlett, 2013, Siliciano and 
Siliciano, 2013). Many studies have shown mutations at gag cleavage sites (CS) 
associated with PI resistance, either in the presence and absence of major PI mutations 
(Dam et al., 2009, Nijhuis M, 2007, Malet et al., 2007).  A study by Rabi et al. (2013) 
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showed that the presence of PIs inhibit the entry, reverse transcription and post-reverse 
transcription steps of the virus life cycle and that inhibition was greatest at the entry step. 
The envelope gene was suggested as a possible site of PI resistance following the 
selection of mutations in envelope. The second study by Rosenbloom et al. (2012) found 
that the pharmacodyamic properties of PIs restrict the evolution of resistance. PIs have a 
very short half-life and a limited mutation selection window (MSW), a window during 
non-adherence where the mutant virus has a selective advantage over wild-type virus. In 
these instances, wild-type virus will emerge rapidly upon therapy interruption.  
 
1.9.1.3.1. The Role of HIV-1 Gag in Protease Inhibitor Drug Resistance 
HIV-1 Protease recognises and cleaves the Gag and Gag-Pol polyproteins at 10 different 
cleavage sites to yield the structural components of matrix (MA), capsid (CA), 
nucleocapsid (NC), spacer peptides 1 and 2, trans-frame protein (TFP) and essential 
enzymes protease (PR), reverse transcriptase (RT), RNase H and integrase (IN). Cleavage 
sites comprise of 5 amino acids flanking either side of the scissile bond with position 1 
(P1) located immediately upstream and position 1 prime (P1’) located immediately 
downstream of the cleavage point (Figure 1.9.) (de Oliveira et al., 2003, Pettit et al., 
1994).  
 
Figure 1.9. Illustration of the gag NC/p1 CS and the nomenclature used for each position 
within the cleavage site. Gag CS span 10 amino acids with 5 amino acids on either side of the 
scissile bond.  
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Earlier studies showed that gag CS mutations compensate for amino acid changes (i.e. 
drug resistance mutations) arising in protease under PI pressure to maintain viral fitness 
(Mammano et al., 1998, Maguire et al., 2002). However, mutations at CS NC/p1 and 
p1/p6Gag have been associated with PI resistance even in the absence of drug resistance 
mutations in protease (Dam et al., 2009, Nijhuis M, 2007). Dam et al., (2009) found that 
the carboxyl terminus of gag was responsible for directly contributing to PI resistance 
mediated primarily by mutations A431V and I437V at NC/p1 in the absence of mutations 
in protease. Studies have also shown that mutations occurring at gag CS co-evolve with 
protease mutations to contribute to drug resistance (Kolli et al., 2014, Maguire et al., 
2002, Sutherland et al., 2013, Gupta et al., 2010).  
 
Few studies have looked at the role of non-CS mutations in drug resistance. An early 
study found that gag non-CS mutations H219Q and R409K were responsible for 
conferring PI resistance and were essential for viral replication in the presence of PIs 
(Gatanaga et al., 2002). The authors suggested that changes at gag non-CS may render the 
cleavage site more accessible to mutant protease thereby making the replication process 
more efficient. Non-CS mutations occurring at the amino terminus of gag have been 
shown to confer PI resistance in the presence of mutant protease and absence of gag CS 
mutations (Parry et al., 2009). 
 
Since changes at gag CS and non-CS have been shown to contribute to PI resistance, 
recent studies advocate for the inclusion of full length gag in addition to protease when 
studying PI resistance (Gupta et al., 2010, Sutherland et al., 2013, Sutherland et al., 2014).  
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1.9.1.4. Integrase inhibitors 
Resistance to RAL, the first approved integrase inhibitor, can occur by three main 
pathways which occasionally overlap: N155H followed by E92Q; Q148HRK+G140SA; 
and Y143CR+T97A (Tang and Shafer, 2012). Most RAL mutations confer cross-
resistance to EVG with the exception of Y143CR. However, DTG has a higher genetic 
barrier compared to RAL and EVG since only G148+G140 can confer resistance to DTG 
(Tang and Shafer, 2012). Further studies with patients on treatment with INs for a long 
period are necessary to determine additional resistance patterns. 
 
1.9.1.5. Fusion inhibitors 
Resistance to the currently available FI, Enfuvirtide (T-20), has been shown to occur by 
the development of mutations in the HR1 region in gp41 at codons 36-45 (Tang and 
Shafer, 2012). T-20 has a low genetic barrier resulting in rapid development of resistance, 
therefore its use in salvage therapy will require a sufficient number of additional active 
drugs (Tang and Shafer, 2012). Major mutations conferring resistance to T-20 include 
G36DS, I37V, V38AME, Q39R, Q40H, N42T and N43D (Rhee et al., 2003), which occur 
in most subtypes (Iyidogan and Anderson, 2014). 
 
1.9.1.6. Entry Inhibitors 
The entry inhibitor MVC is a negative allosteric modulator of CCR5 and blocks gp120 
binding to the coreceptor (Iyidogan and Anderson, 2014). The primary mechanism by 
which HIV-1 develops resistance to MVC is through tropism switching by using the 
CXCR4 co-receptor instead of CXCR5 for entry (Moore and Kuritzkes, 2009). In 
addition MVC resistance can occur through the development of mutations in the envelope 
gene which allow gp120 to bind an MVC-bound CXCR5 receptor (Westby et al., 2007). 
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Most of these mutations are located in the V3 loop of envelope gene (Iyidogan and 
Anderson, 2014).  
 
1.9.2. The South African Antiretroviral Treatment Program 
South Africa has the largest ARV programme worldwide and combined with the ART 
scale-up, there has been significant population-level reduction in HIV-related mortality in 
many populations (Bor et al., 2013). A study by the HIV Prevention Trials Network 
(HPTN) 052 trial was conducted in HIV-1 discordant couples showed that treatment with 
ART significantly lowered the transmission of the virus to the uninfected partner (Cohen 
et al., 2011). This suggests that increased ART coverage could reduce the rate of ARV 
infections at a population level (Tanser et al., 2013). A recent study by the Africa Centre 
in South Africa followed up a total of 16 667 individuals who were uninfected at baseline 
and their seroconversions were monitored from 2004 to 2011 (Tanser et al., 2013). This 
study found that the risk of acquiring HIV-1 significantly declined with increasing ART 
coverage in the surrounding local community.  
 
1.9.3. Monitoring of ARV Drug Resistance 
ARV therapy has been instrumental in improving the health of HIV-1 infected patients 
(Cohen et al., 2008). However, the development of drug resistance most often leads to 
viral load rebound in the infected individual. The monitoring and prevention of drug 
resistance development is imperative for a successful treatment outcome. Infrequent viral 
load monitoring, as is often observed in resource-limited settings, resulting in patients that 
present with more drug resistance mutations and cross-resistance compared to those 
receiving regular viral load monitoring in well-resourced countries (Gupta et al., 2008). 
Regular viral load monitoring and viral genotyping is important to identify non-adherence 
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and ineffective drug regimens. These are valuable tools to guide clinicians in choosing 
appropriate drug regimens (Iyidogan and Anderson, 2014). 
 
1.9.3.1. Viral Load Monitoring 
Viral load monitoring technologies can be characterised as nucleic acid based tests (NAT) 
and non-NAT based tests (Haleyur et al., 2014). NAT testing involves the direct detection 
and quantification of viral RNA while non-NAT technology involves the detection and 
quantification of viral enzymes which are used to determine the amount of viral RNA 
present (Haleyur et al., 2014). The NAT-based assays have wider availability and are 
easily interpreted by clinicians (Haleyur et al., 2014). In addition to the in-house tests 
available, four commercial assays for viral load tests are available, including the Real-
Time HIV-1 assay (Abbott), VERSANT HIV-1 RNA 1.0 assay (Siemens), COBAS 
AMPLICOR HIV-1 MONITOR v1.5 assay (Roche Molecular Systems), COBAS 
AmpliPrep/COBAS TaqMan v2.0 assay (Roche Molecular Systems) (Haleyur et al., 
2014). Viral load monitoring is used to guide regimen switch, as 2 consecutive viral loads 
>1000 copies/mL more than 3 months apart is considered as a sign of possible drug 
resistance (Jordan et al., 2008). A study was done to determine the cost-effectiveness of 
using viral load as an alternative to CD4 monitoring following ART initiation. It was 
found that viral load monitoring alone could save costs since it led to earlier identification 
of patients that required switching to second-line therapy (Hamers et al., 2012). The 
Development of AntiRetroviral Therapy in Africa (DART) trial in Uganda and Zimbabwe 
showed that routine monitoring of CD4 cell counts had a small but significant benefit in 
terms of disease progression and mortality (DART, 2010). 
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1.9.3.2. Drug Resistance Testing 
Drug resistance is measured by genotypic or phenotypic testing: Genotypic testing 
involves sequencing of the HIV-1 gene to detect resistance-associated amino acid 
substitutions (i.e. mutations) while phenotypic testing directly quantifies the concentration 
of drug required to inhibit viral replication (Dunne et al., 2001). Although genotypic tests 
are a powerful tool in predicting drug resistance, phenotypic tests are a more direct 
measure of drug resistance. However, both methods require specialisation. Genotypic 
tests require skilled individuals to perform the laboratory tests and interpretation of results 
and phenotypic tests require special facilities (biosafety level 3 laboratory) and 
experienced personnel.   
 
1.9.3.2.1. Genotyping 
Genotypic tests are more widely used since it is less expensive and has a faster turnaround 
time compared to phenotypic tests (one week vs 6 weeks). Standard genotypic tests 
involves PCR amplification and Sanger sequencing (population-based) of the HIV-1 
protease, reverse transcriptase and integrase genes to detect mutations in the majority of 
circulating viruses (Tang and Shafer, 2012). The use of plasma for genotyping is 
considered to be the most appropriate; however dried blood spots (DBS) are an alternate 
specimen for genotyping in areas where preparation and storage requirements are not 
optimal (Bertagnolio et al., 2010). DBS can be stored at room temperature for ≤2 weeks 
and can be easily transported as non-hazardous material (Bertagnolio et al., 2010) 
The length of sequences obtained for protease is up to 99 amino acids, for reverse 
transcriptase is up to 450 amino acids and for integrase is up to 288 amino acids. The 
sequencing process produces an amino acid sequence which is compared to a reference 
subtype B sequence using a resistance interpretation algorithm. There are currently 8 
different resistance interpretation algorithms available for genotypic testing with few 
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differences usually involving relatively infrequent mutations (Liu et al., 2008). These 
algorithms include HIVdb and CPR (Stanford University Medical Center, CA, USA), 
REGA (Rega Institute for Medical Research and University Hospitals Leuven, Katholieke 
Universiteit Leuven, Belgium), ANRS (Agence Nationale de Recherches sur le SIDA), 
Celera Viroseq Genotyping System (Abbott), TRUGENE HIV-1 Genotyping Assay 
(Bayer), HIV-Grade (developed by a German standardisation initiative) and RetroGram 
Guidelines (Virology Networks BV, Utrecht, the Netherlands) (Sing, 2006). The 
algorithm highlights differences between the reference sequence and the clinical virus and 
provides a predicted phenotype to each ARV drug based on the mutations present, which 
in turn assists clinicians in identifying suitable drugs for future use.  
There are two clinically available genotypic resistance tests i.e. Celera Viroseq 
Genotyping System and TRUGENE HIV-1 Genotyping Assay. However, many in-house 
resistance genotyping methods have been developed to make genotyping more cost-
effective in different settings. In addition to population-based sequencing, allele-specific 
PCR (AS-PCR) and ultra-deep pyrosequencing technology has also been used to detect 
resistant mutations in minority variants within a sample. AS-PCR is based on the 
detection of specific point mutations (Johnson et al., 2007). A study reported on the 
development of a multiplex allele-specific (MAS) drug resistance detection assay for 
high-throughput and sensitive detection of multiple HIV-1 drug resistance mutations 
(Zhang et al., 2013). This assay was designed to detect wild-type and mutant alleles at the 
20 loci of HIV-1 subtype C in the protease and reverse transcriptase genes. The limits of 
detection for the different mutations differed from 1.56% to 12%. AS-PCR may be a 
feasible genotyping tool for large-scale drug resistance surveillance and monitoring in 
resource-limited settings. Ultra-deep pyrosequencing sequencing (UDPS) technology has 
been used by many studies to detect minority variants in as little as 1% of the viral 
population (Fisher et al., 2012). A recent study compared the use of UDPS to Sanger 
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sequencing for detecting HIV-1 drug resistant minority variants (Mohamed et al., 2014). 
There was a significant difference in the mutations picked up by UDPS compared to 
Sanger sequencing for 19 ARV drugs where UPS picked up 60% more clinically relevant 
mutations. This suggests that a cut-off of 1% allows for improved characterization of the 
viral population by identifying additional resistance mutations (Mohamed et al., 2014).  
 
1.9.3.2.2. Phenotyping 
Phenotypic susceptibility assays measure the ability of a virus to replicate in cell culture 
in serial dilutions of ARV drugs (Tang and Shafer, 2012). Traditionally, phenotyping 
involved the growing of whole patient viruses in culture in the presence of varying 
amounts of drug. However, modern assays use cloning techniques where the HIV-1 genes 
of interest are cloned into an expression vector after which virus-like particles are 
produced and tested for drug susceptibility. Phenotypic assay can be limited to a single 
cycle of viral replication or allow for multiple rounds of replication. Results are 
interpreted by plotting a sigmoidal dose-response curve of viral growth over the various 
drug concentrations. The inhibitory concentration-50 (IC50) of the clinical virus is 
compared to that of a reference wild-type virus to calculate the fold change (FC) in 
difference in susceptibility. Two commercial phenotypic tests are available, and include 
the Phenosense assay (Monogram Biosciences) and Antivirogram assay (Virco) (Tang 
and Shafer, 2012). Since phenotyping is expensive and labour intensive, is it not 
considered for testing all patients but recommended for patients with complex mutational 
patterns, especially for those selecting salvage options (Chen and Aldrovandi, 2008). 
Phenotyping is also recommended for patients when starting MVC to determine which 
co-receptor the virus is using since MVC is effective only against CCR5-tropic HIV-1.  
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Approved methods for genotypic and phenotypic tests only include the HIV-1 enzymes 
(RT, PR, IN) and mutations outside of these regions are not considered. In the case of 
protease, the impact of gag mutations is not considered which may underestimate PI 
susceptibility to the drugs tested. 
 
1.9.4. Transmitted Drug Resistance  
Current WHO guidelines recommend early ART initiation at CD4 cell counts <500 in an 
attempt to reduce the number of people acquiring infection. With early ART initiation, 
there may be an increased risk of TDR however, this is outweighed by a reduction in new 
infections (Hamers et al., 2013). Currently, an estimated 10 million individuals are on 
ART globally with the majority receiving first-line NNRTI-based therapy (Phillips et al., 
2014). Virological failure on ART is often accompanied by drug resistant mutations 
which can lead to transmission of drug resistant variants (TDR) to treatment naive 
individuals (Phillips et al., 2014). Global surveys have indicated an increase of TDR in 
recently infected individuals in African countries (such as South Africa, Burkina Faso, 
Uganda and Kenya) owing primarily to NNRTI resistance (WHO, 2012). This raises 
concern especially since NNRTIs are used in most first-line regimens and for PMTCT 
(Hamers et al., 2013). K103N is associated with TDR and is found in patients failing first-
line therapies in Gauteng and Kwa-Zulu Natal provinces in South Africa (Hunt et al., 
2012). The PharmAccess African Studies to Evaluate Resistance Monitoring (PASER-M) 
cohort study conducted in ART naive individuals in South Africa, Kenya, Nigeria, 
Uganda, Zambia and Zimbabwe reported a 5.6% prevalence of drug resistant mutations 
(Hamers et al., 2011). 
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A study by Phillips et al. (2014) investigated the effectiveness and cost-
effectiveness of suggested public health responses to TDR. Due to the high potency of 
PIs, mutations accumulate slowly during poor adherence, therefore, the use of PIs in first-
line was the most cost effective option (Phillips et al., 2014). The study also found that if 
the prevalence of NNRTI resistance mutations in treatment naive individuals should 
exceed >10%, a policy to measure viral load 6 months after ART initiation was cost 
effective while individualised pre-treatment resistance testing was not cost-effective. 
With an increasing number of patients initiating ART, there will inevitably be an 
increased prevalence of TDR, however, maintaining adherence and retention on ART will 
help reduce HIV-1 transmission (Phillips et al., 2014).  
 
1.9.5. Acquired Drug Resistance 
1.9.5.1. Acquired Drug Resistance After First-Line ARV Therapy 
Following exposure to NRTIs in first-line therapy, many individuals develop NRTI 
resistance mutations. Because of high rates of 3TC usage, M184V is very common 
following NRTI treatment but results in reduced viral fitness (Lazarus et al., 2013). A 
study has also shown that patients who are failing therapy due to adherence or drug 
resistance and for whom new drugs are currently unavailable, 3TC monotherapy may be 
used as a holding strategy since it selects for M184V thereby maintaining viral load 
suppression (Lazarus et al., 2013). WHO surveys on acquired drug resistance in adults 
have shown that 12 months after therapy initiation, 91% of patients achieved viral 
suppression, and of the patients failing therapy, 72% had resistance mutations (WHO, 
2012). The drug resistance mutations observed at 12 months suggested that the current 
NRTIs used in second-line combined with a boosted PI would be effective for most 
patients (WHO, 2012).  
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Most patients treated with NVP in first-line therapy develop mutations which compromise 
the effectiveness of future NNRTIs used (Hamers et al., 2013). Mutations selected by 
NVP such as L100I, K101P and Y181IV cause cross resistance to new NNRTIs ETR and 
RPV (Rhee et al., 2003). In addition to these mutations, K103NS, V106AM, Y188LC, 
G190SE and M230L also selected by use of NVP, confer resistance to EFV (Rhee et al., 
2003).  
 
1.9.5.2. Acquired Drug Resistance After Second-Line ARV Therapy 
Protease inhibitors are commonly used in second line regimens. It has been shown that 
boosted PI-based regimens can re-suppress HIV-1 replication even in the presence of 
numerous NRTI mutations (Hosseinipour et al., 2010). However, the use of boosted PI 
monotherapy has been investigated by a few studies and is currently not recommended. 
The ACTG5230 trial found that a third of patients receiving PI monotherapy did not 
achieve complete viral suppression after 24 weeks (Bartlett et al., 2012). Protease 
inhibitor monotherapy was also found to be inferior to triple therapy with NNRTIs in the 
HIV Star Study (Bunupuradah et al., 2012). In resource-limited settings, rates of virologic 
failure on PI-based therapy have been shown to be quite high. However, virological 
failure was associated with poor adherence rather than drug resistance. Therefore 
maintenance of adherence is crucial to avoid unnecessary switching to more expensive 
regimens (Ajose et al., 2012). 
 
1.9.5.3. Acquired Drug Resistance After Prevention of Mother-to-Child 
Transmission (PMTCT) 
The use of single dose NVP (sdNVP) for PMTCT has shown to rapidly select for NNRTI 
mutations thereby compromising subsequent NNRTI-based regimens (Jourdain et al., 
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2004). Following revision of the WHO PMTCT guidelines in 2010, the use of combined 
ART is advocated either as dual therapy (Option A) or triple therapy (Option B) 
(Bateman, 2013). The use of sdNVP together with AZT in women from Mozambique and 
Kenya showed reduced postpartum NVP resistance (Micek et al., 2012, Kesho Bora 
Study and de Vincenzi, 2011). In addition, women who received triple ART in Botswana 
had no resistance after one month of PMTCT discontinuation (Souda et al., 2013). A 
further recommendation by the WHO in 2013 suggested that all HIV-1 positive pregnant 
women be put on triple therapy for life (Option B+) regardless of CD4+ cell count 
(Bateman, 2013). This is expected to reduce the HIV-1 mother-to-child transmission rate 
especially in subsequent pregnancies (Thyssen et al., 2013) 
 
1.9.5.4. Acquired Drug Resistance After Pre-Exposure Prophylaxis (PrEP) 
PrEP is used to protect HIV-uninfected individuals before sexual exposure from an HIV-
infected partner (FDA, 2012). The results of different trials investigating the effectiveness 
of PrEP have produced conflicting results primarily due to differences in regimen 
acceptance and adherence with different population groups studied. The Centre for the 
AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the 
effectiveness and safety of a 1% vaginal gel formulation of TDF, for the prevention of 
HIV acquisition in women (Abdool Karim et al., 2010). It was found that the TDF gel 
reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high 
gel adherence. There was an absence of mutations suggesting little immediate risk of 
TDF-resistant HIV-1 emergence in the seroconverters (Wei et al., 2014). Although further 
studies are needed to evaluate drug resistance acquired from PrEP, a modelling study 
showed that drug resistance from ART is much greater than that from PrEP (Parikh and 
Mellors, 2012). 
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1.9.6. WHO Paediatric Drug Resistance Surveillance 
There was an estimated 740 000 children living with HIV-1 globally by the end of 2013, 
and of these 23% were receiving ART (WHO/UNAIDS, 2013). Monitoring and collecting 
data on HIV-1 infected children is important as these children require life-long care and 
treatment. Currently there is limited surveillance data on infants and children.  
 
Although the use of NNRTIs in pregnant and breastfeeding women results in a much 
lower proportion of children being infected with HIV-1, some children are infected with 
NNRTI resistant variants (Bertagnolio et al., 2012). This compromises the use of NNRTI-
based regimens as first-line treatment in these children. The WHO, HIV Resistance 
Network (HIVResNet) and the Centers for Disease Control (CDC) developed a 
surveillance protocol to assess drug resistance among children <18 months of age and 
newly diagnosed with HIV-1 using dried blood spots (Bertagnolio et al., 2012). This 
surveillance programme was designed to be repeated over time so that evolving drug 
resistance patterns could be monitored as PMTCT regimens change and coverage 
increases (Bertagnolio et al., 2012). The programme requires minimal infrastructure and 
resources, and can be easily implemented therefore encouraging countries to monitor 
paediatric HIV-1 drug resistance over time (Bertagnolio et al., 2012).  
 
It is important to monitor the PMTCT program and HIV-1 drug resistance in order to  
support decision making about paediatric ART guidelines. 
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1.10. Project Aim and Objectives 
 
Due to the limited knowledge of drug resistance in subtype C paediatric patients failing 
PI-based therapy, this study aimed to investigate the effect of gag on PI resistance in 
paediatric patients at baseline and failing a PI-based regimen. The objectives of this study 
were as follows: 
 
1. To genotype the HIV-1 gag-pol region of paediatric patients failing a PI-based regimen 
and to compare these to the baseline sequences. 
2. To phenotypically assess the effect of patient-derived gag-protease on susceptibility to 
lopinavir and ritonavir. 
3. To determine the levels of cross-resistance to other PIs conferred by patient-derived 
gag-protease. 
4. To assess the impact of key protease and gag mutations introduced by site-directed 
mutagenesis on phenotypic resistance.  
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Chapter Two 
Materials and Methods 
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2.1. Summary 
 
Plasma samples from 20 matched paediatric patients at baseline (pre-treatment) and 
failing a protease inhibitor (PI)-based therapy were genotyped to identify changes in HIV-
1 subtype C gag and protease. In addition, amino acid changes at gag cleavage sites (CS) 
and non-CS sites were analysed to determine if they were associated with the 
development of PI resistance, and/or under HLA and/or KIR immune-mediated pressure. 
The gag-protease products from both the baseline and failing samples were cloned into an 
expression vector.  The resulting clones were tested in vitro using a single-cycle assay to 
identify the susceptibility of the patient-derived gag-proteases to different protease 
inhibitors. The IC50 of the failing samples were compared to that of the baseline samples 
to determine the fold change in susceptibility. Site-directed mutants were generated based 
on specific gag and protease changes found in the patient samples. These mutants were 
phenotyped using the single cycle assay to determine their individual contribution to PI 
susceptibility.  
 
2.2. Cohort Details 
A retrospective cohort study was undertaken on 20 matched baseline and post-treatment 
plasma samples from children less than 24 months of age and failing PI-based therapy. 
These children were initiated on treatment and followed as part of the pre-randomization 
screening phase of a randomized clinical trial between 2005 and 2009 (Coovadia et al., 
2010, Reitz et al., 2010). Children over 6 months of age were treated with lamivudine 
(3TC), stavudine (d4T) and ritonavir-boosted lopinavir (LPV/r) as per standard clinical 
practice at the time. Those younger than 6 months of age and those receiving rifampicin-
based regimens for treatment of tuberculosis or Bacille Calmette Guerin (BCG) disease 
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received ritonavir (RTV) until reaching 6 months of age and/or completing TB treatment 
at which point they were started on or returned to a LPV/r-based regimen. For children 
who suppressed and then rebounded, genotyping was done on the first sample where an 
elevated viral load was observed.  For children who did not suppress, a sample within the 
first 3 to 6 months of treatment was selected. This study was approved by the institutional 
review boards of Columbia University (NEVEREST II M040912) and the University of 
the Witwatersrand (M110971). 
 
2.3. Genotypic Analysis of HIV-1 gag and protease Genes 
 
The HIV-1 gag and protease genes from paediatric patients were genotyped to identify 
genetic changes at baseline and PI failure. The sequences and positions relative to the 
HXB2 viral genome of the primers used for the sequencing of HIV-1 gag-protease are 
shown in Table 2.1. Components used in the cDNA synthesis mixture are shown in Table 
2.2. An alignment of the primers relative to the HIV-1 gag-protease genes are shown in 
Figure 2.2.  
 
2.3.1. RNA Extraction 
Extraction of RNA was performed using the QIAamp Viral RNA Mini Kit (QIAGEN, 
Belgium) according to the manufacturer’s protocol. Briefly, RNA was extracted from 140 
μl of plasma using a spin-column procedure carried out in an Eppendorf Centrifuge 
5415D (Eppendorf, Germany). The viral RNA was eluted in 50 μl elution buffer (RNase-
free). 
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2.3.2. cDNA Synthesis 
The Thermoscript RT-PCR kit (Invitrogen, CA, USA) was used for cDNA synthesis. The 
HXB2 position and sequence of the gene specific primer (3’InProt) used for cDNA 
synthesis is shown in Table 2.1. In a 0.2 μl tube, a reaction mixture (Table 2.2) containing 
10 μl of the patient specific RNA was denatured on a GeneAmp 9700 thermal cycler 
(Applied Biosystems, Carlsbad, CA) at 65˚C for 5minutes. Following denaturation, 7 μl 
of the cDNA mastermix (Table 2.3) was added to the RNA and run on the thermal cycler 
for 1 hour at 53˚C, followed by 5 minutes at 85˚C and a final hold at 4˚C. One microlitre 
of RNase H was added to each reaction to ensure degradation of RNA still bound to 
cDNA and incubated a 37˚C for 20 minutes. A negative control (distilled water) was used 
for all reactions set up. Reactions were either used immediately for 1st round PCR or 
stored at -20˚C.  
 
Table 2.1. Primers used for cDNA synthesis and amplification of the gag-protease region  
 
 Primer 
Name 
HXB2 
Positions 
Primer Sequence (5’ – 3’) 
cDNA Synthesis 3’InProt 2569 to 2593 CCTGGCTTTAATTTTACTGGTACAG 
1st round PCR BKT03 690 to 706 CGCAGGACTCGGCTTGC  
ProOutR 2589 to 2607 TTGGGCCATCCATTCCTGG  
2nd Round PCR GagNot 769 to 798 GCGGCGGCCGCAAGGAGAGAGATGGGTGCG 
ProXhoR2 2550 to 2570 CTGGTACAGTCTCGAGRGGACTRATKGG 
First- and second-round PCR primers were previously described by Sutherland et al. (2013). 
Primer 3’InProt was designed by Dr Michelle Gordon. 
 
Table 2.2. Components of the cDNA synthesis mixture 
 Final Concentration μl / reaction 
Primer 3’ InProt 10μM 1 
dNTP 10μM 2 
Water  1 
RNA  10 
Final Reaction Volume  14 
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Table 2.3. cDNA Mastermix 
 Final Concentration μl / reaction 
Thermoscript buffer 5x 4 
DTT 0.1 M 1 
RNase OUT 40 U/μl 1 
Thermoscript RT 15 U/μl 1 
Final Reaction Volume  7 
 
 
 
2.3.3. Amplification of HIV-1 gag-protease 
 
The Expand High Fidelity PCR System (Roche Applied Science, Basel, Switzerland) was 
used for first and second round nested PCR (Tables 2.4 and Table 2.5). Two microlitres 
of cDNA was used as a template for first round amplification. For the first-round PCR, 
the thermal cycler was programmed for 2 minutes at 94°C for initial denaturation, 
followed by 35 cycles of 30s at 94°C for denaturation, 30s at 53°C for annealing, 2 
minutes at 72°C for extension, and 7 minutes at 72°C for the final extension. For the 
second-round PCR it was the same as the first-round except for the annealing step that 
was reduced to 51°C. To confirm the presence of positive PCR products after nested 
(second-round) PCR four microlitres of PCR product was loaded with 1 μl of GelPilot 
DNA 5x loading dye (QIAGEN, Belgium), on a 0.7% agarose gel and run at 100V for 45 
minutes. An example of the correct gag-protease PCR product on a gel is shown in 
Figure 2.1. The gel was viewed on a Bio-Rad ChemiDoc XRS Imaging system (Bio-Rad, 
CA, USA). 
 
Table 2.4. First-round PCR mastermix 
 Final Concentration μl / reaction 
dH2O  17.9 
Expand HiFi Buffer/MgCl2 1x 6 
dNTP 0.2 mM 0.6 
Primer BKT03 0.5 μM 1.5 
Primer ProOutR 0.5 μM 1.5 
Expand HiFi Enzyme 0.05 U/μl 0.5 
Final Reaction Volume   28 
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Table 2.5. Second-round PCR mastermix 
 
 Final Concentration μl / reaction 
dH2O X 17.9 
Expand HiFi Buffer/MgCl2 1x 6 
dNTP 0.2 mM 0.6 
Primer GagNot 0.5 μM 1.5 
Primer ProXhoR 0.5 μM 1.5 
Expand HiFi Enzyme 0.05 U/μl 0.5 
Final Reaction Volume  28 
                     
                                 
 
Figure 2.1. Picture of a PCR gel showing the presence of 1.8 kb gag-protease fragments 
A DNA molecular weight marker VI (0.15-2.1 kbp) (Roche Applied Sciences, Mannheim, 
Germany) was used to identify the 1.8 kb fragment. A negative control was included in each assay 
which consisted of distilled water instead of template DNA. A positive control was a sample 
which had previously amplified. 
 
 
2.3.3.1. Purification of PCR Products 
Amplified products were purified using the QIAquick PCR Purification Kit (QIAGEN, 
Belgium). Binding buffer was added to the PCR product and this mixture was applied to 
the QIAquick spin column which has a silica membrane to allow the binding of DNA in 
high salt conditions provided by the buffer. The column was spun down in a Heraeus 
Biofuge fresco centrifuge (Thermo Electron Corporation, Germany) at 13 000 x g for 1 
bp 
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minute. The column was washed with wash buffer at 13 000 x g for 1 minute twice, to 
remove all impurities from the DNA samples. Pure DNA was eluted with 55 μl in a low 
salt elution buffer. 
 
2.3.4. Sequencing of HIV-1 gag-protease 
 
The sequencing reaction was performed using the BigDye® Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, California, USA) (Table 2.10). Primers used for 
sequencing the HIV-1 gag and protease genes from the baseline and failing samples are 
shown in Table 2.6. and Figure 2.2. The sequencing reaction was plated in a MicroAmp 
Optical 96-well Reaction Plate (Applied Biosystems, China) and sealed with Microseal 
plate covers (Bio-Rad, UK). The reaction was performed on GeneAmp 9700 thermal 
cycler (Applied Biosystems, Carlsbad, CA). The thermal cycler was programmed for 1 
minute at 96°C for initial denaturation, followed by 35 cycles of 10s at 96°C for 
denaturation, 5s at 50°C for annealing, 4 minutes at 60°C for extension and a final hold at 
4°C.  
Table 2.6. Primers used for sequencing the gag-protease region  
 
Primer Name HXB2 Positions Primer Sequence (5’ – 3’) 
GagNot  769 to 798 GCGGCGGCCGCAAGGAGAGAGATGGGTGCG 
Gag1F* 1090 to 1109 TTAGACAAGATAGAGGAAGA 
Gag1.5R*  1414 to 1431 TCTATCCCATTCTGCAGC 
Gag2F 1825 to 1844 ATGATGACAGCATGTCAGGG 
DuGagIn2  1282 to 1303 ACATGGGTATTAGCTCTGGGCT 
ProXhoR2 2550 to 2570 CTGGTACAGTCTCGAGRGGACTRATKGG  
Gag5F* 1697 to 1716 CTTTAAGAGCTGAACAAGCT 
Gag6R* 1771 to 1790 AAAATGGTCTTACAATCTGG 
Primers marked with an asterisk were designed by Dr Michelle Gordon. Primer DuGagIn2 was designed by 
Dr Jaclyn Wright. Primers GagNot, Gag2F and ProXhoR2 were previously described by Sutherland et al. 
(2013). 
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Figure 2.2. Diagram illustrating the positions of the primers used for PCR and sequencing 
Positions of forward primers (green) and reverse primers (red) which were used for PCR 
amplification and sequencing of gag-protease are shown.  
 
                            
Table 2.7. Sequencing mastermix 
 
 Final Concentration μl / reaction 
dH2O  5 
5x Buffer 0.75x 1.5 
BigDye  1 
Primer  0.48 μM 1.5 
DNA  ~ 50 -100 ng 1 
Final Reaction Volume 10 
                              
 
2.3.4.1. Sequencing Cleanup 
Prior to running the sequencing reaction on the ABI 3130xl Genetic Analyser (Applied 
Biosystems, Foster City, CA), the reaction was cleaned up by sodium acetate 
precipitation. A mixture containing 3.0 M sodium acetate (pH 4.6) and 100% ethanol was 
prepared. The amount required was calculated according to the number of samples being 
sequenced: 1 μl/well of 3.0 M sodium acetate + 25 μl/well of 100% ethanol. Twenty-six 
microlitres of the sodium acetate and ethanol mix was added to each well and mixed 
using a multi-channel pipette. The plate was sealed with Microseal plate covers (Bio-Rad, 
UK) and centrifuged in a Jouan B4i multifunction centrifuge (Thermo Electron 
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Corporation, Germany) at 2000 x g for 30 minutes to allow the DNA to be precipitated. 
The plate seal was then removed and the plate was inverted and centrifuged at 150 x g for 
1 minute to remove all sodium acetate and ethanol. To wash the DNA pellet, 35 μl of 
70% ethanol was added to each well, the plate was sealed and centrifuged at 2000 x g for 
5 minutes. The plate seal was removed and the plate was inverted and centrifuged at 150 
x g for 1 minute to remove remaining ethanol. The pellet was then dried on a thermal 
cycler at 65˚C for 5 minutes. Prior to sequencing, the dried pellet was resuspended with 
10 μL formamide and denatured in a thermocycler at 95°C for 3 minutes. The samples 
were loaded and run on the ABI 3130xl Genetic Analyser which is a 16-capillary 
electrophoresis system which allows for increased sequencing throughput.  
 
2.3.4.2. Sequence Analysis 
Sequences were analysed on Sequencher 4.10.1 sequence analysis software (Gene Codes 
Corporation, Ann Arbor, MI USA). Each sequence read was assembled to form a contig. 
The ends of each contig were manually trimmed off to remove regions which were 
ambiguous. Each contig was exported in a fasta file format for analysis with other 
sequencing analysis programs. Patient sequences were imported into and aligned using 
ClustalW in BioEdit version 7.0 (Hall, 1999). Sequences were aligned with HXB2 and 
consensus C.  
 
Major and minor PI mutations were identified using the Stanford Drug Resistance 
Database algorithm (http://hivdb.stanford.edu/). Changes in gag at baseline were 
identified by comparing each sequence to consensus C. Subtype C consensus sequence 
was downloaded from the Los Alamos Sequence Database 
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). Changes at failure 
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were defined as those developing following PI therapy compared to baseline sequences. 
Changes at gag CS and non-CS which have been associated with PI resistance from the 
literature were noted. All sequences were aligned to HXB2 to determine the appropriate 
numbering of amino acids and also aligned to consensus C to compare the baseline 
samples to. A phylogenetic tree was constructed using MEGA version 5.05 (Tamura et 
al., 2011) for quality control purposes and to ensure clustering of the baseline and failing 
sample sequence. Bootstrap was set at 1000 replicates.  
 
2.4. Prediction of HLA and KIR Associated Mutations 
Genetic changes in gag which have not been previously associated with PI resistance 
were investigated for their association with immune escape via HLA and KIR-mediated 
immune pressure. A published immune escape map was used to identify HLA-associated 
immune escape mutations selected in the patients gag gene (Figure 2.3). Briefly, the q-
value threshold used for constructing the immune escape maps was q ≤ 0.05, meaning 
that only a 5% false-positive proportion was expected among associations displayed on 
the maps. All changes in gag associated with HLA-mediated immune pressure on the 
escape map and present in the patient sample was noted. KIR-associated sequence 
polymorphisms in gag were identified in a study (Alter et al., 2011) at 5 different codons 
(Table 2.8) and these codons were compared to changes in the patient’s gag sequences.  
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Figure 2.3. Gag immune escape map. 
The location according to HXB2, specific residues and HLA restrictions of HLA-associated 
polymorphisms are shown. The map is based on HIV-1 consensus B amino acid sequence. The 
alternating black and brown letters in the consensus amino acid sequence distinguish the different 
proteins in HIV-1 Gag (MA, CA, p2, NC, p1, p6). The map shows all HLA-associated 
polymorphisms with q≤0.05. Picture taken from Brumme et al. (2009).   
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Table 2.8. KIR footprints in HIV-1 gag sequence 
 Amino-acid 
Position 
KIR association Consensus 
amino acid 
1 93 KIR2DS3 E 
2 138 KIR2DL2 L 
3 138 KIR2DS2 L 
4 371 KIR2DS5 T 
5 389 KIR3DS1 T 
6 479 KIR2DS1 I 
 
2.5. Positive Selection in Patient gag Genes 
The fixed effects likelihood (FEL) test was performed using Datamonkey 
(http://www.datamonkey.org/) (Kosakovsky Pond and Frost, 2005) to test for selection 
pressure and estimate the ratio of synonymous to non-synonymous (dN/dS) evolutionary 
changes. Calculations were performed for the entire dataset containing 20 gag baseline 
and failure nucleotide sequences. Fasta files containing aligned sequences were submitted 
to the database. The program FEL estimates the probability of obtaining the dN and dS 
values under a neutral mode, with lower P –values indicating rejection of neutrality in 
favour of positive selection. Positions with a dN/dS ratio >1 were considered to be under 
positive selection pressure.  
 
2.6. Phenotypic Analysis of HIV-1 gag and protease Genes from Patient 
Samples  
 
Phenotypic analysis of the patient-derived gag-protease genes was done to determine the 
effect of gag and protease on PI susceptibility. For the expression of HIV-1 gag-pol, a 
HIV-1 expression vector, p8.9NSX+, was used. Virus-like particles or pseudoviruses that 
are produced with this expression vector are capable of a single infectious event (Parry et 
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al., 2009, Sutherland et al., 2013). The p8.9NSX+ vector contains a NotI restriction site at 
the beginning of gag (HXB2 position 772) and a XhoI restriction site at the end of 
protease (HXB2 position 2563). This allows for the cloning of a 1.8kb gag-protease 
fragment from patient samples (Fig 2.4). Gag-protease amplicons from the patient 
samples contained NotI and XhoI restriction sites which were introduced by the second 
round primers (Chapter 2.3.3) to allow cloning into p8.9NSX+. The clones with inserts of 
the correct size, assessed by NotI/XhoI restriction were sequenced to confirm the presence 
of the relevant mutations and polymorphisms. Polymorphisms in the protease and gag 
genes were defined as changes in amino acid sequence between the failing and baseline 
sequences. The sequences were submitted to the Stanford drug resistance database 
(http://hivdb.stanford.edu/) to determine the phenotypic levels of resistance based on 
mutation penalty scores which have been based on previously published phenotypic data. 
The mutation penalty scores are based on three considerations: studies linking mutations 
to ARV therapy; studies linking mutations to decreased ARV susceptibility; and studies 
linking pre-therapy mutations with the virological response to a new ARV treatment 
regimen 
 
2.6.1. Cloning of Patient-derived gag-protease Genes  
The purified gag-protease PCR products (see Chapter 2.3.3.1.) were first cloned into a 
commercial vector (pCR-2.1 TOPO) to allow for more efficient cloning into the 
expression vector. This process was also found to reduce the number of false positive 
clones. 
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2.6.1.1. Cloning into pCR 4-TOPO Cloning Vector 
Purified second-round PCR products were cloned into a pCR-2.1 TOPO cloning vector 
(TOPO TA Cloning Kit, Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. The TOPO TA cloning kit consists of a plasmid vector (pCR 4-TOPO) that has 
a 3’ thymidine overhang to allow it to ligate to the deoxy-adenosine at the 3’end of PCR 
products which was inserted by Taq polymerase.  
To clone the PCR product into the pCR-2.1 TOPO vector, 40 ng of the PCR product was 
used. The reaction mixture for the TOPO cloning is shown in Table 2.9. The reaction was 
incubated at room temperature for 5 minutes to allow the vector and PCR product to 
ligate.  
 
2.6.1.1.1. Transformation into One Shot TOP 10 Competent Cells 
The pCR 4-TOPO construct was then transformed into One Shot TOP 10 chemically 
competent E. coli cells. Two microlitres of the cloning reaction was added to a vial of 
competent cells and mixed by flicking the tube gently. The reaction was incubated on ice 
for 30 minutes. The cells were then heat-shocked for 30 seconds at 42˚C and placed on 
ice to stop the reaction. Two hundred and fifty microlitres of S.O.C medium was added to 
tube, and placed in the shaking incubator (225 rpm) for 1 hour at 37˚C. Fifty microlitres 
of the reaction was plated on pre-warmed agar plates and incubated at 37˚C for 16 hours. 
Clones carrying the correct inserts were confirmed by colony PCR and sequencing. 
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Table 2.9. TOPO cloning reaction mastermix 
Reagent Volume (μl)  
Fresh PCR product (~ 80 ng) 0.5 – 4  
Salt solution 1 
Water Add to a total volume of 5 μl 
TOPO vector (10 ng/μl) 1 
Final Volume 6 
 
2.6.1.1.2. Colony PCR 
To screen for positive colonies, PCR was performed using primers GagNot and Gag 1.5R 
and a thermostable DNA polymerase SuperTherm (Table 2.10). The master mix was 
added to a 96-well plate. A masterplate was created by spotting colonies on a specific 
area of the LB agar plate using a pipette tip and then touching that tip in a corresponding 
well containing PCR mastermix. The DNA and mastermix were placed in the thermal 
cycler which was programmed for 2 minutes at 94°C for initial denaturation, followed by 
30 cycles of 30s at 94°C for denaturation, 30s at 53°C for annealing, 45s at 72°C for 
extension, and 2 minutes at 72°C for the final extension. 
 
To identify positive PCRs containing positive colonies a 0.7% agarose gel was run at 100 
V for 45 minutes. The gel was visualized under UV-light and bands of the correct size 
identified. Corresponding bacterial colonies on the master plate were grown up overnight 
in 5 ml LB-ampicillin (100 μg/ml) broth in a shaking incubator at 225 rpm.  
 
Table 2.10. Colony PCR mastermix 
 Final Concentration μl / reaction 
10X Buffer 1x 1 
MgCl2 1.5mM 0.5 
GagNot 0.2μM 0.2 
Gag 1.5R 0.2μM 0.2 
dNTP 0.08mM 0.8 
SuperTherm 1.25U 0.03 
Water  7.3 
Final Reaction Volume  10.00 
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2.6.1.1.3. Plasmid Extraction 
The following day, DNA from each clone was extracted from bacterial cultures using the 
QIAprep Spin miniprep kit (QIAGEN, Belgium) according to the manufacturer’s 
protocol. The QIAprep kit comes with spin columns which have a silica membrane that 
binds up to 20 μg plasmid DNA. The bacterial cultures were spun down in a Hettich 
centrifuge (Hettich, Germany) at 5000 rpm for 10 minutes to pellet the bacteria. The 
supernatant was discarded and the bacteria were lysed with lysis buffer. This reaction was 
neutralized with neutralization buffer and centrifuged at 13 000 x g for 10 minutes to 
separate the supernatant containing bacterial DNA from the waste products. Lysed 
bacteria was added to the silica membrane of the QIAprep spin columns and centrifuged 
at 13 000 x g for 1 minute to allow for the DNA to be adsorbed onto the membrane. Wash 
buffer was added to the membrane and centrifuged at 13 000 x g to wash away impurities 
from the membrane. Pure DNA was eluted in 55 μl of elution buffer. The extracted 
plasmid DNA was quantified on the NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, DE, USA). The clones were sequenced (see Chapter 2.3.4.) to identify 
those with the correct insert. Sequences generated were analysed on Sequencher 4.10.1 
sequence analysis software (Gene Codes Corporation, Ann Arbor, MI USA). Clustal W in 
BioEdit sequence alignment editor was used for alignment of sequences. Phylogenetic 
trees were generated using Molecular Evolutionary Genetics Analysis (MEGA) 5.0 as a 
quality control to identify possible DNA contamination.  
 
2.6.1.2. Cloning into p8.9NSX+ Expression Vector 
2.6.1.2.1. Digestion of TOPO Clones and p8.9NSX+ Expression Vector 
Clones were digested using restriction enzymes Not I and Xho I as shown in Figure 2.4. 
and Table 2.11. The reaction mixture was incubated at 37˚C for 2hrs and heat inactivated 
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at 65˚C for 15 minutes. To confirm successful restriction of products, all sample digests 
were run on a 0.7% agarose gel at 100V for 1.5hrs as shown in Figure 2.5. As a control an 
unrestricted plasmid (p8.9NSX+) was included.  
 
 
Figure 2.4. Cloning of patient-derived and p8.MJ4-derived gag-protease into the p8.9NSX+ 
expression vector 
Restriction enzymes (Not I and Xho I) were used to digest p8.9NSX+ and allow for cloning of 
patient-derived (baseline and failure) and p8.MJ4 derived gag-protease resulting in a patient-
derived expression vector and p8.9MJ4GP respectively. The p8.9MJ4GP vector was used as a 
control in each assay containing patient samples and was also used to calculate the assay cut-offs 
for the PIs tested.  
 
 
Table 2.11. Digestion of TOPO clones and p8.9NSX+ expression vector 
 Final Concentration μl / reaction  
TOPO patient clone 1 μg X 
p8.9NSX+ plasmid vector 1 μg X 
Buffer A  2 
Not I 0.02 0.5 
Xho I 0.02 0.5 
Total   19 
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Figure 2.5. Picture of a gel showing the digested products from the TOPO clones 
A DNA molecular weight marker X (0.07-12.2kbp) (Roche, Mannheim, Germany) was used to 
identify clones with the correct sized inserts (1.8 kb).  
 
2.6.1.2.2. Gel purification of Insert from TOPO Vector 
The insert bands of the patient-derived gag-protease and the vector band were cut out of 
the gel with brief exposure to ultraviolet (UV) light as to minimize DNA damage through 
thymine dimerization. The DNA products were gel purified using the PureLink Quick Gel 
Extraction kit (Life Technologies, Germany) according to the manufacturer’s protocol. 
The kit allows for the removal of primers, dNTPs, enzymes and salts from the PCR 
product. Binding buffer and was added to the gel slice and heated on a heating block at 42 
˚C for 15 mins and vortexing every 5 minutes. This was to ensure complete dissolution of 
the DNA in the binding buffer. This sample was added to a spin column and centrifuged 
at 10 000 x g for 1 minute to allow the DNA to bind to the silica-based membrane. The 
membrane was then washed with Wash buffer at 10 000 x g for 1 minute. DNA products 
were eluted in 35 μl Elution buffer and quantified on the NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific, USA).  
 
 
 
bp 
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2.6.1.2.3. Dephosphorylation of p8.9NSX+ Expression Vector 
The Rapid DNA Dephos and Ligation kit (Roche, Basel, Switzerland) was used for 
dephosphorylation of the vector and ligation step. The rAPid Alkaline Phosphatase 
included in the kit, removes phosphate groups from the DNA thereby preventing vector 
self-ligation and reducing vector background when cloning. To dephosphorylate the 
p8.9NSX+ vector, 3μl Rapid Dephos (10X) Buffer and 1μl Rapid Dephos Enzyme (1 
U/μl) was added to the digested vector. This mixture was incubated at 37˚C for 30 
minutes and heat-inactivated at 75˚C for 2 minutes. 
 
2.6.1.2.4. Ligation of Patient-derived gag-protease with p8.9NSX+ Expression Vector 
For ligation of the 1.8kb gag-protease insert with the restricted 10.2kb p8.9NSX+ 
expression vector the ratio of vector-to-insert was 1 copy (114 ng): 3 copies (86 ng). This 
ratio was to increase the chances of the insert ligating with the vector and to prevent the 
vector from self-ligating. For efficient cloning, the total DNA amount did not exceed 200 
ng. The Rapid DNA Dephos and Ligation kit (Roche, Basel, Switzerland) was used for 
ligation. DNA ligation involves creating a phosphodiester bond between the 3' hydroxyl 
group of one nucleotide and the 5' phosphate of another. The reagents used to make the 
ligation mastermix are shown in Table 2.12. The amount of vector and insert differed for 
each reaction according to their concentrations. T4 DNA Ligase which is included in the 
lit is used to ligate DNA fragments which have blunt ends. To each reaction 10μl T4 
DNA ligation buffer and 1μl T4 DNA ligase was added. The ligation mixture was 
incubated at 25˚C for 30 minutes and used directly for transformation or stored at -20˚C.  
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Table 2.12. Ligation mastermix 
 Final Concentration μl / reaction 
DNA dilution buffer 1x 2 
Plasmid vector  X 
Gag-protease insert  X 
Water  3.7 
Final Reaction Volume  10 
The final concentration of the plasmid vector and insert was different  
for each patient but had a ratio of 1: 3 and did not exceed a total  
concentration of 200 ng. 
 
 
2.6.1.2.5. Transformation into XL-Gold Ultracompetent E.coli Cells 
For efficient transformation of the 12kb vector+insert XL10-Gold Ultracompetent cells 
E.coli cells (Stratagene, California) were used. The competent cells were thawed on ice 
till the last ice crystals disappeared. Two microlitres of β-Mercaptoethanol was added to 
45μl of competent cells and incubated for 10 min on ice while flicking every 2 minutes to 
mix cells and β-Mercaptoethanol. Two microlitres of ligation mixture was added to the 
cells and left on ice for 30 min. The cells were heat shocked in a 42ºC water bath for 30 
seconds without shaking and then placed on ice for 2 minutes. Five hundred microlitres of 
pre-warmed S.O.C medium was added to the tubes and incubated in a 37ºC shaker for 1hr 
at 225 rpm. Transformed bacterial cells were then pelleted at 4000 x g for 3 minutes. Four 
hundred and fifty microlitres of supernatant was removed and the pellet was resuspended 
in 100 µL of the remaining supernatant and plated on pre-warmed LB-ampicilin (100 
μg/ml) agar plates. Plates were inverted and incubated at 37ºC for ~16hrs. Clones 
carrying the correct inserts were confirmed by colony PCR, extraction of plasmid DNA 
and sequencing as described in Chapter 2.6.1.1.2. 
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2.6.2. Transfection of Patient-derived gag-protease Clones 
Susceptibility of the patient-derived gag-protease genes to the different PIs was 
determined using a vector-based non-replicative phenotypic assay (Figure 2.6) was used 
as previously described (Parry et al., 2009, Gupta et al., 2010), with minor modifications. 
The expression vector p8.9NSX+ in which the gag-protease genes were inserted only 
contained HIV-1 gag-pol and none of the other HIV-1 proteins. Baseline and failure 
clones were transfected into HEK293T cells in 6-well plates. DNA transfection mixes 
were prepared with 300 ng of plasmid pMDG, 500 ng of plasmid pCSFLW and 300 ng of 
patient derived expression vector. The pMDG vector encodes the vesicular stomatitis 
virus G protein which associates with envelope-deficient plasmid DNA to enhance DNA 
transfection. The pCSFLW plasmid encodes the firefly luciferase reporter gene needed 
for measuring luciferase activity in the target cells.  
To enhance transfection, 3.3 ug polyethylenimine (PEI) (Polyscience, Inc., 
Warrington, Pennsylvania, USA) was added to Dulbecco’s Modified Eagles Medium 
(DMEM) (Gibco, New York) containing fetal bovine serum (FBS) and antibiotics (see 
Appendix I), gently swirled to mix and incubated for 2 minutes at room temperature. The 
DNA mix containing the vectors was added to the media drop by drop, swirled to mix and 
incubated at room temperature for 10 minutes. The transfection mix was then added to the 
6-well plates at incubated at 37˚C for 18 hours. Transfected cells were harvested and 
seeded in the presence of three-fold serial dilutions of protease inhibitors (drug plate). 
Fresh HEK293T cells were plated (1x106 cells/ 96-well plate) and incubated for 24 hours. 
Supernatants containing infectious virus-like particles were transferred from the drug 
plate to the corresponding wells of a 96-well cell culture plate that contained fresh 
uninfected 293T cells in complete DMEM medium.  
The final concentration of PIs used is shown in Table 2.13. The degree of 
infection was determined by the expression of firefly luciferase in infected target cells at 
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48 hours post-infection. Bright-Glo Luciferase (Promega, CA, USA) was added to each 
well and incubated for 2 minutes prior to reading the luminescence on the Victor 3 
Luminometer (Perkin Elmer, Massachusetts).  
 
For each drug-virus combination, the 50% inhibitory concentration (IC50) was 
calculated. The phenotypic susceptibility of patient samples at PI failure was expressed as 
a fold-change (FC) in IC50, relative to that of the baseline virus. For the site-directed 
mutants, the phenotypic susceptibility was expressed as a FC in IC50, relative to that of 
the control, p8.MJ4. Assay cut-offs are shown in Table 2.15. The lower FC cut-off value 
for each drug was determined using the 99th percentile of the average IC50 for p8.MJ4GP 
(control for patient samples) assessed in multiple repeat screens of each drug (Table 
2.15). The cut-off values used in this study were not linked to clinical correlates or 
outcomes. The classifications susceptible, reduced susceptibility and resistant serve to 
rank the response of the PIs used in our assay. Examples of the different phenotypic 
classifications for patients are shown in Figure 2.10. The curve for a susceptible patient 
virus is characterised by a little or no change in IC50 compared to the baseline sample. 
The curves of the patient virus at failure are close to the baseline controls. Reduced 
susceptibility and resistant is characterised by the curve of the patient sample shifting to 
the right of the control indicating that a higher concentration of drug is needed to inhibit 
the virus. Fold changes above the upper cut-off distinguishes resistant virus from those 
showing reduced susceptibility. The PIs (amprenavir, atazanavir, darunavir, lopinavir, 
ritonavir and saquinavir) used in this study were obtained from the AIDS Reagent 
Program, Division of AIDS, NIAID, NIH (https://www.aidsreagent.org/).  
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Figure 2.6. Illustration of the genotyping and phenotyping of patient-derived gag-protease 
genes into p8.9NSX+ 
 
Table 2.13. Final concentration of protease inhibitors 
Drug Final drug concentration 
APV  1000nM 
ATV 100nM 
DRV 200nM 
LPV 200nM 
RTV 200nM 
SQV 100nM 
 
 
Table 2.14. Phenotypic assay fold change cut-offs for patient-derived gag-protease 
 Phenotypic classification of patient-derived Gag-Protease 
 Susceptible Reduced 
Susceptibility 
Resistant 
LPV < 3.8 3.8 – 10.0 >10 
RTV < 3.2 3.2 – 10.0 >10 
APV < 4.0 4.0 – 10.0 >10 
ATV < 1.6 1.6 – 10.0 >10 
DRV < 4.9 4.9 – 10.0 >10 
SQV < 3.4 3.4 – 10.0 >10 
                 Abbreviations: LPV, lopinavir; RTV, ritonavir; APV, amprenavir, ATV,  
                 atazanavir; DRV, darunavir; SQV, saquinavir 
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Table 2.15. Calculation of lower cut-offs for each drug for patient samples 
   LPV RTV APV ATV DRV SQV 
Average 0.0009056 0.0055222 0.0046857 0.0007964 0.00008 0.0004457 
Standev 0.0003556 0.0022691 0.0026842 0.0001043 0.00004 0.0002168 
95% Confidence interv. 0.0001643 0.0010483 0.0019884 0.00005 0.00002 0.0001606 
Number (n=) 18 18 7 12 11 7 
Minimum 0.0004 0.0023 0.0023 0.00055 0.00003 0.00023 
1st Quartile (Q1) 0.000625 0.003675 0.00275 0.0007375 0.00005 0.00029 
Median 0.0008 0.00595 0.0033 0.00082 0.00008 0.00036 
3rd Quartile (Q3) 0.001225 0.007375 0.00605 0.0008725 0.00012 0.00058 
Maximum 0.0015 0.0088 0.0096 0.00092 0.00017 0.00079 
1st Percentile 0.000417 0.0023 0.002324 0.0005676 0.00003 0.0002306 
99th Percentile 0.0015 0.008732 0.009408 0.0009186 0.000166 0.0007834 
Lower FC cut-off 3.797122 3.196522 4.048193 1.61834 4.868035 3.397225 
 
2.7. Phenotypic Analysis of gag and protease Mutants 
To investigate the individual contribution of mutations in protease and gag, site-directed 
mutants were created and tested against the protease inhibitors in a vector backbone. This 
allows for the impact of an individual mutation and drug susceptibility to be tested. 
 
2.7.1. Site-directed Mutagenesis 
An expression vector (p8.MJ4) containing the gag-pol region  of a subtype C reference 
strain (MJ4, GenBank: AF321523.1) was used for the construction of site-directed 
mutants (Ndung'u et al., 2001). Primers used for the generation of mutants are listed in 
Appendix II. Protease mutants created and tested were based on those shown to cause 
high-level resistance to the different PIs from the Stanford drug resistance database 
(Figure 2.7.). Gag mutations were selected from patient samples based on their known or 
potential involvement in PI resistance. Additional gag non-CS mutants, which were 
shown to develop under positive selection pressure were also created and tested. 
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Figure 2.7. Protease mutations chosen based on the Stanford drug resistance database 
Protease mutations were created by site directed mutagenesis as single mutants or combination of 
multiple mutants. Red refers to mutations which have been associated with high levels of 
resistance to the relevant PI. Orange refers to mutations which contribute to resistance in 
combination with other PI-resistance mutations to the relevant PIs. Green refers to mutations 
which do not have an effect on resistance to the relevant PI. 
 
 
The primers were designed using the QuikChange Primer Design online tool: 
(http://www.genomics.agilent.com/primerDesignProgram.jsp) and were ordered from 
Integrated DNA Technologies (Coralville, Iowa, USA). Mutations were selected from 
patient samples based on their known or potential involvement in PI resistance. The 
QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California, 
USA) was used according to the manufacturer’s protocol (Figure 2.8) to create the single 
site-directed mutants in a subtype C plasmid p8.MJ4. The site-directed mutagenesis 
reaction uses a PfuUltra high-fidelity DNA polymerase for replication of both plasmid 
strands. During the reaction, the primers containing the desired mutation are extended by 
the DNA polymerase to generate a plasmid containing staggered nicks. The reagents of 
the mastermix are shown in Table 2.15. The thermal cycler was programmed for 1 minute 
at 95°C for initial denaturation, followed by 18 cycles of 50s at 95°C for denaturation, 50 
s at 60°C for annealing, 12 minutes and 30s at 68°C for extension, and 7 minutes at 68°C 
for the final extension. The product is then treated with Dpn I endonuclease for 1 hour at 
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37˚C to digest the parental DNA template and select for the mutation containing 
synthesized DNA. The vector DNA was then transformed into XL10-Gold ultracompetent 
cells as mention in section 2.6.1.2.5. Mutants with multiple mutations were created by 
successive rounds of site-directed mutagenesis. Clones were sequenced (section 2.3.4.) to 
confirm the presence of the correct mutant. 
 
Figure 2.8. Overview of the QuikChange II XL site-directed mutagenesis method. 
Taken from the QuikChange II XL site-directed mutagenesis kit insert. 
 
Table 2.16. Site-directed mutagenesis mastermix 
 Final Concentration μl / reaction  
10X Buffer 1x 5 
dsDNA template 10 ng 2 
Oligonucleotide Primer 1 125 ng 1.25 
Oligonucleotide Primer 2 125 ng 1.25 
dNTP  1 
QuikSolution  3 
Water Make up to 50 μl 36.5 
Total   50.00 
 
 
 
63 
 
2.7.2. Transfection of Site-directed Mutants 
The correct clones were then tested against the PIs in the phenotypic assay described in 
section 2.6.2. The phenotypic susceptibility of mutants was expressed as a fold-change 
(FC) in IC50, relative to that of p8.MJ4. Assay cut-offs are shown in Table 2.17. 
Calculation of the FC for each drug is shown in Table 2.18.  
 
Table 2.17. Phenotypic assay fold change cut-offs for site-directed mutants 
 Site Directed Mutants 
 S RS R 
LPV < 3.8 3.8 – 10.0 > 10 
RTV < 3.2 3.2 – 10.0 > 10 
APV < 2.0 2.0 – 10.0 > 10 
ATV < 3.1 3.1 – 10.0 > 10 
DRV < 1.2 1.2 – 10.0 > 10 
SQV < 1.3 1.3 – 10.0 > 10 
                             Abbreviations: S, susceptible; RS, reduced susceptibility; 
                             R, resistant; LPV, lopinavir; RTV, ritonavir; APV, amprenavir 
                             ATV, atazanavir; DRV, darunavir; SQV, saquinavir 
 
 
Table 2.18. Calculation of lower cut-offs for site-directed mutants 
 LPV RTV APV ATV DRV SQV 
Average 0.00040 0.00285 0.00222 0.00058 0.00008 0.00032 
Standev 0.00020 0.00102 0.00052 0.00023 0.00001 0.00003 
95% Confidence interv. 0.00008 0.000431 0.00026 0.00011 0.00001 0.00002 
Number (n=) 22 22 15 15 9 12 
Minimum 0.00018 0.00141 0.00141 0.00024 0.00005 0.00025 
1st Quartile (Q1) 0.00024 0.00226 0.00183 0.00037 0.00008 0.00029 
Median 0.00031 0.00265 0.00213 0.00063 0.00008 0.00031 
3rd Quartile (Q3) 0.00053 0.00381 0.00269 0.00078 0.00008 0.00034 
Maximum 0.00086 0.00482 0.00296 0.00100 0.00009 0.00038 
1st Percentile 0.00019 0.00148 0.00142 0.00024 0.00007 0.00025 
99th Percentile 0.00075 0.00481 0.00295 0.00079 0.00009 0.00035 
Lower FC cut-off 3.88761 3.23450 2.07716 3.14507 1.19942 1.29363 
 
2.8. Analysis of Phenotypic Results  
Examples of phenotypic data (susceptible, reduced susceptibility and resistant) for patient 
samples and site-directed mutants are shown in Figure 2.9 and 2.10 respectively. For 
patient samples the IC50 of the sample at failure was compared to the IC50 of the matched 
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baseline sample to calculate the fold change (FC). p8.MJ4GP was included in all 
phenotypic assays containing patient samples as a wild-type reference. For the site-
directed mutants, the IC50 of each mutant was compared to the IC50 of the p.MJ4 plasmid.
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Figure 2.9. Phenotypic levels of susceptibility among patient samples to LPV 
The phenotypic susceptibility of each patient-derived virus at failure (red) was  
determined relative to the baseline (blue) sample. As the slope of the curve of the 
failing sample shifts further to the right, more drug is required to inhibit the virus,  
thereby resulting in increased resistance. 
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   Figure 2.10. Phenotypic levels of susceptibility of site-directed mutants to LPV 
   The phenotypic susceptibility of each mutant (red) was determined relative to  
   p.MJ4 (blue). As the slope of the curve of the failing sample shifts further to the  
   right, more drug is required to inhibit the virus, thereby resulting in increased  
   resistance.  
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3.1.1. Abstract 
 
Introduction 
Studies have shown a low frequency of protease mutations in patients failing protease-
inhibitor (PI)-based therapy. Recent studies have identified mutations in gag as an alternate 
pathway for PI drug resistance in subtype B viruses.  
Materials and Methods 
We genotyped the gag and protease genes from 20 HIV-1 subtype C infected paediatric 
patients failing a PI-based regimen. 
Results 
Major protease resistance mutations (M46I, I54V and V82A) were identified in 8 (40%) 
patients, as well as gag cleavage site (CS) mutations (at codons 373, 374, 378, 428, 431, 449, 
451 and 453) in 9 (45%) patients. Four of these gag non-CS mutations occurred in the 
absence of major protease mutations at PI failure. In addition, amino acid changes at gag 
non-CS were noted, some of which were under HLA/KIR immune-mediated pressure and/or 
drug selection pressure. Of these, 6 sites (15, 54, 69, 90, 339 and 386) were under positive 
selection pressure and could not be accounted for. 
Conclusion 
Changes in gag during PI failure suggest drug selection pressure and warrant further 
investigation of the gag gene and its role in PI failure in HIV-1 subtype C. 
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3.1.2. Introduction 
 
South Africa has an estimated 410 000 children infected with HIV-1 of whom 58% were 
eligible and receiving antiretroviral treatment by the end of 2012 (UNAIDS, 2013). The 
national treatment guidelines follow World Health Organization recommendations to treat 
HIV-infected infants <3 years of age with a protease inhibitor (PI)-based regimen. This is due 
to the high rates of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance in 
infants treated for prevention-of-mother-to-child transmission (PMTCT) and the effectiveness 
of using a first-line PI-based regimen to reduce mortality and disease progression in children 
(Palumbo et al., 2010, Violari et al., 2012).  
 
Lopinavir co-formulated with ritonavir (LPV/r) is used as part of a triple antiretroviral 
treatment regimen for infants >6 months of age. Prior to 2008, for infants <6 months of age 
or children receiving rifampicin for co-treatment of tuberculosis, ritonavir (RTV) alone was 
used. LPV/r was subsequently licensed for use in infants <6 months, and the boosting of 
LPV/r with additional RTV or double-dosing of LPV/r when using rifampicin introduced 
(Van Zyl et al., 2013). 
 
PI drug resistance is mediated by an accumulation of major mutations in the protease gene 
resulting in reduced binding of the inhibitor to the protease enzyme (Lee et al., 2012). In 
addition, minor PI mutations, which have little or no effect on PI susceptibility, contribute to 
reduced susceptibility in combination with major mutations (Rhee et al., 2003). Studies have 
shown that mutations in gag cleavage sites (CS) also contribute to PI resistance development 
71 
 
(Fun et al., 2012, Maguire et al., 2002, Dam et al., 2009, van Maarseveen et al., 2012). HIV-1 
Protease recognises and cleaves the Gag and Gag-Pol polyproteins to release the structural 
components: matrix (MA), capsid (CA), p6, nucleocapsid (NC), enzymes protease (PR), 
reverse transcriptase (RT), RNase H, integrase (IN), the small polypeptides p1 and p2, as well 
as transframe protein (TFP) (Pettit et al., 1994). Cleavage sites in gag comprise five amino 
acids flanking either side of the scissile bond, with position 1 (P1) located immediately 
upstream and position 1 prime (P1’) located immediately downstream of the cleavage point 
(de Oliveira et al., 2003). Gag CS mutations such as A431V (CS NC/p1), L449P, and P453L 
(CS p1/p6Gag) have been shown to co-evolve with the HIV-1 protease gene under drug 
selection pressure (Maguire et al., 2002, Dam et al., 2009, Fun et al., 2012). While these sites 
are the most commonly described, substitutions at all CS have been observed at PI failure 
(Fun et al., 2012, Maguire et al., 2002, Verheyen et al., 2006). In addition, studies have 
shown that certain non-CS mutations in gag can contribute to reduced susceptibility to PIs in 
the presence of major protease mutations in vitro (Adamson, 2012, Gatanaga et al., 2002). 
However the mechanism of resistance is not well understood since these mutations occur 
outside of the functionally related regions.  
 
There is limited genetic data on paediatric patients infected with HIV-1 subtype C failing PI-
based therapy, with no published data on gag. Given the large numbers of children initiating 
LPV/r -based regimens, identifying reasons for therapy failure is increasingly important. 
Recent studies in HIV-1 subtype C infected children and adults have shown a lack of 
protease mutations at failure, possibly suggesting alternate routes of PI resistance (Wallis et 
al., 2011, van Zyl et al., 2009). In this study, the protease and gag genes of paediatric patients 
were sequenced at baseline and at the time of virological failure to identify changes 
associated with PI failure taking into account both drug and immune selection pressures.    
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3.1.3. Materials And Methods 
3.1.3.1. Study cohort 
A retrospective cohort study was undertaken on 20 matched baseline and post-treatment 
plasma samples from children less than 24 months of age and failing PI-based therapy. These 
children were initiated on treatment and followed as part of the pre-randomization screening 
phase of a randomized clinical trial between 2005 and 2009. Because these children failed 
their initial LPV/r-based therapy they were not eligible for randomization as part of the trial 
which was designed to assess the feasibility of switching to an NNRTI-based regimen 
following one year of suppressive PI-based therapy (Coovadia et al., 2010, Taylor et al., 
2011, Reitz et al., 2010). Children over 6 months of age were treated with lamivudine (3TC), 
stavudine (d4T) and ritonavir-boosted lopinavir (LPV/r). Those younger than 6 months of age 
and those receiving rifampicin-based regimens for treatment of tuberculosis or Bacille 
Calmette Guerin (BCG) disease, received ritonavir (RTV) until reaching 6 months of age 
and/or completing TB treatment, at which point they were initiated on or switched back to 
LPV/r. For children who suppressed and then rebounded, genotyping was done on the first 
sample where an elevated viral load was observed. For children who did not suppress, a 
sample within the first 3 to 6 months of treatment was selected. Whole blood specimens were 
collected at baseline (pre-treatment) and during regimen failure, defined as not having 
achieved a HIV-1 plasma RNA < 1000 copies/ml by 52 weeks on treatment. This study was 
approved by the institutional review boards of Columbia University and the University of the 
Witwatersrand. 
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3.1.3.2. Genotypic analysis of gag-protease 
Viral RNA was extracted from plasma at baseline and failure using the QIAamp Viral RNA 
Mini Kit (QIAGEN, Belgium) and reverse transcribed using Thermoscript RT-PCR kit 
(Invitrogen, CA, USA). A 1.8 kb gag-protease fragment spanning HXB2 positions 792 to 
2549 was amplified by nested PCR using Expand High Fidelity PCR kit (Roche Applied 
Science, Basel, Switzerland) as previously descibed.(Sutherland et al., 2013) Primers BKT03 
(5’ CGCAGGACTCGGCTTGC 3’) and ProOutR (5’ TTGGGCCATCCATTCCTGG 3’) 
were used for first round PCR and primers GagNot+ 
(5’GCGGCGGCCGCAAGGAGAGAGATGGGTGCG3’) and ProXhoR2 
(5’CTGGTACAGTCTCGAGRGGACTRATKGG 3’) for nested PCR. Population-based 
sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA) on an ABI3130 Genetic Analyser (Applied Biosystems, Foster 
City, CA).  Patient sequences were aligned using ClustalW in BioEdit version 7.0.  (Hall, 
1999) Minor and major protease mutations were defined according to the Stanford University 
Drug Resistance Database (http://hivdb.stanford.edu/DR/PIResiNote.html). Genetic changes 
in gag and protease were defined as those which developed at regimen failure compared to 
the baseline sequence, excluding those which reverted to the subtype C consensus sequence. 
Subtype C consensus sequence was downloaded from the Los Alamos Sequence Database 
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html). 
 
3.1.3.3. Prediction of sites selected by HLA- and KIR-mediated immune pressure 
HLA-associated polymorphisms in gag were predicted from previously published mutation 
maps which presented the locations of common escape mutations in HIV-1 subtype B 
(Brumme et al., 2009). Briefly, the q-value threshold used for constructing the immune 
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escape maps was q ≤ 0.05, meaning that only a 5% false-positive proportion was expected 
among associations displayed on the maps. Sites in gag selected by KIR-mediated immune 
pressure were identified as published (Alter et al., 2011).  
 
3.1.3.4. Positive Selection Analysis 
The fixed effects likelihood (FEL) test was performed using Datamonkey (Kosakovsky Pond 
and Frost, 2005) to test for selection pressure and estimate the ratio of synonymous to non-
synonymous evolutionary changes (dN/dS). Calculations were performed for the entire 
dataset containing 20 gag baseline and failure nucleotide sequences. FEL estimates the 
probability of obtaining the dN and dS values under a neutral mode, with lower P–values 
indicating rejection of neutrality in favour of positive selection. Positions with a dN/dS ratio 
>1 were considered to be under positive selection pressure. 
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3.1.4. Results 
 
3.1.4.1. Clinical characteristics of study population 
Of the 20 children included in this study, 7 (35%) received both LPV/r and RTV while 7 
(35%) received RTV as the only protease inhibitor and 6 (30%) were treated with LPV/r 
only. In addition to the PI, all children received two NRTIs (d4T and 3TC) (Table 3.1.1). The 
length of RTV-only treatment ranged from 27- 252 days. Of the 14 children that at some 
point received RTV as a single PI, 10 were co-treated for mycobacterial disease whilst 4 were 
<6 months of age. The mean viral load and CD4 count at time of measurement of drug 
resistance was 103, 880 copies/ml (range 1,240 - 750,000) and 28.4% (range 9.6 - 49.6) 
respectively. Of the 20 children, 2 (10%) had a CD4 count of ≤14%.  
 
3.1.4.2. Genotypic analysis of protease and gag mutations at PI failure 
Eight children (40%) had detectable major PI resistance mutations at failure, with V82A 
(n=8, 40%), I54V (n=4, 20%) and M46I (n=3, 15%) identified as the only major protease 
mutations (Figure 3.1.1 and Table 3.1.2). All patients who had at least one major PI mutation 
had received RTV-only therapy at some point, while patients who received LPV/r only did 
not have any major PI resistance mutations.  Patients who developed ≥2 major protease 
mutations were more likely to have been on RTV therapy for a longer period of time. In 
addition, several minor PI mutations and polymorphisms (L10I, S12T, K20R, L33F, K43E, 
D60E, Q61H/E, L63P/T, K70R and N83S) were detected in both LPV/r- and RTV-treated 
patients.  
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When analysing the 20 patients at baseline and failing PI therapy, 10 showed no changes in 
protease after PI failure (highlighted in gray in Table 3.1.2), and six of these had received 
LPV/r exclusively. The majority of these patients had pre-existing baseline changes in the 
entire protease region, relative to consensus C sequence, that were also present following PI 
failure. 
 
Nine of 20 patients had detectable gag CS mutations at failure, 5 of whom also had protease 
major mutations (Figure 3.1.2). HIV-1 drug resistance associated CS mutations A431V 
(NC/p1), L449P and P453L (both in p1/p6Gag) were found in 4 of the 9 patients. The A431V 
mutation was selected in patients numbered 1 and 10 in the presence of major PI mutations 
I54V and V82A. Patients 11 and 20 had no major PI mutations, but both had mutations 
L449P and/or P453L. The most variable cleavage site was p2/NC where 4/9 patients had at 
least one mutation at this site at failure (positions N373A, T374A/S, M378A). Other CS 
mutations occurred at NC/p1 (position E428D) and p1/p6Gag (position N451S). The most 
conserved cleavage sites were MA/CA, CA/p2, NC/TFP and TFP/P6pol where no changes 
were observed. 
  
Changes were also detected at gag non-CS at failure that differed from the consensus C. 
These changes were found in the majority of patients (17/20) and occurred mainly in the 
matrix and capsid regions in the N-terminus of gag (Supplementary Table 3.1.3).  
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3.1.4.3. Predicted HLA and KIR immune escape mutations in gag 
Previously published immune escape maps were used to determine if some of the identified 
changes in gag that developed at failure were due to immune pressure. Seven of 20 patients 
had changes at the failure time point relative to baseline, at sites shown to be selected by 
known HLA A, B and C alleles reported to occur in South African Black and Caucasian 
populations (Table 3.1.4). In total, 8 sites were predicted to be associated with HLA or KIR-
mediated immune pressure (Figure 3.1.3). One site at codon 374 was also a gag CS (p2/NC) 
mutation and another at codon 79 was at a gag non-CS that is associated with PI exposure 
(Parry et al., 2011).  The E93D KIR-associated polymorphism in gag was identified in one 
patient (patient 8, Figure 3.1.3) and has been associated with HLA-mediated immune 
pressure (Alter et al., 2011, Brumme et al., 2009). 
 
3.1.4.4. Positive selection in gag 
A total of 53 amino acid residues were identified in gag that had changed between baseline 
and failure among these 20 patients (Figure 3.1.3).  To determine which of these changes 
were under positive selection pressure following PI failure, a dN/dS analysis on the matched 
baseline and failing sample was performed (Table 3.1.5). A total of 7 sites in gag were found 
to be under significant selection pressure (Figure 3.1.3). Position 62, which has previously 
been reported to be associated with PI exposure, (Koh et al., 2009) had the highest dN/dS 
ratio of 6.033 (p = 0.001) and was found in 4 patients. The remaining 6 positively selected 
sites (positions 15, 54, 69, 90, 339 and 386) have not previously been associated with PI 
exposure nor predicted to be HLA/KIR. Two additional sites in gag have been reported to be 
associated with PI failure, (Parry et al., 2011, Gatanaga et al., 2002) including the HLA/KIR-
selected position 79, but were not found to be positively selected in this analysis. In total, 23 
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of the 53 changes identified in gag following PI failure showed some evidence of selection 
pressure.   
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3.1.5. Discussion 
 
This is the first study to describe the genotypic changes in both the gag and protease genes in 
HIV-1 subtype C paediatric patients failing PI-based therapy. The study showed that 
virologic failure during PI exposure may have led to the selection of protease resistance 
mutations as well as gag CS and non-CS mutations. Only patients on failing RTV regimens 
were observed to have developed all the major PI mutations and a majority of gag CS 
mutations. Mutations at gag CS were found in some cases to occur in the absence of major 
protease mutations implicating them as potentially resistance-conferring. Furthermore, sites 
in gag non-CS were found to be under various selection pressures following PI failure. 
Collectively these data warrant further investigation of the gag gene in contributing to PI 
drug resistance.   
 
In this study, all PI resistance associated mutations were selected in patients who had 
received RTV compared to those treated with LPV/r exclusively, as previously reported 
(Taylor et al., 2011). Similar to previously published data, the major PI mutations detected at 
failure were M46I, I54V and V82A, all of which are well described as causing high-level 
resistance to multiple PIs (Johnson et al., 2011). Of interest was that nearly half of the 
patients in this study acquired changes at gag CS at failure. Gag and protease function as a 
single unit with enzyme and substrate co-evolving to optimise viral replication (Parry et al., 
2009). Mutations at the gag CS A431V, L449P and P453L have been shown to contribute to 
protease inhibitor resistance (Dam et al., 2009, Maguire et al., 2002). A431V has been found 
to occur in combination with the protease mutation V82A and can be selected as 
compensatory or as a direct protease inhibitor mutation in the absence of mutations in 
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protease (Dam et al., 2009). The CS mutation L449P has been directly associated with 
exposure to ritonavir, indinavir, fosamprenavir, nelfinavir, saquinavir and atazanavir, while 
P453L has been found to enhance resistance in the presence of protease mutations I50V and 
I84V in vitro (Ali et al., 2010, Maguire et al., 2002, Fun et al., 2012). In this study these well 
described gag-CS mutations were found in 4 patients, 2 in the absence of protease mutations, 
and it is likely that they contributed to PI failure in these patients. In addition, 5 patients had 
gag-CS mutations that are less well defined, mainly at p2/NC, which is a more variable CS 
(de Oliveira et al., 2003). In some cases these also occurred in the absence of protease 
mutations. Whether these gag CS changes contributed to LPV/r and RTV failure in these 
patients is unknown and would require further phenotypic testing. 
 
 A large number of changes at gag non-CS were also detected at failure in this cohort. 
Eight sites were predicted to be under HLA/KIR-mediated immune pressure suggesting that 
they may be cytotoxic CD8+ T lymphocyte escape mutations (Brumme et al., 2009). One of 
these, codon 79, has previously been associated with PI exposure thus suggesting dual 
pressure from antiretroviral drugs and the immune system (Parry et al., 2011). HLA alleles 
associated with these predicted sites have all been identified in the South African population 
(Paximadis et al., 2012). However, it is important to note that the immune escape maps used 
to determine HLA-associated changes were based on HIV-1 subtype B gag sequences. 
Therefore this data may underestimate the sites associated with HLA immune pressure in 
subtype C patients. Only one KIR-associated polymorphism at position 93 in gag was 
identified in one patient suggesting this was not a major contributor to the gag changes. 
However, a more in-depth analysis involving high resolution HLA and KIR typing is required 
to determine whether these alleles were present in these patients and selected these mutations. 
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Nevertheless, this prediction analysis does suggest that some of the gag non-CS changes seen 
in this cohort are the result of immune selection pressures.  
  Positive selection analysis on the gag region identified seven sites to be under 
selection pressure, one of which was previously shown to be associated with PI exposure 
(position 62) (Koh et al., 2009). The remaining six sites under positive selection pressure 
occurred in 6 patients, 3 of whom developed gag CS changes at failure and one who had a 
pre-existing CS change from baseline. Therefore, these changes may be indicative of adaptive 
change possibly offering a fitness advantage and warrant further study. Of the 53 changes 
identified in this study, 23 could be accounted for by various selection pressures. The 
remaining thirty changes occurred mainly in the conserved matrix and capsid regions of gag 
and as such may have a function which is yet to be defined.  
 
The availability of baseline and failure samples provides a robust analysis of drug resistance 
in patients failing treatment. However, the use of population sequencing may limit the 
detection of minority variants in gag already present at baseline. Furthermore, due to the 
small sample size, caution should be taken in generalising the findings to patients on RTV 
and/or LPV/r treatment. Almost half of the patients in this study failed RTV and LPV/r 
treatment without any changes in protease or gag CS. Poor adherence and sub-optimal drug 
levels in patients presenting with wild-type protease and gag cannot be excluded, but this 
data was not available. A recent study identified changes in gp41 of the envelope gene as an 
alternate route of PI resistance suggesting that sites outside of protease and gag may also be 
involved. (Rabi et al., 2013) Others have suggested that due to the short half life of PIs, there 
is a limited mutation selection window such that wild-type virus emerges faster than mutant 
virus resulting in restricted evolution of drug resistance. (Rosenbloom et al., 2012) Thus 
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further studies are needed to determine the reasons why patients fail PIs in the absence of 
known resistance mutations. Nevertheless, the availability of pre-and post- treatment samples 
allowed us to identify and correlate gag mutations selected with PI failure in the presence or 
absence of protease mutations in a sub-set of patients. This data suggests that it may be 
beneficial to include the gag gene when screening for protease inhibitor resistance. Further 
studies on the effects of gag mutations on protease inhibitor resistance, and development of 
drug resistance interpretation algorithms for both gag and protease, may prove beneficial.   
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Table 3.1.1. Clinical characteristics and treatment information of HIV-1 infected 
infants and young children failing protease-inhibitor based antiretroviral therapy 
 
Pt. No. Time on 
Treatment 
(days)  
Treatment1 Reason for 
RTV2 
Viral Load  
at Resistance 
Test 
CD4% 
1 365 RTV +LPV/r < 6 months 7, 980 46.6 
2 363 RTV +LPV/r TB 48, 400 22.9 
3 252 RTV +LPV/r TB 17, 800 17.0 
4 251 RTV +LPV/r TB 28, 200 45.8 
5 252 RTV +LPV/r TB 15, 000 16.6 
6 367 RTV +LPV/r < 6 months, 
TB 
1, 240 26.9 
7 370 RTV +LPV/r TB 100, 000 9.6 
8 254 RTV TB 15, 400 18.9 
9 252 RTV TB 4, 980 12.6 
10 261 RTV TB 66, 400 NA 
11 84 RTV TB 750, 000 NA 
12 85 RTV < 6 months, 
TB 
750, 000 NA 
13 27 RTV < 6 months 6, 910 NA 
14 161 RTV TB 100, 000 20.4 
15 254 LPV/r - 100, 000 16.4 
16 384 LPV/r - 10, 100 25.4 
17 369 LPV/r - 2, 010 44.2 
18 363 LPV/r - 4, 220 41.2 
19 253 LPV/r - 8, 720 49.6 
20 734 LPV/r - 100, 000 31.0 
1 RTV + LPV/r: Patients received both RTV as a single PI as well as LPV/r;  
RTV: Patients received RTV as a single PI; LPV/r: patients received LPV/r only 
2 < 6 months, age less than 6 months; TB, tuberculosis; NA, not available 
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Table 3.1.2. Genotypic characterisation of protease and gag from HIV-1 infected infants and young children failing protease-inhibitor based antiretroviral 
therapy 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aRTV + LPV/r: Patients received both RTV as a single PI as well as LPV/r at some point;  
RTV: Patients received RTV as a single PI only; LPV/r: patients received LPV/r only  
Protease mutations in bold represent major PI mutations 
Mutations underlined represent changes which developed following PI-based therapy 
For 10 patients there were no changes in protease at failure (highlighted in gray) although 9 had baseline protease  
polymorphisms 
Pt. No. Treatmenta Protease Genotype Gag CS Genotype 
1 RTV +LPV/r I54V, V82A, K20R, L23I, E35D, L63P V378A, A431V 
2 RTV +LPV/r M46I, I54V, V82A, L10I, K20R, E35D, Q61H, L63P E428D 
3 RTV +LPV/r V82A, K20R, K45R - 
4 RTV +LPV/r M46I, I54V, V82A,  K20R, L33F, E35D, T74S V128T, N374S 
5 RTV +LPV/r - - 
6 RTV +LPV/r K43E, N83S  S373A 
7 RTV +LPV/r A71T - 
8 RTV V82A, S12T, L10I, K20R, E35D, D60E, Q61E   N451S 
9 RTV M46I, V82A, A63T V128I 
10 RTV I54V, V82A, I36M, N37S, L63P, V77I  A431V 
11 RTV N37S, L63S, V82I V128I,  L449P, P453L 
12 RTV V82A, K20R, E35D, R57K, D60E, L63P - 
13 RTV E35D, L63V, T74S E428K, L449P, P453L  
14 RTV L10M, I36M, N37K, K41I, L63T, K70R - 
15 LPV/r K20R, E35D, L63V - 
16 LPV/r I36M, K41R, T74S, V77I I437L  
17 LPV/r L63V - 
18 LPV/r V82I Y132F 
19 LPV/r I36L, N37E, K41R, L63V T374A, P453L 
20 LPV/r L63P, V77I L449P 
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Figure 3.1.1. Frequency of gag and protease mutations in patient samples relative to their 
treatment. The number of patients with any PI drug resistance mutations (DRMs), any gag cleavage 
site mutations (CSMs) and any gag non-cleavage site mutations (non-CSMs) are shown. Individual PI 
mutations (M46I, I54V and V82A), and mutations occurring at gag CS and non-CS are shown. The 
proportion of patients on RTV+LPV/r is indicated by black bars, RTV only is indicated by grey bars 
and LPV/r only is indicated by white bars.  
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Figure 3.1.2. Position of Gag CS amino acid changes in patients at PI failure 
Nine patients with gag CS changes at PI failure are shown. Of these, 5 also had major PI mutations (positions 46, 54 and 82). Gag CS mutations are reported 
relative to the baseline sample. The sequences at consensus C cleavage sites are shown.
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Figure 3.1.3. Changes in gag following PI-based therapy failure. 
Amino acids positions in gag (n= 53) that change following PI-based therapy were classified 
according to those at CS (n= 8) and those at non CS (n= 45). Non-CS changes were further classified 
as those known to be associated with PI exposure from published literature (n= 3) those predicted to 
be HLA/KIR -associated polymorphisms (n= 8) and those under positive selection pressure (n= 7). 
*Position 93 was predicted to be an HLA and KIR associated polymorphism.  The remaining 30 gag 
non-CS changes may represent natural polymorphisms. 
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Table 3.1.3. Genotypic characterisation of gag non-cleavage sites from HIV-1 infected infants and 
young children failing protease-inhibitor based antiretroviral therapy 
 
 
 
 
 
 
 
  
Pt. No. Additional Changes at Failure 
1 - 
2 - 
3 G62S, H219Q 
4 V88A 
5 A55T, T62A, K69R, S148L 
6 - 
7 V35A, E106G, A357G 
8 S54A, L64I, N90K, E93D, K103T, V191I, I256V, D295E  
9 I7V, D15E, G25E, Y79H, S234G,  
10 R28K 
11 A67S, P339Q, K410R, K411G 
12 E454G 
13 R275K, S281N, A341S 
14 Q69K 
15 K263R, I266V, A280V, P292T, K411R 
16 Q59R, A62Q, L215I, T239A, D425E 
17 R39G, L46P, E454G 
18 K62N, T320A 
19 P386S, R403K 
20 K114R, L215I 
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Table 3.1.4. Positions predicted to be under HLA-mediated immune pressure 
Pt. No. Amino Acid Change HLA Allele 
Prevalence in South African Populationa 
Blacks Caucasians 
7 A357G B07 1 – 4% 1 – 14% 
8 E93D B40 1% 1 – 2% 
9 Y79H C14 1% 1% 
10 R28K A03, A30 6%; 1 - 10% 12%; 1 – 2% 
11 A67S A02 2 – 8% 1 – 26 % 
19 R403K A03, A30 6%; 1 - 10% 12%; 1 – 2% 
 
T374A B45 1 – 6% 1% 
20 K114R C03 1 – 5% 1 – 5% 
aA range of frequencies are given since there are > 1 subgroup for the HLA alleles eg. B07:02, B07:06  
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Table 3.1.5. Sites in gag found to be positively selected using the FEL test  
Gag Amino Acid No. Of Patients dN/dS P value 
62* 4 6.033 0.001 
90* 1 3.470 0.077 
15* 1 3.445 0.031 
54* 1 2.711 0.006 
69* 2 2.702 0.001 
386* 1 1.256 0.068 
339* 1 1.060 0.078 
453 1 0.788 0.123 
7 1 0.577 0.409 
148 1 0.575 0.193 
106 1 0.426 0.313 
374 2 0.295 0.167 
263 1 0.222 0.466 
55 1 0.217 0.887 
35 1 0.214 0.415 
67 1 0.205 0.427 
341 1 0.203 0.428 
275 1 0.194 0.460 
266 1 0.173 0.690 
281 1 0.167 0.533 
357 1 0.034 0.975 
403 1 0.032 0.976 
46 1 -0.042 0.950 
103 1 -0.097 0.886 
191 1 -0.103 0.900 
431 2 -0.146 0.812 
114 1 -0.294 0.713 
215 2 -0.326 0.698 
219 1 -0.351 0.143 
454 2 -0.366 0.538 
25 1 -0.369 0.464 
39 1 -0.532 0.257 
410 1 -0.533 0.408  
292 1 -0.597 0.562 
320 1 -0.755 0.208 
234 1 -0.943 0.215 
64 1 -1.038 0.219 
59 1 -1.260 0.183 
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280 1 -1.263 0.068 
451 1 -1.384 0.077 
88 1 -1.745 0.041 
93 1 -1.873 0.100 
239 1 -1.977 0.045 
79 1 -2.287 0.303 
449 2 -2.322 0.065 
425 1 -2.810 0.022 
295 1 -3.218 0.009 
428 1 -3.444 0.003 
256 1 -4.061 0.030 
28 1 -5.514 0.387 
411 2 -6.270 0.008 
373 1 -25.108 0.001 
378 1 -26.494 0.030 
Significance set at 0.1 
Codons are ranked according to the dN/dS ratios. 
Codons that were under positive selection pressure  
are shown in bold with an asterisk. 
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Figure 3.1.4. Phylogenetic tree showing clustering of the samples at baseline and failure 
Neighbour joining tree constructed using MEGA using 1000 bootstrap replications. All 1.8kb gag-
protease sequences were aligned according to consensus C downloaded from the Los Alamos 
Sequence Database. Group N 1.8kb gag-protease sequence was used to root the phylogenetic tree. 
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3.2.1. Abstract 
 
Introduction 
There is a low frequency of protease inhibitor (PI) resistance in patients failing PI-based 
therapy. We have previously reported on genotypic changes in gag-protease of paediatric 
patients failing PI-based therapy. Here we investigated the phenotypic effects of these 
changes on lopinavir and ritonavir susceptibility.  
Materials and Methods 
The gag-protease regions from pre- and post-treatment time points of 20 subtype C paediatric 
patients failing a lopinavir (LPV) and/or ritonavir (RTV)-based regimen were analysed in a 
non-replicative in vitro assay. Gag and protease mutations associated with PI resistance, were 
reconstructed by site-directed mutagenesis and tested.  
Results 
Phenotypic resistance to LPV was observed in 40% (n=8/20) of patients while 50% 
(n=10/20) were phenotypically resistant to RTV. Phenotypic resistance to LPV and/or RTV 
was associated with prior RTV treatment. Three patients showed a reduced PI susceptibility 
in the absence of PI mutations but had changes at gag cleavage sites (CS) (V128I, L449P and 
P453L) and/or non-CS. Site-directed mutagenesis showed that these changes in gag 
contributed to PI resistance but only in the presence of major PI mutations.  
Conclusion 
These results suggest that gag mutations in combination with major protease mutations can 
contribute to PI resistance. However, in some patients with wild-type protease, changes in 
gag may be responsible for reduced PI susceptibility. These findings warrant further 
investigation of the gag gene and its role in PI resistance. 
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3.2.2. Introduction 
 
Protease inhibitors (PI) are potent antiretroviral drugs which inhibit HIV-1 Protease and  
prevent viral maturation (Santos and Soares, 2010). The South African national treatment 
guidelines recommend the use of ritonavir-boosted lopinavir (LPV/r) as a first-line regimen 
for paediatric patients <3 years of age and a second-line regimen for adults and older children 
(Department of Health, 2013). Prior to 2008, ritonavir (RTV) was used as a single PI to treat 
paediatric patients <6 months of age and those receiving rifampicin-based regimens for the 
treatment of tuberculosis (van Zyl et al., 2011). RTV monotherapy has been characterised by 
the selection of major protease resistance mutations during regimen failure and is therefore 
no longer recommended (Taylor et al., 2011, Orrell et al., 2013). Presently, RTV is used to 
boost LPV-based therapy and increase LPV bioavailability. Due to high viral loads and 
challenges with accurate dosing, paediatric patients are at a greater risk for developing HIV-1 
drug resistance than adult patients on PI treatment (Gupta et al., 2009). 
 
Resistance to PIs is characterised by the accumulation of various major and minor mutations 
in the protease gene (Johnson et al., 2011), including M46I, I54V and V82A. However, many 
patients failing protease inhibitor-based therapy do so in the absence of protease mutations 
(Levison et al., 2012, Wallis et al., 2011, Bartlett, 2013). While poor adherence is often 
associated with therapy failure in the absence of genotypic resistance mutations, it has been 
suggested that regions outside of the protease gene may contribute to PI resistance in some of 
these cases (Fun et al., 2012, Gupta et al., 2009, Orrell et al., 2013, Rabi et al., 2013, Siliciano 
and Siliciano, 2013).  HIV-1 Protease recognises and cleaves the Gag and Gag-pol poly-
proteins at 10 distinct cleavage sites (CS) to generate viral structural components such as 
matrix (MA), capsid (CA) and nucleocapsid (NC), and enzymes protease (PR), reverse 
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transcriptase (RT) and integrase (IN), necessary for viral replication (de Oliveira et al., 2003). 
Protease inhibitors act by binding to HIV-1 Protease and preventing cleavage of the Gag and 
Gag-Pol polyproteins (Ali et al., 2010). Changes at gag CS and  non-CS have been identified 
that act as compensatory mutations to restore viral fitness in the presence of protease 
mutations, or directly by affecting PI susceptibility (Dam et al., 2009, Gupta et al., 2010, Fun 
et al., 2012, Verheyen et al., 2006, Kolli et al., 2009). Gag CS mutations such as those at 
positions 431, 436 and 437 have been associated with reduced PI susceptibility and 
virological failure during PI therapy in the absence of PI mutations (Nijhuis M, 2007, Fun et 
al., 2011). A recent study has shown the interdependency between a nelfinavir (NFV) 
resistant protease (D30N/N88D) and p1/p6Gag cleavage site mutations (L449F and S451N) 
(Kolli et al., 2014). Furthermore, it has been suggested that this association may strengthen 
the inter-molecular interactions between the substrate and the active site of protease to allow 
for co-evolution of the substrate and mutant protease. 
The genetic changes in 20 subtype C paediatric patients failing a PI-based regimen were 
previously reported (Giandhari et al., 2015). Changes in both protease and gag were 
identified. In this study, phenotypic testing of the 20 paediatric patients was performed to 
understand the role of gag mutations in paediatric PI resistance.  
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3.2.3. Materials and Methods 
 
3.2.3.1. Samples from HIV-1 infected children 
Twenty matched baseline and post-treatment plasma samples from children less than 2 years 
of age and failing PI-based therapy were studied (Chapter 3.1.3.1). Briefly, these children 
were initiated on treatment and followed as part of a randomized clinical trial between 2005 
and 2009. Briefly, children <6 months of age and hose receiving rifampicin for concomitant 
tuberculosis were treated with a ritonavir (RTV)-based regimen. Once the patients had passed 
6 months of age or the tuberculosis had cleared, they were switched onto a ritonavir-boosted 
lopinavir (LPV) regimen. This study was approved by the institutional review boards of 
Columbia University and the University of the Witwatersrand. 
 
3.2.3.2. Construction of patient derived test vectors 
Phenotypic susceptibility to LPV and RTV was determined by using a retroviral vector 
system, capable of a single infectious event as previously described (Gupta et al., 2010, Parry 
et al., 2009). HIV-1 expression vector p8.9NSX+ (Parry et al., 2009, Sutherland et al., 2013) 
contained a NotI restriction site at the beginning of gag (HXB2 position 772) and a XhoI 
restriction site at the end of protease (HXB2 position 2563) to allow for the cloning of a 
1.8kb gag-protease fragment from patient samples. Restriction enzymes (Not I and Xho I) 
were used to digest p8.9NSX+ and allow for cloning of patient-derived (baseline and failure) 
and p8.MJ4 derived gag-protease resulting in patient-derived expression vector and 
p8.9MJ4GP respective. Viral RNA was extracted from plasma using the QIAamp Viral RNA 
Mini Kit (QIAGEN, Belgium) and reverse transcribed using Thermoscript RT-PCR kit 
(Invitrogen, CA, USA). A 1.8 kb gag-protease fragment spanning HXB2 positions 792 to 
2549 was amplified by nested PCR using Expand High Fidelity PCR kit (Roche Applied 
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Science, Basel, Switzerland) (Chapter 3.1.3.2). Second round primers  GagNot+ 
(5’GCGGCGGCCGCAAGGAGAGAGATGGGTGCG3’) and ProXhoR2 
(5’CTGGTACAGTCTCGAGRGGACTRATKGG 3’) were used to introduce the NotI and 
XhoI restriction sites (underlined) into the 1.8 kb gag-protease amplicons during the second 
round of amplification. Amplicons were sequenced and analyzed for changes in the gag and 
protease genes. Protease sequences were submitted to the Stanford HIVdb Drug Resistance 
database (hivdb.stanford.edu/) to identify PI resistance mutations and predict phenotypic PI 
susceptibility. Polymorphisms in the protease and gag genes were defined as changes in 
amino acid sequence between the failing and baseline sequences. In addition, baseline and 
failing protease sequences were submitted to the Stanford Drug Resistance database to 
determine the predicted phenotype for LPV/r. For the Stanford predicted phenotype, each 
mutation present in the patient sample is assigned a mutation penalty score to determine the 
predicted level of phenotypic resistance for that particular drug. Predicted phenotype for RTV 
was not available since use of RTV on its own is no longer recommended. 
 
The second-round products were cloned into the pCR-2.1 TOPO cloning vector 
(TOPO TA Cloning Kit, Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. 
Clones containing the gag-protease inserts of the correct size were sub-cloned into the 
p8.9NSX+ expression vector by NotI/XhoI restriction digest (Roche, Basel, Switzerland) and 
ligation with the Rapid DNA Dephos and Ligation Kit (Roche, Basel, Switzerland). Ligation 
products were transformed into Escherichia coli (E.coli) XL10-Gold ultra-competent cells 
(Stratagene, La Jolla, California, USA) by a standard heat-shock method. All pCR-2.1 TOPO 
and p8.9NSX+ clones were sequenced, as described above, to confirm the presence of the 
relevant mutations and polymorphisms.  
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3.2.3.3. Site-directed mutagenesis  
A 3,6 kb gag-protease-reverse transcriptase fragment (base pairs 775 to 4,403 of HXB2) in 
the p8.9NSX+ expression plasmid was replaced with the corresponding fragment restricted 
from the pMJ4 (GenBank: AF321523.1)  subtype C reference strain  to create p8.MJ4 
(Ndung'u et al., 2001). This plasmid was utilized for the construction of site-directed mutants. 
Protease and gag mutations were selected from patient samples based on their known or 
potential involvement in PI resistance. Site-directed mutants were created in the p8.MJ4 
expression plasmid by use of the QuickChange II XL Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, California, USA). The mutagenesis primers were designed using the 
QuikChange Primer Design online tool: 
(http://www.genomics.agilent.com/primerDesignProgram.jsp) and were ordered from 
Integrated DNA Technologies (Coralville, Iowa, USA). Site-directed mutants containing 
additional gag non-CS mutants, that have previously been shown to develop under positive 
selection pressure, (Chapter 3.1.)(Giandhari et al., 2015), were also created. Mutants with 
multiple mutations were created by successive rounds of site-directed mutagenesis, and the 
presence of mutations confirmed by population-based sequencing. Sequencing was 
performed using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, 
Foster City, CA) on an ABI3130 Genetic Analyser (Applied Biosystems, Foster City, CA). 
p8.9MJ4 was used as a control in all patient PI susceptibility assays. 
 
 3.2.3.4. Phenotypic assessment of protease inhibitor susceptibility 
A vector-based non-replicative phenotypic assay was used as previously described (Parry et 
al., 2009, Gupta et al., 2010), with minor modifications. Briefly, 1.25x106 HEK293T cells 
were transfected with 300 ng of plasmid pMDG (encoding the vesicular stomatitis virus G 
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protein), 500 ng of plasmid pCSFLW (encoding the firefly luciferase protein) and 300 ng 
HIV-1 expression vector containing patient-derived inserts or site-directed mutations) using 
3.3 μg polyethylenimine (PEI) (Polyscience, Inc., Warrington, Pennsylvania, USA). 
Transfected cells were harvested after 18 hours and seeded in the presence of serial dilutions 
of LPV and RTV. Supernatants were transferred after 24 hours to the corresponding wells of 
the 96-well culture plates that contained fresh 293T cells. The degree of infection was 
determined by measuring the expression of firefly luciferase in infected target cells, 48 hours 
after supernatant transfer. For each drug-virus combination, the 50% inhibitory concentration 
(IC50) was calculated. For patient derived clones, the phenotypic susceptibility was expressed 
as a fold-change (FC) in IC50, relative to that of the baseline virus. The fold change (FC) was 
calculated by comparing the IC50 of the sample at failure to that of the baseline sample. The 
standard phenotypic curves showed minimal change in IC50 for viruses showing PI 
susceptibility. Standard phenotypic curves of the resistant viruses typically show a greater 
shift to the right indicating that additional drug is required to inhibit the virus. An expression 
vector (p8.MJ4) containing the gag-pol region of a subtype C reference strain (MJ4, 
GenBank: AF321523.1) was used for the construction of site-directed mutants (Ndung'u et 
al., 2001). The assay-specific lower FC cut-off value for each drug was determined using the 
99th percentile of the average IC50 for p8.MJ4GP and p8.MJ4 assessed in multiple repeat 
screens of each drug. An upper assay cut-off value of 10 FC was arbitrarily chosen. The 
phenotypes were classified as sensitive (S) (LPV: <4.4 FC, RTV: <3.2 FC), having a reduced 
susceptibility (RS) (LPV: 4.4 - 10 FC, RTV: 3.2 – 10 FC) or as resistant (R) (LPV: >10 FC, 
RTV: >10 FC). The classifications susceptible, reduced susceptibility and resistant serve to 
rank the response of the PIs used in our assay. The upper cut-off was arbitrarily chosen to 
distinguish those showing reduced susceptibility from those phenotypically resistant.  
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3.2.3.5. Statistical Analysis 
Two-way analysis of variance (ANOVA) was used to identify significant differences in FC 
values between of site-directed mutants using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, California, USA).  
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3.2.4. Results 
 
3.2.4.1. Phenotypic susceptibility of patient-derived protease and gag genes 
We previously reported the genotypic changes in gag and protease among 20 paediatric 
patients failing PI-based therapy. In order to examine the impact of these mutations on 
phenotypic resistance, the gag-protease fragment from each patient’s baseline and failing 
sample were cloned into the HIV-1 expression vector. A single-cycle phenotypic assay was 
used to assess the impact of mutations in gag and protease on PI susceptibility. Treatment 
history, genotypic profiles, predicted phenotypes and in vitro phenotypic drug susceptibility 
of the 20 children are shown in Table 3.2.1. All changes in protease and gag CS are reported 
in the failing samples, relative to their corresponding baseline samples.  
 
Seven of the eight patients with major PI mutations showed reduced susceptibility or 
high-level resistance to LPV and RTV. One patient (Pt. 12) with V82A only that was 
predicted to be resistant by the database, was shown to be susceptible in our assay. Five of 
these 8 patients also harboured gag CS mutations. A further 9 patients carrying gag CS and 
non-CS mutations only, showed susceptibility to LPV and RTV. Phenotypic resistance to 
LPV and/or RTV was only seen in patients that had received RTV only at some time-point. 
Interestingly, the remaining 3 patients (Pt. 5, 11 and 14) showed reduced susceptibility in the 
absence of PI mutations to RTV, one of which (Pt. 11) also showed reduced susceptibility to 
LPV. These three patients had gag CS and/or non-CS mutations. All gag non-CS changes 
were previously reported (Chapter 3.1) (Table 3.1.3.). 
 
The phenotypic classification of resistance for the 20 patients was similar between 
LPV and RTV except for two patients. Patient 5 showed a reduced susceptibility to RTV (FC 
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6.0) but was susceptible to LPV (FC 4.2). This patient did not have any changes in protease 
or gag CS but did have four gag non-CS changes (A55T, T62A, K69R and S148L). Patient 
14 showed a reduced susceptibility to RTV (FC 3.8) while remaining susceptible to LPV (FC 
2.6). This patient had no major protease or gag CS mutations, but did contain a gag non-CS 
change (Q62K).  
 
The phenotypic curves of the gag-protease regions of the 20 patients for LPV and RTV are 
shown in Figures 3.2.1 and 3.2.2 respectively. Differences were observed in the IC50 values 
of the baseline samples (LPV: range 0.0003-0.0142, mean- 0.00345; RTV: range 0.0019-
0.0687, mean 0.0174), indicating the possible effect of patient-specific polymorphisms in 
protease and gag on PI susceptibility.  
 
When comparing the predicted phenotype (Stanford) to the in vitro phenotype, discordance 
was observed for six patient samples (Pt. 1, 3, 4, 8, 11 and 12). All six patients had received 
RTV as a single PI at some point. Patient 1 showed high-level phenotypic resistance to LPV 
(FC 109.0) although intermediate resistance was predicted by the database. This patient had 
two major PI mutations (I54V and V82A) in addition to gag CS mutations V378A and 
A431V. High-level resistance to LPV (FC 68.0) was seen in patient 3, although the database 
predicted low-level resistance. One major protease mutation (V82A) and non-CS changes 
(G62S, and H219Q) were present in this patient. Reduced susceptibility to LPV (FC 5.2) was 
shown for patient 4 although it was predicted to have high-level resistance due to the 
presence of 3 major PI mutations (M46I, I54V and V82A). In addition to the major PI 
mutations, one gag CS mutation (N374S) and one non-CS change (V88A) was also present. 
High-level resistance to LPV (FC 12.1) was shown for patient 8, although a low-level of 
resistance was predicted. This patient had one major PI mutation (V82A), one gag CS 
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mutation (N451S) and non-CS changes (S54A, L64I, N90K, E93D, K103T, V191I, I256V 
and D295E). Although the database had predicted a susceptible phenotype for patient 11, the 
in vitro phenotypic assay showed a reduced susceptibility (FC 5.9). Although no major PI 
mutation was observed in this patient sample, gag CS mutations (L449P and P453L) and 
non-CS mutations (A67S, P339Q, K410R and K411G) were present. Phenotypic 
susceptibility to LPV (FC <4.4) was observed in patient 12, whilst the database had predicted 
low-level resistance due to the presence of a single PI mutation (V82A). This patient had one 
gag non-CS mutation (E454G). 
 
3.2.4.3. Phenotypic susceptibility of site-directed mutants with protease and/or gag 
mutations 
In order to evaluate the contribution of specific gag and protease mutations to PI resistance, 
site-directed mutagenesis was used to recreate these mutations in p8.MJ4, individually or in 
combination. A total of 22 mutants were generated and tested for phenotypic susceptibility to 
LPV and RTV, as shown in Figures 3.2.4 and 3.2.6. The protease mutations (M46I, I54V and 
V82A) and gag CS mutations (N374S, A431V, L449P, S451N and P453L) were selected 
based on their presence in the patient samples. Gag non-CS mutations (Q62S and F79H), 
which were shown to be under positive selection pressure or associated with PI exposure 
(Chapter 3.1.) (Giandhari et al., 2015), were also included.  
 
A comparison of the fold change in resistance to LPV and RTV between the patient samples 
and the mutants based on them are shown in Table 3.2.2 and 3.2.3 respectively. Mutants 
tested against LPV generally showed a lower fold change in resistance compared to the 
respective patient samples. Most mutants tested against RTV showed a lower fold change 
compared to the respective patients on which they were based. Patients 1 and 2 showed high-
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level resistance to RTV but had a fold change ~3 times lower than that of the patient samples. 
However, mutant N374S+M46I+I54V+V82A had a 4 times higher fold change in resistance 
to RTV compared to patient 4. 
 
High-level resistance to RTV (Figure 3.2.5 and 3.2.6 ) was seen in 4 mutants containing gag-
protease mutations (E428D+M46I+I54V+V82A, A431V+K20R+I54V+V82A, 
N374S+M46I+I54V+V82A, A431V+I54V+V82A), and 1 mutant containing 3 protease 
mutations (M46I+I54V+V82A). Mutant I54V+V82A caused a reduced susceptibility (FC 
4.06) to RTV. No resistance was displayed to LPV by any mutants (Figure 3.2.4). A reduced 
susceptibility to LPV was seen in 4 mutants (I54V+V82A, M46I+I54V+V82A, 
N374S+M46I+I54V+V82A and E428D+M46I+I54V+V82A) (Figure 3.2.3). No decrease in 
PI susceptibility was observed for any of the single gag or protease mutations. Double 
protease mutant I54V+V82A showed a reduced susceptibility to both LPV (FC 6.0) and RTV 
(FC 4.0) while M46I+I54V and M46I+V82A were susceptible to LPV and RTV. The triple 
protease mutant M46I+I54V+V82A showed a reduced susceptibility to LPV (FC 4.7) (Figure 
3.2.3 and 3.2.4) and a high-level resistance to RTV (FC 13.7) (Figure 3.2.5 and 3.2.6).  
 
Gag mutants (L449P+P453L and F79Y+L449P+P453L) and a combination of gag-protease 
mutants (Q62S+V82A, M46I+V82A+F79H and V82A+S451N) showed susceptibility to 
both LPV and RTV. Addition of N374S to M46I+I54V+V82A caused a further decrease in 
susceptibility to LPV (p > 0.001) and caused an increased resistance (FC 22.1) to RTV (p < 
0.001). The addition of the A431V gag CS mutation to I54V+V82A increased susceptibility 
to LPV (FC 3.2) while significantly (p < 0.001) reducing RTV susceptibility (FC 11.3). 
Further addition of the minor PI mutation K20R to I54V+V82A+A431V did not alter 
susceptibility to either LPV or RTV (p > 0.001). Interestingly, addition of E428D to 
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M46I+I54V+V82A did not alter susceptibility to LPV but caused an increase in resistance 
(FC 16.4) to RTV (p < 0.05) (Figure 3.2.4).  
 
The frequency of these mutations in the patient samples and the database are shown in Table 
3.2.4. The gag CS mutations N374S and A431V, and non-CS mutation Q62S and F79H 
occurred only in the samples from failing patients in our cohort. Of these 4 mutations, N374S 
had a high frequency of 21% in the downloaded subtype C naive sequences suggesting that it 
may be a polymorphism. Gag mutations L449P and P453L were observed in both baseline 
and failure time-points. L449P occurred in 3 patients (15%) at failure and in one of these 
patients (5%) it was also present at baseline. P453L occurred in 3 patients (15%) at failure 
and was present in two of these patients at baseline. Both L449P and P453L have a low 
frequency (< 5%) in subtype C naive patients. Major PI mutations were only observed in the 
samples failing PI therapy with V82A (40%), I54V (20%) and M46I (15%). The Stanford 
drug resistance database reported that major PI mutations (M46I, I54V and V82A) occurred 
at higher frequencies in PI-treated patients, 9.1%, 11% and 12%, respectively.   
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3.2.5. Discussion 
 
Recent studies have shown a low frequency of protease drug resistance mutations in the 
majority of patients failing PI-based therapy (Siliciano and Siliciano, 2013, Wallis et al., 
2011, Levison et al., 2012). It has been suggested that regions outside of protease may 
contribute to treatment failure (Siliciano and Siliciano, 2013). Previous genotyping of these 
paediatric patients showed the presence of changes at gag CS and non-CS at PI failure 
implicating the role of gag in PI resistance. Overall, the majority of patients in the current 
study that lacked PI major mutations showed complete phenotypic susceptibility to LPV and 
RTV. However, in some patients, changes in gag caused a reduced susceptibility to LPV and 
RTV in the absence of PI mutations, or a further decrease in PI susceptibility in the presence 
of major PI mutations. This study therefore suggests that changes in gag could have an 
impact on PI susceptibility in some cases but are unlikely to be the reason for PI failure in 
most patients.  
 
Phenotypic analysis showed that most patients with PI resistance mutations had 
reduced susceptibility or high-level resistance to LPV and/or RTV. However, a reduced 
susceptibility to both drugs was also seen in three patients with gag CS and or non-CS 
changes in the absence of PI mutations. This suggests that gag has an effect on PI 
susceptibility in the absence of PI mutations. Dam et al. (2009) had similarly shown the direct 
effect of gag CS A431V mutation in highly PI-experienced patients on PI susceptibility.  
From our dataset, there were no associations found between gag CS and non-CS changes 
which caused reduced susceptibility to the PIs since each patient’s gag genotype differed. 
However, few studies have investigated the effects of non-CS mutations on PI susceptibility. 
Further studies on full-length gag will be beneficial in providing more insight on the role of 
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non-CS mutations. The gag non-CS mutations may in combination with CS mutations 
influence PI susceptibility as seen with the three patients having no major PI mutations but 
reduced phenotypic susceptibility.  
 
Individual gag CS and non-CS mutants created by site-directed mutagenesis did not 
show any effect on PI susceptibility. However, the combination of protease and gag 
mutations showed a decreased susceptibility to RTV similar to what was seen with the patient 
samples. In the presence of protease mutations, gag appeared to contribute to decreased PI 
susceptibility. The addition of gag CS mutations N374S and E428D to major protease 
mutations caused a slight increase in resistance to LPV and a 3- and 8-fold increase in 
phenotypic resistance to RTV respectively. The site-directed mutagenesis results did not 
correlate directly to the phenotypic data of the patient samples. This may be due to the 
background polymorphisms present in the patient samples which may in combination with 
other changes in gag and protease influence PI susceptibility. Nevertheless, the combination 
of gag-protease mutations did show the contributing effect of certain gag mutations to PI 
resistance. The results also demonstrated that an accumulation of mutations is required to 
develop resistance to PIs. 
 
Although this study has shown that gag may in some cases contribute to PI resistance, 
in the presence or absence of protease mutations, the phenotypic susceptibility shown by 
some patient samples (n=9, 45%) in the absence of PI mutations does not support drug 
resistance as a cause for failure. Studies have suggested other possible reasons for PI-based 
therapy failure in the absence of protease mutations. The first suggests the involvement of 
PIs at viral entry where the envelope gene was identified as a possible site for PI resistance 
(Rabi et al., 2013). A second suggests that the sharp dose-response curve and short half-life 
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of PIs provides only a short window period in which resistance mutations can develop 
(Rosenbloom et al., 2012). This is likely to result in little resistance mutations observed at 
failure. Implicitly, this phenotypic data confirms that the lack of PI mutations corresponds 
with a lack of phenotypic resistance. 
 
The phenotypic susceptibility to LPV and RTV in vitro varied amongst patients with different 
treatment histories. Most samples from patients treated with RTV or RTV+LPV/r showed a 
reduced susceptibility or resistance to LPV and/or RTV while all patients that received LPV/r 
remained susceptible to both drugs. Those exposed to RTV+LPV/r and RTV monotherapy 
contained mutations in both protease and gag while those exposed to LPV/r did not. Previous 
studies have also shown the selection of major PI mutations by RTV (Orrell et al., 2013, van 
Zyl et al., 2009), therefore RTV monotherapy is no longer recommended. The increased 
selection of protease and gag CS mutations by RTV monotherapy, as observed in the patient 
samples indicates that inaccurate dosage of the RTV component of LPV/r treatment may 
result in the selection of mutations.  
 
Differences were observed between the phenotypes determined in this study and the 
predicted phenotypes reported by the Stanford HIV-1 Drug Resistance Database. This may be 
due to the inclusion of gag in our analysis compared to the database which only considers 
mutations in the protease gene. Additionally, the database determines the levels of resistance 
based on mutation penalty scores which have been based on previously published phenotypic 
data as compared to the assay which uses the patient’s baseline sample as a reference to 
calculate the IC50. The baseline resistance level to LPV and RTV vary widely between most 
patients. Therefore, changes which pre-exist in the baseline sample may influence the fold 
change. Currently, patient-specific changes in the gag gene are not considered in standard 
 116 
 
genotypic or phenotypic resistance assays. Our study has shown that this may result in an 
inaccurate assessment of PI resistance. Furthermore, since certain gag CS are highly variable 
and differ between the various subtypes, this may create difficulty in establishing a list of gag 
resistance associated mutations to help easily identify these sites (de Oliveira et al., 2003). 
Therefore, further research on a larger number of patients at baseline and failing PI-based 
therapy is warranted to understand the role and mechanism by which gag CS and non-CS 
mutations affect PI susceptibility. Also further work involving the generation of gag chimeras 
to determine the individual contribution of gag to PI susceptibility would be valuable. 
 
In conclusion, this study found that changes in gag contributed to PI resistance only in the 
presence of PI major mutations. A few patients showed the effect of gag mutations directly 
on PI resistance causing reduced susceptibility in the absence of PI major mutations. 
Therefore, further investigation of the gag gene in a larger cohort of patients failing PI-based 
therapy in the absence of major PI mutations is warranted to understand the role of gag in PI 
resistance. Nearly half of the patients showed a lack of PI mutations and had in vitro 
phenotypic susceptibility to LPV and RTV indicating that resistance was not the reason for 
PI-therapy failure in this subset of patients. This suggests sub-optimal adherence in these 
patients and switching to a new regimen may not prevent future therapy failure. Therefore, 
especially for paediatric patients who have limited treatment options, improving the 
tolerability and palatability of drugs will help increase adherence and retention on regimen. 
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Table 3.2.1. Phenotypic resistance of paediatric patient samples to lopinavir and ritonavir 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a RTV + LPV/r: Patients received both RTV as a single PI as well as LPV/r at some point; RTV: Patients received RTV as a single PI only;  
LPV/r: patients received LPV/r only  
b Predicted phenotype according to Stanford drug resistance database. Six patients (indicated by an asterisk) showed discordance between the predicted and actual phenotype 
c Levels of drug resistance: S= sensitive; RS= reduced susceptibility, H= High-level resistance (Highlighted by different levels of shading). The assay cut-offs were determined 
to be: sensitive (S) (LPV: <4.4 FC, RTV: <3.2 FC), reduced susceptibility (RS) (LPV: 4.4 - 10 FC, RTV: 3.2 – 10 FC) and resistant (R) (LPV: >10 FC, RTV: >10 FC).  
Protease mutations in bold represent major PI mutations. Mutations underlined represent changes which developed following PI-based therapy 
Pt. No. Treatmenta Protease Genotype Predicted  
Phenotypeb 
Gag-CS Genotype  LPV Phenotype RTV Phenotype 
  
 FC 
(S<4.4) 
Levelc FC 
(S<3.2) 
Levelc 
1* RTV +LPV/r I54V, V82A, K20R, L23I, E35D, L63P Intermediate V378A, A431V  109.0 R 32.0 R 
2 RTV +LPV/r M46I, I54V, V82A, L10I, K20R, E35D, Q61H, L63P High E428D  191.0 R 44.4 R 
3* RTV +LPV/r V82A, K20R, K45R Low-level -  68.0 R 26.0 R 
4* RTV +LPV/r M46I, I54V, V82A,  K20R, L33F, E35D, T74S High V128T, N374S  5.2 RS 5.0 RS 
5 RTV +LPV/r - Susceptible -  4.2 S 6.0 RS 
6 RTV +LPV/r K43E, N83S Susceptible  S373A  1.3 S 0.8 S 
7 RTV +LPV/r A71T Susceptible -  0.8 S 0.8 S 
8* RTV V82A, S12T, L10I, K20R, E35D, D60E, Q61E  Low-level N451S  12.1 R 49.0 R 
9 RTV M46I, V82A, A63T Intermediate V128I  6.0 RS 5.7 RS 
10 RTV I54V, V82A, I36M, N37S, L63P, V77I Intermediate A431V  7.6 RS 3.4 RS 
11* RTV N37S, L63S, V82I Susceptible V128I,  L449P, P453L  5.9 RS 7.4 RS 
12* RTV V82A, K20R, E35D, R57K, D60E, L63P Low-level -  1.2 S 2.3 S 
13 RTV E35D, L63V, T74S Susceptible E428K, L449P, P453L   0.1 S 1.0 S 
14 RTV L10M, I36M, N37K, K41I, L63T, K70R Susceptible -  2.6 S 3.8 RS 
15 LPV/r K20R, E35D, L63V Susceptible -  0.4 S 1.2 S 
16 LPV/r I36M, K41R, T74S, V77I Susceptible I437L   1.3 S 1.6 S 
17 LPV/r L63V Susceptible -  0.4 S 0.4 S 
18 LPV/r V82I Susceptible Y132F  2.1 S 1.9 S 
19 LPV/r I36L, N37E, K41R, L63V Susceptible T374A, P453L  1.0 S 1.4 S 
20 LPV/r L63P, V77I Susceptible L449P  0.1 S 0.3 S 
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Figure 3.2.1. Phenotypic assay standard curves for patient samples to LPV 
Fold changes are calculated based on the IC50 value of the failing sample (red line) relative to the 
baseline sample (blue line). Each patient sample was tested in duplicate and the average of that is 
represented by the curve. The 4 resistant patients are shown in red at the top, the 4 with reduced 
susceptibility in orange and the 12 susceptible in green. 
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Figure 3.2.2. Phenotypic assay standard curves for patient samples to RTV 
Fold changes are calculated based on the IC50 value of the failing sample (red line) relative to the 
baseline sample (blue line). Each patient sample was tested in duplicate and the average of that is 
represented by the curve. The 4 resistant patients are shown in red at the top, the 6 with reduced 
susceptibility in orange and the 10 susceptible in green. 
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Table 3.2.2. Comparison of fold change between patient samples and gag-protease mutants based 
on patient samples for LPV 
Patient Fold change SDM Fold change 
1 109.0 A431V+K20R+I54V+V82A 3.9 
2 191.0 E428D+M46I+I54V+V82A 5.9 
3 68.0 Q62S+V82A 0.7 
4 5.2 N374S+M46I+I54V+V82A 5.9 
8 12.1 N451S+V82A 1.4 
9 6.0 F79H+M46I+V82A 1.7 
10 7.6 I54V+V82A 6.0 
11 5.9 L449P+P453L 0.8 
12 1.2 V82A 1.3 
20 0.1 L449P 0.7 
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Figure 3.2.3. Phenotypic assay standard curves for protease and gag mutants to LPV 
Multiple mutants were created by successive rounds of site-directed mutagenesis. The fold change 
of each mutant was calculated relative to p8.MJ4. The protease only mutants in the upper graph 
show that I54V+V82A and M46I+I54V+V82A mutants show reduced susceptibility. From the 
combination of protease and gag mutants, the addition of gag mutations was shown to have 
minimal change on LPV susceptibility. 
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Figure 3.2.4. Phenotypic susceptibility of protease and gag mutations to LPV 
Phenotypic response of single and multiple site-directed mutations created in p8.MJ4 subtype C 
HIV-1 expression plasmid to LPV. Phenotypic susceptibility was determined with a single-cycle 
non-replicative phenotypic assay. Protease and gag mutations were selected from patient samples 
based on their known or potential involvement in PI resistance. The patient sample to which each 
SDM is associated with is indicated on the graph. The fold change of each mutant was calculated 
relative to p8.MJ4. The lower and upper cut-offs are indicated by dotted lines. Error bars indicate 
the standard error of the mean (SEM). Each mutant was tested in at least two independent 
experiments, in duplicate. 
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Table 3.2.3. Comparison of fold change between patient samples and gag-protease mutants based 
on patient samples for RTV 
Patient Fold change SDM Fold change 
1 32.0 A431V+K20R+I54V+V82A 10.8 
2 44.4 E428D+M46I+I54V+V82A 16.4 
3 26.0 Q62S+V82A 1.1 
4 5.0 N374S+M46I+I54V+V82A 22.1 
8 49.0 N451S+V82A 1.0 
9 5.7 F79H+M46I+V82A 3.0 
10 3.4 I54V+V82A 4.0 
11 7.4 L449P+P453L 1.5 
12 2.3 V82A 1.2 
20 0.3 L449P 0.6 
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Figure 3.2.5. Phenotypic assay standard curves for protease and gag mutants to RTV 
Multiple mutants were created by successive rounds of site-directed mutagenesis. The fold change 
of each mutant was calculated relative to p8.MJ4. The protease only mutants in the upper graph 
show the triple mutant M46I+I54V+V82A being the least susceptible to RTV.  Addition of gag 
mutations N374S and E428D caused a distinct increase in resistance to RTV (second graph). 
Addition of gag mutation A431V to I54V+V82A caused a further increase in resistance to RTV.  
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Figure 3.2.6. Phenotypic resistance of protease and gag mutations to RTV 
Phenotypic response of single and multiple site-directed mutations created in p8.MJ4 subtype C 
HIV-1 expression plasmid to RTV. Phenotypic susceptibility was determined with a single-cycle 
non-replicative phenotypic assay. Protease and gag mutations were selected from patient samples 
based on their known or potential involvement in PI resistance. The patient sample to which each 
SDM is associated with is indicated on the graph. The fold change of each mutant was calculated 
relative to p8.MJ4. The lower and upper cut-offs are indicated by dotted lines. Error bars indicate 
the standard error of the mean (SEM). Each mutant was tested in at least two independent 
experiments, in duplicate. 
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Table 3.2.4. Frequency of site-directed mutations in patient samples and in the Stanford drug 
resistance database 
Mutation 
Frequency in 
Cohort (%) 
Frequency in HIV-1 
Subtype C in the 
Stanford database (%) 
Protease 
 
Baseline 
(n=20) 
Failure 
(n=20) 
PI Naive 
(n=10466) 
PI Treated 
(n=1208) 
M46I 0.0 15.0 0.2 9.1 
I54V 0.0 20.0 0.0 11.0 
V82A 0.0 40.0 0.1 12.0 
Gag 
 
Baseline 
(n=20) 
Failure 
(n=20) 
PI Naive* 
(n=2152) 
 
Q62S 0.0 5.0 0.8 
F79H 0.0 5.0 2.2 
N374S 0.0 5.0 21.0 
A431V 0.0 10.0 0.1 
L449P 5.0 15.0 0.0 
P453L 10.0 15.0 3.2 
* The subtype C naive sequences used to determine the frequency of the gag mutations  
were obtained from the Los Alamos Sequence Database. 
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3.3.1. Abstract 
 
Introduction 
The South African national guidelines recommend the use of ritonavir boosted-lopinavir 
(LPV/r) as a first line regimen for HIV-infected children <3 years of age. After failure of 
protease inhibitor (PI)-based therapy, options are limited for the treatment of paediatric 
patients. Here we investigated the phenotypic susceptibility of patients failing a RTV 
and/or LPV/r-based regimen to other PIs. 
 Materials and Methods 
A phenotypic analysis of the gag-protease genes from 20 children failing a LPV/r and/or 
ritonavir (RTV)-based regimen was performed to determine their susceptibility to other 
PIs.  
Results 
Among the 20 patients tested, phenotypic susceptibility was shown for lopinavir (LPV) 
(n= 12), ritonavir (RTV) (n= 10), amprenavir (APV) (n= 16), atazanavir (ATV) (n= 11), 
darunavir (DRV) (n= 18), saquinavir (SQV) (n= 16). Four patients showed multi-drug 
resistance to LPV, RTV, APV, ATV and SQV. A reduced susceptibility in the absence of 
PI mutations was seen in 4 patients. These 4 patients contained gag cleavage site (CS) 
and/or non-CS changes. The majority of samples remained susceptible to DRV, with only 
2 patients showing reduced susceptibility. One of these patients had a wild type protease 
with mutations in gag.  
Conclusion 
Mutations in protease acquired from RTV and LPV/r-based therapy, cause cross-
resistance to other PIs. DRV, which remained phenotypically active against most mutants, 
is an effective alternative option for patients failing LPV/r-based therapy. Furthermore, 
since gag could influence the sensitivity of viruses to PIs the analysis of gag in addition 
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to protease could be useful in identifying effective drugs for use in future PI-based 
regimens.  
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3.3.2. Introduction 
 
The use of protease inhibitors (PIs) for treatment of HIV-1-infected infants is 
recommended following possible exposure to NNRTI-based regimens for PMTCT, and 
has been adapted as standard-of-care in South Africa.  In most resource-limited countries 
LPV/r is used in PI-based regimens. While LPV/r has a high genetic barrier to resistance, 
its effectiveness is limited due to drug-drug interactions and poor palatability resulting in 
poor adherence and treatment failure. Unfortunately, paediatric patients face limited 
subsequent PI options upon failure on a LPV/r-based regimen. Since HIV-1 infected 
children require life-long antiretroviral treatment, optimal adherence and identification of 
effective PIs will limit the need for unnecessary regimen change.  
 
PIs target the HIV-1 protease enzyme and function by inhibiting the cleavage of HIV-1 
Gag and Gag-Pol polyproteins resulting in the formation of immature viruses (Arts and 
Hazuda, 2012). There are currently 10 PIs approved for use by the US Food and Drug 
Administration (National Institutes of Health, 2014). Only 5 of these PIs (LPV/r, 
tipranavir (TPV/r), fosamprenavir (FTC), ritonavir (RTV) and nelfinavir (NFV)) have 
formulation options that are approved for use in children <3 years of age. In addition, 
mutations that are selected during LPV/r-based therapy, such as M46I, I54V and V82A, 
provide cross-resistance to the other PIs (Rhee et al., 2010). Protease mutation M46I has 
been associated with a decreased susceptibility to LPV, APV, IDV, and NFV. I54V 
decreases susceptibility to LPV, ATV, IDV, NFV AND SQV while V82A decreases 
susceptibility to LPV and IDV (Rhee et al., 2010).  
 
Failure on PI-based regimens in the absence of mutations in protease have been reported 
in several studies (Zanoni et al., 2012, Levison et al., 2012, Orrell et al., 2013, Babiker et 
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al., 2011). Non-adherence is often the cause of the absence of resistance mutations, 
however, certain changes occurring at the gag CS have been shown to contribute to or 
directly cause resistance to PIs even in the absence of mutations in protease (Dam et al., 
2009, Fun et al., 2012, Nijhuis M, 2007). Furthermore, an increased prevalence of gag CS 
mutations has been observed in PI treated patients compared to treatment naive patients 
(Verheyen et al., 2006, Nijhuis M, 2007). The gag CS mutations A431V and I437V/T 
have been associated with DRV resistance (Lambert-Niclot et al., 2008). A431V was 
associated with selection of protease mutation L76V during DRV therapy while I437V/T 
was associated with a lower rate of DRV resistance mutations. The exact role of gag non-
CS mutations is not well understood, however it has been speculated that changes at non-
CS may render the CS more available to protease via conformational changes in gag 
(Gatanaga et al., 2002). A study looking at the effect of non-CS mutations on PI 
susceptibility identified novel mutations in gag (codons 12, 75, 219, 390 and 409) which 
increased resistance to APV and delayed the emergence of resistance to RTV and NFV 
(Aoki et al., 2009).  
 
Since HIV-1 Protease and its substrate Gag appear to co-evolve during resistance 
selection, both should be considered as a single functional unit when investigating PI 
resistance (Kolli et al., 2014, Gupta et al., 2010). To identify PIs that remain effective 
after LPV/r failure and investigate the role of gag in resistance to these PIs, patient-
derived samples and gag-protease site-directed mutants were assessed for phenotypic 
susceptibility to APV, ATV, DRV and SQV. 
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3.3.3. Materials and Methods 
3.3.3.1. Samples from HIV-1 infected children 
Samples from 20 HIV-1 infected subtype C paediatric patients at baseline and failing a 
PI-based regimen were collected and analysed (Chapter 3.1.3.1.). All children >6 months 
of age were treated with ritonavir-boosted lopinavir (LPV/r) and two NRTIs. Children <6 
months of age and those receiving treatment for tuberculosis, were treated with ritonavir 
(RTV) and two NRTIs. This study was approved by the institutional review boards of 
Columbia University and the University of the Witwatersrand. 
 
3.3.3.2. Construction of patient-derived test vectors 
A retroviral vector system, capable of a single infectious event was used to determine the 
phenotypic susceptibility to PIs (Gupta et al., 2010, Parry et al., 2009) (Chapter 3.2.3.2). 
Briefly, 1.8kb gag-protease amplicon from patient samples containing NotI and XhoI 
restriction sites was sequenced and cloned into the HIV-1 expression vector p8.9NSX+. 
Sequences were submitted to the Stanford HIVdb drug resistance algorithm 
(hivdb.stanford.edu) for identification of protease inhibitor resistance mutations and to 
predict phenotypic PI resistance. Polymorphisms in the protease and gag genes were 
defined as changes in amino acid sequence between the failing and baseline sequences. 
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3.3.3.3. Site-directed mutagenesis  
An HIV-1 expression vector containing the gag-protease-reverse transcriptase fragments 
of the MJ4 subtype C reference strain (GenBank: AF321523.1) (Ndung'u et al., 2001) was 
used for construction of site-directed mutants (Chapter 3.2.3.3). The protease mutations 
were chosen based on the genotype of the patient samples and those in the Stanford 
Database which showed high-level resistance to each PI. The gag changes were selected 
from patient samples based on their known or potential involvement in PI resistance. 
Additional gag non-CS mutants, which were shown to develop under positive selection 
pressure (Chapter 3.1), were also created. Briefly, single site-directed mutants were 
created by use of the QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, La 
Jolla, California, USA). Mutants with multiple mutations were created by successive 
rounds of site-directed mutagenesis.  
 
3.3.3.4. Phenotypic assessment of PI susceptibility 
A single cycle phenotypic assay was performed as previously described (Parry et al., 
2009, Gupta et al., 2010), with minor modifications (Chapter 3.2.3.4). Briefly, HEK293T 
cells were transfected with 300 ng of pMDG, 500 ng of pCSFLW  and 300 ng of patient 
derived expression vector using 3.3 μg polyethylenimine (PEI) (Polyscience, Inc., 
Warrington, Pennsylvania, USA). Transfected cells were harvested and seeded in the 
presence of serial dilutions of PIs. Infectious supernatants were used to infect fresh 
HEK293T cells. The degree of infection was determined by measuring the expression of 
firefly luciferase in infected target cells at 48 hours post-infection. The phenotypic 
susceptibility of patient’s samples at PI failure was expressed as a fold-change (FC) 
relative to the baseline sample. The phenotypic susceptibility of site-directed mutants was 
expressed as a FC relative to p8.MJ4. The lower cut-off values differed for the patient 
samples and site-directed mutants due to the different controls used in each assay.  For the 
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patient samples, the p8.9NSX+ vector containing the gag-protease fragment from p8.MJ4 
creating p8.MJ4GP was used as a control. For the site-directed mutants, p8.MJ4 was used 
as a control since all mutants were created in p8.MJ4. The phenotypes were classified as 
sensitive (S), reduced susceptibility (RS) and resistant (R). Sensitive referred to FC which 
was < the lower cut-off, reduced susceptibility referred to FC > lower cut-off but less than 
10 FC, and resistant referred to FC >10. A 10 FC was arbitrarily chosen as an upper cut-
off value. The assay cut-offs for the patient samples and site-directed mutants are shown 
in Table 3.3.7. 
  
3.3.3.5. Statistical Analysis 
Two-way analysis of variance (ANOVA) was used to identify significant differences in 
FC values between the site-directed mutants using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, San Diego, California, USA).  
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3.3.4. Results 
 
3.3.4.1. Phenotypic susceptibility of patient-derived protease and gag genes 
Genetic changes in the gag and protease genes of paediatric patients were previously 
reported (Chapter 3.1) (Giandhari et al., 2015). In addition these changes were 
phenotypically tested to examine the impact of these changes on LPV and RTV 
susceptibility (Chapter 3.2). To determine the impact of these changes on other PIs the 
baseline and failing samples were tested against APV, ATV, DRV and SQV. Protease 
inhibitor exposure, phenotypic drug susceptibility and genotypic profiles of the 20 
children are shown in Table 3.3.1. All protease and gag changes were based on the failing 
sample relative to the baseline. The gag non-CS mutations were previously reported in 
section 3.1.3.  
 
Of the 7 patients treated with RTV+LPV/r, one patient (Pt. 7) showed phenotypic 
susceptibility to 6 of the PIs tested. Patient 7 contained no major PI mutations or gag CS 
mutations. Three patients (Pt. 1, Pt. 2 and Pt. 3) treated with RTV+LPV/r showed cross-
resistance to ≥ 5 PIs. All 3 of these patients had major PI mutations and gag changes. Of 
the 7 patients treated with RTV monotherapy, 2 patients (Pt. 12 and Pt. 13) showed 
susceptibility to all PIs tested while 4 patients (Pt. 8, Pt. 9, Pt.10 and Pt. 11) showed 
cross-resistance to ≥ 3 PIs. Of these 4 patients, 3 had PI mutations while one only had 
changes in gag. All 6 patients treated with LPV/r that lacked PI mutations were 
phenotypically susceptibile to all the PIs tested.  
 
Of the 20 patients tested, phenotypic susceptibility to DRV was seen in 18 (90%), to APV 
in 16 (80%), to and to SQV in 16 (80%), to LPV was seen in 12 (60%), to ATV in 11 
(55%) and to RTV in 10 (50%). Reduced susceptibility was seen in 8 (40%) patients to 
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LPV, 10 (50%) patients to RTV, 4 (20%) patients to APV, 9 (45%) patients to ATV, 2 
(10%) patients to DRV and 4 (20%) patients to SQV. DRV showed the least phenotypic 
resistance with 2 patients having reduced susceptibility of 5.5 FC and 5.3 FC. The 
phenotypic curves of all patients are shown in Figures 3.3.1, 3.3.2, 3.3.3 and 3.3.4 for 
APV, ATV, DRV and SQV. The phenotypic curves for LPV and RTV were previously 
shown in Chapter 3.2. The fold change for each failing patient was calculated relative to 
its matched baseline sample.  
 
Four patients (Pt. 5, Pt. 6, Pt. 11 and Pt. 14) showed reduced susceptibility to PIs in the 
absence of PI mutations. Reduced susceptibility to RTV (6.0 FC) and ATV (3.8 FC) in 
the presence of gag non-CS mutations was seen in patient 5. Although marginally above 
the cut-off, reduced susceptibility to ATV (2.4 FC) was seen in patient 6 in the presence 
of gag CS and non-CS changes. Interestingly, patient 11 showed reduced susceptibility to 
4 PIs: ATV (FC 11.5), LPV (FC 5.9), RTV (FC 7.4) and DRV (FC 5.3), whilst having 
only gag changes. Reduced susceptibility to RTV (FC 3.8) was seen in patient 14 in the 
presence of gag non-CS changes.   
 
Patients with both major PI mutations and gag CS mutations showed greater reduced 
susceptibility to all the PIs compared to patients with only protease mutations, gag CS 
mutations and those with only gag non-CS mutations (Figure 3.3.5). This demonstrated 
the contribution of gag CS to PI resistance in the presence of PI mutations. Patients with 
only gag CS mutations showed increased susceptibility to LPV, APV, DRV and SQV. 
 
3.3.4.2. The predicted phenotype versus the phenotypic assay 
The predicted phenotype of each patient to 5 PIs (LPV, APV, ATV, DRV and SQV) was 
determined using the Stanford HIV-1 Drug Resistance database. Phenotypic predictions 
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for RTV are not available on the database. Discordance between the database and the 
assay were defined as: i) any sample showing susceptibility in the phenotypic assay and 
any level of resistance predicted by the database; ii) any sample having predicted 
susceptibility by the database and showing either reduced susceptibility or high-level 
resistance in the assay. Discordance between the database prediction and the phenotypic 
assay was seen for 8 patients (Pt 2, 4, 5, 6, 9, 10 and 11) as shown in Table 3.3.2 and 
Figure 3.3.6. For 4 patients (Pt 2, 5, 6 and 11) the database had predicted susceptibility 
however the phenotypic assay showed reduced susceptibility for these patients. The 
inclusion of gag in our assay may be responsible for this reduced susceptibility. The 
remaining 4 discordant patients (Pt 4, 9, 10 and 12) the database predicted low to high 
levels of resistance to the different PIs however the phenotypic assay predicted 
susceptibility.  
  
3.3.4.3. Phenotypic susceptibility of control protease site-directed mutants 
Single, double and triple protease mutants were created in p8.MJ4 and tested for 
phenotypic susceptibility to LPV, RTV, APV, ATV, DRV and SQV (Figures 3.3.7 and 
3.3.8). These mutants included those which occurred in the patient samples (M46I, I54V 
and V82A) as well as additional combinations of mutations (G48V, I47V and I84V) 
which were predicted by the Stanford database to show resistance to each drug (Chapter 
2.2, Figure 2.7). From the single protease mutants G48V showed reduced susceptibility to 
APV (FC 2.1) and SQV (7.6 FC) (P < 0.001). Mutant I54V showed reduced susceptibility 
(1.5 FC) to SQV modestly above the cut-off. M46I+I47V showed reduced susceptibility 
to APV (FC 5.8) which was statistically significant (P < 0.001) compared to ATV, DRV, 
LPV, RTV and SQV. I54V+V82A caused reduced susceptibility to LPV (FC 6.0) and 
RTV (FC 4.0). For LPV, the reduced susceptibility was significantly (P < 0.001) higher 
compared to RTV, APV, ATV, DRV and SQV. Triple protease mutant 
 144 
 
M46I+I54V+V82A showed resistance to RTV (FC 13.7) and reduced susceptibility to 
ATV (FC 3.6) and LPV (FC 4.7). For RTV, the increase in resistance was significant (P < 
0.001) compared to LPV, APV, ATV, DRV and SQV. For ATV, a significant (P < 0.001) 
change in susceptibility was seen compared to APV, DRV and SQV. The reduced 
susceptibility to LPV was significant (P < 0.001) compared to APV, DRV and SQV. 
M46I+I54V+I84V showed reduced susceptibility to RTV (FC 3.2) (P < 0.05) compared 
to ATV, DRV and LPV. G48V+I54V+V82A showed reduced susceptibility to RTV (FC 
6.9) and high-level resistance to ATV (FC 16.8), LPV (FC 10.6) and SQV (FC 26.9). All 
protease mutants showed susceptibility to DRV.  
 
3.3.4.4. Phenotypic susceptibility of gag site-directed mutants 
Single and multiple protease and gag mutants were created in p8.MJ4 and tested for 
phenotypic susceptibility to APV, ATV, DRV and SQV (Figure 3.3.10, 3.3.12, 3.3.14 and 
3.3.16). These mutations and combinations were based those found in the patient samples. 
A comparison of the fold change in resistance between the patient samples and the 
mutants based on them are shown in Tables 3.3.3, 3.3.4, 3.3.5 and 3.3.6. All mutants had 
a lower fold change compared to the respective patient samples. 
 
Cross-resistance conferred by site-directed mutants were noted primarily with the PI 
major mutations (M46I, I54V and V82A) to ATV and SQV. Of the single gag mutants, 
cleavage site mutations N374S showed reduced susceptibility to SQV and P453L showed 
reduced susceptibility to DRV (Figure 3.3.13) which were marginally above the assay cut 
off. Gag mutants (L449P+P453L and F79Y+L449P+P453L) and gag-protease mutants 
(Q62S+V82A, F79H+M46I+V82A and S451N+V82A) showed susceptibility to all PIs 
tested. Reduced susceptibility and resistance was seen with mutants carrying ≥ 3 gag-
protease mutations. Mutant N374S+M46I+I54V+V82A caused reduced susceptibility to 
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LPV (5.9 FC) and high-level resistance to RTV (22.1 FC). The resistance caused by 
N374S+M46I+I54V+V82A to RTV was significant (P < 0.001) compared to APV, ATV, 
DRV and SQV. Mutant A431V+I54V+V82A caused resistance (11.3 FC) to RTV which 
was significant (P < 0.05) compared to APV, ATV, DRV and SQV. A431V+I54V+V82A 
caused reduced susceptibility to SQV (Figure 3.3.15) slightly above the cut off (1.2 FC). 
Addition of minor protease mutation K20R to A431V+I54V+V82A did not affect 
resistance to RTV (10.8 FC) or any of the other PIs. Interestingly, for APV, there was a 
slight increase in FC seen with the addition of K20R to A431V+I54V+V82A (Figure 
3.3.9.). Mutant E428D+M46I+I54V+V82A caused reduced susceptibility to LPV (5.8 
FC) and SQV (1.4 FC) (Figure 3.3.15) and high-level resistance to RTV (16.4 FC). 
Resistance caused by E428D+M46I+I54V+V82A to RTV was significant (P < 0.001) 
compared to APV, ATV, DRV and SQV.  For ATV, although not significant, the addition 
of gag mutations to protease mutations slightly increased the FC (Figure 3.3.11). Overall, 
all mutants were susceptible to APV and ATV. Mutants had a minimal effect on 
sensitivity to DRV and SQV with fold changes < 1.5.  
 
In comparison to the patients’ phenotypic susceptibility, differences were observed for 
some mutations by site-directed mutagenesis. For APV and DRV the mutants created 
based on the patients samples did not correlate with the patient’s phenotype as most 
mutants showed susceptibility to the PIs. For ATV, M46I+I54V+V82A based on patient 2 
and 4, showed reduced susceptibility compared to patient 2 which showed high-level 
resistance. In patient 4, susceptibility to ATV was seen while the triple protease mutant 
showed reduced susceptibility. Interestingly, with a further addition of gag CS mutations 
E428D and N374S an increase in susceptibility was seen. For SQV, the triple protease 
mutant (M46I+I54V+V82A) based on patient 2, showed reduced susceptibility whereas 
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patient 2 had a phenotype showing high-level resistance. Further addition of gag CS 
mutation E428D reduced susceptibility to SQV marginally above the cut-off. 
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3.3.5. Discussion 
 
Protease inhibitors are potent antiretroviral drugs used to treat HIV-1 infection, with 
LPV/r being the most widely used in resource limited settings. Recent studies have shown 
a low frequency of protease mutations in patients failing LPV-based therapy. Earlier 
studies have shown that changes in gag at failure contributed to resistance to LPV and 
RTV in the presence and absence of PI mutations in some patients. This data shows that 
major PI mutations from a prior RTV-based regimen caused cross-resistance to other PIs. 
Additionally, in some patients with no PI mutations, changes in gag were found to cause 
reduced susceptibility to some of the PIs. However, patients who remained susceptible to 
the PIs in the absence of PI mutations reflect what is currently seen in clinical settings 
where majority patients failing PI therapy have a wild-type protease.    
 
As previously shown with LPV and RTV, phenotypic resistance was higher in patients 
who had received prior RTV monotherapy compared to those treated with LPV/r 
exclusively (Chapter 3.2). This was primarily due to the selection of PI mutations in the 
RTV treated patients. Some patients carrying PI mutations showed cross-resistance to five 
of the six PIs tested. In these patients, only DRV showed efficacy suggesting that this 
may be a good PI for future use in LPV/r failures. Interestingly one patient with wild type 
protease showed cross-resistance to 4 PIs i.e LPV, RTV, ATV and DRV. In this patient 
changes in gag were present both at CS and non-CS. Screening of relevant site-directed 
mutants did not disclose a particular pattern of PI mutations and/or gag changes that 
could be associated with PI resistance. However, as an entity the presence of PI and gag 
CS mutations were associated with greater phenotypic resistance compared to patients 
with PI mutations only. A comparison between the Stanford database and the phenotypic 
assay showed that half of the discordant samples in the database had under estimated the 
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phenotypic response which may be due to the inclusion of gag in the phenotypic assay. 
Since the database assigns a score to every mutation for a particular PI, the phenotypic 
prediction is based on the accumulative mutation scores. However, the presence of 
polymorphisms and their effects are not taken into account by the database and this may 
be a reason for differences seen with our phenotypic assay.  
 
Since the patients did not have protease mutations associated with resistance to all PIs a 
subset of additional PI mutations were created and tested based on the Stanford drug 
resistance database. Each drug showed reduced susceptibility to high-level resistance with 
≥ 2 mutants except for DRV which showed complete susceptibility further confirming the 
effectiveness of DRV in patients failing LPV/r with PI mutations. Individual gag site-
directed mutants did not show resistance to the PIs, but in combination with protease 
mutations, high-level resistance was seen to RTV confirming the weakness of RTV as a 
single PI. The results from the site-directed mutagenesis show that gag contributes to PI 
resistance especially when tested against RTV as shown by mutants 
A431V+I54V+V82A, N374S+M46I+I54V+V82A and E428D+M46I+I54V+V82A. Thus 
suggesting that most gag mutations present in the patient samples may have been selected 
due to RTV monotherapy.  
 
For some patients, treatment failure could not be explained by using patient-derived gag-
protease in the phenotypic assay. In these patients reasons for failure may include poor 
adherence to regimen especially since these were paediatric patients. This would result in 
the absence of PI mutations and susceptibility of patients to PIs as was shown in our 
study. Incorrect dosing of the RTV component in LPV/r may have led to decreased 
plasma concentrations of LPV resulting in reduced drug selection pressure.  
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Protease mutations conferring resistance to one or more PIs have been well described and 
supported by databases (Rhee et al., 2010, Rhee et al., 2003, Shafer, 2006). However, 
sufficient data to identify specific gag determinants of PI susceptibility is still required. 
Most studies have focused on specific gag CS in the context of PI susceptibility, but it has 
been shown that full-length gag should be considered for PI resistance especially since 
changes outside of the CS also influence PI susceptibility (Gupta et al., 2010, Gatanaga et 
al., 2002). 
 
This study has shown the importance of including gag in addition to protease when 
determining PI susceptibility. In patients failing RTV and/or LPV/r-based therapy, the 
pre-existence of PI and gag mutations may result in cross-resistance to other PIs thereby 
limiting effective PI options. These results demonstrate the importance of genotypic 
testing of PI-based therapy failures to guide future PI therapy options.  
 
There is an increased need for more PIs to be made available for children who are failing 
PI therapy especially since they have limited options available (van Zyl et al., 2011, 
Gupta et al., 2009). This study demonstrated the in vitro effectiveness of other PIs on 
paediatric patients failing LPV/r therapy. Currently ATV and APV are not available for 
children < 6 years and SQV and DRV are not recommended in children <2 and <3 years 
respectively (National Institutes of Health, 2014). We are faced with the pharmacokinetic 
challenges and tolerability of these drugs in paediatric patients. Especially in children 
where adherence is a concern, improving the palatability of drugs is important. In 
addition, making more PIs more easily accessible in resource limited settings is essential.  
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Table 3.3.1. Phenotypic susceptibility and genotypic changes in patient samples 
 
Pt. No. Treatment 
PI Susceptibility Genotype 
LPV 
(S< 4.4) 
RTV 
(S< 3.2) 
APV 
(S< 4.0) 
ATV 
(S< 1.6) 
DRV 
(S< 4.9) 
 
SQV 
(S< 3.4) 
Proteasea Gag-CS 
1 RTV +LPV/r 109.0 32.0 8.7 24.9 3.0 7.7 I54V, V82A, K20R, L23I, E35D, L63P V378A, A431V 
2 RTV +LPV/r 191.0 44.4 51.8 90.1 5.5 14.9 M46I, I54V, V82A, L10I, K20R, E35D, Q61H, L63P E428D 
3 RTV +LPV/r 68.0 26.0 13.5 45.5 4.0 8.0 V82A, K20R, K45R - 
4 RTV +LPV/r 5.2 5.0 0.8 1.4 0.6 1.1 M46I, I54V, V82A,  K20R, L33F, E35D, T74S V128T, N374S 
5 RTV +LPV/r 4.2 6.0 1.7 3.8 1.8 0.9 - - 
6 RTV +LPV/r 1.3 0.8 0.2 2.4 0.3 0.1 K43E, N83S  S373A 
7 RTV +LPV/r 0.8 0.8 0.6 0.9 1.2 1.3 A71T - 
8 RTV 12.1 49.0 4.8 28.3 2.2 4.1 V82A, S12T, L10I, K20R, E35D, D60E, Q61E   N451S 
9 RTV 6.0 5.7 1.4 3.8 1.3 0.5 M46I, V82A, A63T V128I 
10 RTV 7.6 3.4 0.8 4.3 1.4 0.9 I54V, V82A, I36M, N37S, L63P, V77I  A431V 
11 RTV 5.9 7.4 1.2 11.5 5.3 0.9 N37S, L63S, V82I V128I,  L449P, P453L 
12 RTV 1.2 2.3 1.5 1.0 1.6 0.6 V82A, K20R, E35D, R57K, D60E, L63P - 
13 RTV 0.1 1.0 0.5 1.5 1.4 0.8 E35D, L63V, T74S E428K, L449P, P453L  
14 RTV 2.6 3.8 1.0 0.9 0.9 0.2 L10M, I36M, N37K, K41I, L63T, K70R - 
15 LPV/r 0.4 1.2 0.6 0.3 0.4 0.6 K20R, E35D, L63V - 
16 LPV/r 1.3 1.6 0.7 1.1 0.6 2.2 I36M, K41R, T74S, V77I I437L  
17 LPV/r 0.4 0.4 0.3 0.5 0.5 0.5 L63V - 
18 LPV/r 2.1 1.9 0.5 1.4 0.8 0.5 V82I Y132F 
19 LPV/r 1.0 1.4 1.4 1.4 1.3 1.3 I36L, N37E, K41R, L63V T374A, P453L 
20 LPV/r 0.1 0.3 0.4 0.1 0.2 0.2 L63P, V77I L449P 
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aRTV + LPV/r: Patients received both RTV as a single PI as well as LPV/r; RTV: Patients received RTV as 
a single PI only; LPV/r: patients received LPV/r only  
LPV, Lopinavir; RTV, Ritonavir; APV, Amprenavir; ATV, Atazanavir; DRV, Darunavir; SQV, Saquinavir  
Protease mutations in bold represent major PI mutations. Mutations underlined represent changes which 
developed following PI-based therapy 
a Mutations highlighted in bold represent major PI mutations according to Stanford Drug Resistance 
Database 
 Levels of drug resistance: S= sensitive; RS= reduced susceptibility, H= High-level resistance (Highlighted 
by different levels of shading) 
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Figure 3.3.1. Phenotypic assay standard curves for patient samples to ATV 
Fold changes are calculated based on the IC50 value of the failing sample (red line) relative to the 
baseline sample (blue line). Each patient sample was tested in duplicate and the average of that is 
represented by the curve. The 5 resistant patients are shown in red at the top, the 4 with reduced 
susceptibility in orange and the 11 susceptible in green. 
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Figure 3.3.2. Phenotypic assay standard curves for patient samples to DRV 
Fold changes are calculated based on the IC50 value of the failing sample (red line) relative to the 
baseline sample (blue line). Each patient sample was tested in duplicate and the average of that is 
represented by the curve. The 2 patients with reduced susceptibility are shown in orange and the 
18 susceptible in green. 
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Figure 3.3.3. Phenotypic assay standard curves for patient samples to APV 
Fold changes are calculated based on the IC50 value of the failing sample (red line) relative to the 
baseline sample (blue line). Each patient sample was tested in duplicate and the average of that is 
represented by the curve. The 2 resistant patients are shown in red at the top, the 2 with reduced 
susceptibility in orange and the 16 susceptible in green. 
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Figure 3.3.4. Phenotypic assay standard curves for patient samples to SQV 
Fold changes are calculated based on the IC50 value of the failing sample (red line) relative to the 
baseline sample (blue line). Each patient sample was tested in duplicate and the average of that is 
represented by the curve. The 1 resistant patient is shown in red at the top, the 3 with reduced 
susceptibility in orange and the 16 susceptible in green. 
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Figure 3.3.5. Association of genotype with phenotypic response to protease inhibitors.  
Patients with both PI drug resistance mutations (DRMs) and gag CS mutations (CSMs) are shown 
by black bars, patients with PI DRMs only are shown by white bars, patients with only gag CSMs 
by light grey bars and patients with gag non-CSMs only are shown by dark grey bars. The lower 
cut-offs for each drug are indicated by a dashed line.   
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Table 3.3.2. Phenotypic susceptibility of patient-derived gag-protease relative to the Stanford 
Drug Resistance Database prediction for Protease      
Predicted: Predicted phenotype based on the Stanford drug resistance database; S, susceptible; 
Low, low level resistance;  
IM, intermediate resistance; H, high-level resistance 
Assay: Phenotypic assay; Level, level of resistance; S, susceptible; RS, reduced susceptibility; R, 
resistant 
Pt. 
ID 
LPV APV ATV DRV SQV 
Predicted Assay Predicted Assay Predicted Assay Predicted Assay Predicted Assay 
1 IM R IM RS IM R S S IM RS 
2 H R IM R H R S RS IM R 
3 Low R Low R Low R S S Low RS 
4 H RS H S H S S S IM S 
5 S S S S S RS S S S S 
6 S S S S S RS S S S S 
7 S S S S S S S S S S 
8 Low R Low RS Low R S S Low RS 
9 IM RS IM S IM RS S S Low S 
10 IM RS IM S IM RS S S IM S 
11 S RS S S S R S RS S S 
12 Low S Low S Low S S S Low S 
13 S S S S S S S S S S 
14 S S S S S S S S S S 
15 S S S S S S S S S S 
16 S S S S S S S S S S 
17 S S S S S S S S S S 
18 S S S S S S S S S S 
19 S S S S S S S S S S 
20 S S S S S S S S S S 
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Figure 3.3.6. Phenotypic susceptibility of patient-derived gag-protease relative to the Stanford Drug Resistance Database prediction for Protease 
Grey shaded areas represent levels of phenotypically similar resistance. Points represented by a star indicate patients with major PI mutations.  
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Figure 3.3.7. Protease inhibitor susceptibility of control protease mutants Susceptibility of protease mutants created in p8.MJ4 was determined using a single-
replication cycle drug susceptibility assay. Data displayed are fold-change in IC50 values in comparison to the reference strain (p8.MJ4) for each of six PIs: LPV, RTV, 
APV, ATV, DRV and SQV. Each mutant was repeated at least twice. 
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Figure 3.3.8. Phenotypic susceptibility standard curves of the control protease mutants 
All curves of the protease mutants were plotted against the assay control p8.MJ4 (black line). The fold change was calculated by comparing the IC50 of each 
mutant to the IC50 of the control.  
0
10
20
30
40
50
60
70
80
90
100
0.000001 0.00001 0.0001 0.001 0.01 0.1 1
P
e
rc
e
n
t 
c
o
n
tr
o
l
Concentration (uM)
LPV 
Protease Controls
MJ4
M46I
G48V
I54V
V82A
M46I+I47V
M46I+I54V
M46I+V82A
I54V+V82A
M46I+I54V+V82A
M46I+I54V+I84V
G48V+I54V+V82A 0
10
20
30
40
50
60
70
80
90
100
0.000001 0.00001 0.0001 0.001 0.01 0.1 1
P
e
rc
e
n
t 
c
o
n
tr
o
l
Concentration (uM)
RTV
Protease Controls
MJ4
M46I
G48V
I54V
V82A
M46I+I47V
M46I+I54V
M46I+V82A
I54V+V82A
M46I+I54V+V82A
M46I+I54V+I84V
G48V+I54V+V82A
0
10
20
30
40
50
60
70
80
90
100
0.00001 0.0001 0.001 0.01 0.1 1
P
e
rc
e
n
t 
c
o
n
tr
o
l
Concentration (uM)
APV
Protease Controls
MJ4
M46I
G48V
I54V
V82A
M46I+I47V
M46I+I54V
M46I+V82A
I54V+V82A
M46I+I54V+V82A
M46I+I54V+I84V
G48V+I54V+V82A
0
10
20
30
40
50
60
70
80
90
100
0.000001 0.00001 0.0001 0.001 0.01 0.1 1
P
e
rc
e
n
t 
c
o
n
tr
o
l
Concentration (uM)
ATV
Protease Controls
MJ4
M46I
G48V
I54V
V82A
M46I+I47V
M46I+I54V
M46I+V82A
I54V+V82A
M46I+I54V+V82A
M46I+I54V+I84V
G48V+I54V+V82A
0
10
20
30
40
50
60
70
80
90
100
0.000001 0.00001 0.0001 0.001 0.01 0.1 1
P
e
rc
e
n
t 
c
o
n
tr
o
l
Concentration (uM)
DRV
Protease Controls
MJ4
M46I
G48V
I54V
V82A
M46I+I47V
M46I+I54V
M46I+V82A
I54V+V82A
M46I+I54V+V82A
M46I+I54V+I84V
G48V+I54V+V82A 0
10
20
30
40
50
60
70
80
90
100
0.000001 0.00001 0.0001 0.001 0.01 0.1 1
P
e
rc
e
n
t 
c
o
n
tr
o
l
Concentration (uM)
SQV
Protease Controls
MJ4
M46I
G48V
I54V
V82A
M46I+I47V
M46I+I54V
M46I+V82A
I54V+V82A
M46I+I54V+V82A
M46I+I54V+I84V
G48V+I54V+V82A
166 
 
 
Table 3.3.3. Comparison of fold change between patient samples and gag-protease mutants based 
on patient samples for APV 
Patient Fold change SDM Fold change 
1 8.7 A431V+K20R+I54V+V82A 1.5 
2 51.8 E428D+M46I+I54V+V82A 0.5 
3 13.5 Q62S+V82A 0.3 
4 0.8 N374S+M46I+I54V+V82A 0.6 
8 4.8 N451S+V82A 0.4 
9 1.4 F79H+M46I+V82A 0.7 
10 0.8 I54V+V82A 0.4 
11 1.2 L449P+P453L 0.7 
12 1.5 V82A 0.4 
20 0.4 L449P 0.7 
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Figure 3.3.9. Phenotypic susceptibility standard curves of gag and protease site-directed 
mutants for APV 
Multiple mutations were created by successive rounds of site directed mutagenesis. The top graph 
represents standard curves of protease mutants. The bottom graph demonstrates changes in 
susceptibility to APV when gag mutation A431V is added to protease mutations.  
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Figure 3.3.10. Phenotypic susceptibility of protease and gag site-directed mutants to APV  
Susceptibility of gag mutants created in p8.MJ4 was determined using a single-replication cycle 
drug susceptibility assay. Data displayed are fold-change in IC50 values in comparison to the 
reference strain (p8.MJ4). The patients on which these mutations were based on are indicated. 
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Table 3.3.4. Comparison of fold change between patient samples and gag-protease mutants based 
on patient samples for ATV 
Patient Fold change SDM Fold change 
1 24.9 A431V+K20R+I54V+V82A 1.4 
2 90.1 E428D+M46I+I54V+V82A 1.5 
3 45.5 Q62S+V82A 0.5 
4 1.4 N374S+M46I+I54V+V82A 1.4 
8 28.3 N451S+V82A 0.5 
9 3.8 F79H+M46I+V82A 0.5 
10 4.3 I54V+V82A 2.8 
11 11.5 L449P+P453L 0.8 
12 1.0 V82A 0.5 
20 0.1 L449P 0.5 
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Figure 3.3.11. Phenotypic susceptibility standard curves of gag and protease site-directed 
mutants for ATV 
Multiple mutations were created by successive rounds of site directed mutagenesis. The top graph 
represents standard curves of protease mutants showing reduced susceptibility to the triple 
protease mutant M46I+I54V+V82A. The middle and bottom graphs demonstrate changes in 
susceptibility to ATV when gag mutations are added to protease mutations.  
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Figure 3.3.12. Phenotypic susceptibility of protease and gag site-directed mutants to ATV  
Susceptibility of gag mutants created in p8.MJ4 was determined using a single-replication cycle 
drug susceptibility assay. Data displayed are fold-change in IC50 values in comparison to the 
reference strain (p8.MJ4). The patients on which these mutations were based on are indicated. 
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Table 3.3.5. Comparison of fold change between patient samples and gag-protease mutants based 
on patient samples for DRV 
Patient Fold change SDM Fold change 
1 3.0 A431V+K20R+I54V+V82A 0.1 
2 5.5 E428D+M46I+I54V+V82A 0.2 
3 4.0 Q62S+V82A 0.3 
4 0.6 N374S+M46I+I54V+V82A 0.6 
8 2.2 N451S+V82A 0.3 
9 1.3 F79H+M46I+V82A 0.4 
10 1.4 I54V+V82A 0.1 
11 5.3 L449P+P453L 0.6 
12 1.6 V82A 0.1 
20 0.2 L449P 0.7 
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Figure 3.3.13. Phenotypic susceptibility standard curves of gag and protease site-directed 
mutants for DRV 
Multiple mutations were created by successive rounds of site directed mutagenesis. The top graph 
represents standard curves of protease mutants. The bottom graph demonstrates no notable 
change in susceptibility by combining gag CS mutations L449P and P453L. 
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Figure 3.3.14. Phenotypic susceptibility of protease and gag site-directed mutants to DRV  
Susceptibility of gag mutants created in p8.MJ4 was determined using a single-replication cycle 
drug susceptibility assay. Data displayed are fold-change in IC50 values in comparison to the 
reference strain (p8.MJ4). The patients on which these mutations were based on are indicated. 
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Table 3.3.6. Comparison of fold change between patient samples and gag-protease mutants based 
on patient samples for SQV 
Patient Fold change SDM Fold change 
1 7.7 A431V+K20R+I54V+V82A 0.1 
2 14.9 E428D+M46I+I54V+V82A 1.4 
3 8.0 Q62S+V82A 0.1 
4 1.1 N374S+M46I+I54V+V82A 0.7 
8 4.1 N451S+V82A 0.2 
9 0.5 F79H+M46I+V82A 0.3 
10 0.9 I54V+V82A 1.0 
11 0.9 L449P+P453L 0.3 
12 0.6 V82A 0.1 
20 0.2 L449P 0.1 
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Figure 3.3.15. Phenotypic susceptibility standard curves of gag and protease site-directed 
mutants for SQV 
Multiple mutations were created by successive rounds of site directed mutagenesis. The top graph 
represents standard curves of protease mutants. The bottom graph demonstrates reduced 
susceptibility to SQV when E428D is added to the triple protease mutant M46I+I54V+V82A. 
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Figure 3.3.16. Phenotypic susceptibility of protease and gag site-directed mutants to SQV 
Susceptibility of gag mutants created in p8.MJ4 was determined using a single-replication cycle 
drug susceptibility assay. Data displayed are fold-change in IC50 values in comparison to the 
reference strain (p8.MJ4). The patients on which these mutations were based on are indicated. 
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Table 3.3.7. Phenotypic assay cut-offs for patient-derived gag-protease and site-directed mutants 
 
    
 Patient-derived Gag-Protease Site-directed mutants 
 S RS R S RS R 
LPV < 4.4 4.4 – 10.0 >10 < 3.8 3.8 – 10.0 >10 
RTV < 3.2 3.2 – 10.0 >10 < 3.2 3.2 – 10.0 >10 
APV < 4.0 4.0 – 10.0 >10 < 2.0 2.0 – 10.0 >10 
ATV < 1.6 1.6 – 10.0 >10 < 3.1 3.1 – 10.0 >10 
DRV < 4.9 4.9 – 10.0 >10 < 1.2 1.2 – 10.0 >10 
SQV < 3.4 3.4 – 10.0 >10 < 1.3 1.3 – 10.0 >10 
Abbreviations: S, susceptible; RS, reduced susceptibility; R, resistant; LPV, lopinavir; RTV, 
ritonavir; APV, amprenavir ATV, atazanavir; DRV, darunavir; SQV, saquinavir 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
179 
 
3.3.7. References 
AOKI, M., VENZON, D. J., KOH, Y., AOKI-OGATA, H., MIYAKAWA, T., 
YOSHIMURA, K., MAEDA, K. & MITSUYA, H. 2009. Non-Cleavage Site Gag 
Mutations in Amprenavir-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) 
Predispose HIV-1 to Rapid Acquisition of Amprenavir Resistance but Delay 
Development of Resistance to Other Protease Inhibitors. Journal of Virology, 83, 
3059-3068. 
BABIKER, A., CASTRO NEE GREEN, H., COMPAGNUCCI, A., FISCUS, S., 
GIAQUINTO, C., GIBB, D. M., HARPER, L., HARRISON, L., HUGHES, M., 
MCKINNEY, R., MELVIN, A., MOFENSON, L., SAIDI, Y., SMITH, M. E., 
TUDOR-WILLIAMS, G. & WALKER, A. S. 2011. First-line antiretroviral therapy 
with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and 
switch at higher versus low viral load in HIV-infected children: an open-label, 
randomised phase 2/3 trial. Lancet Infect Dis, 11, 273-83. 
DAM, E., QUERCIA, R., GLASS, B., DESCAMPS, D., LAUNAY, O., DUVAL, X., 
KRÄUSSLICH, H.-G., HANCE, A. J., CLAVEL, F. & GROUP, A. S. 2009. Gag 
Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly 
Drug-Experienced Patients besides Compensating for Fitness Loss. PLoS Pathog, 5, 
e1000345. 
FUN, A., WENSING, A. M., VERHEYEN, J. & NIJHUIS, M. 2012. Human 
Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology, 9, 
63. 
GATANAGA, H., SUZUKI, Y., TSANG, H., YOSHIMURA, K., KAVLICK, M. F., 
NAGASHIMA, K., GORELICK, R. J., MARDY, S., TANG, C., SUMMERS, M. F. 
& MITSUYA, H. 2002. Amino Acid Substitutions in Gag Protein at Non-cleavage 
Sites Are Indispensable for the Development of a High Multitude of HIV-1 
Resistance against Protease Inhibitors. Journal of Biological Chemistry, 277, 5952-
5961. 
GUPTA, R. K., KOHLI, A., MCCORMICK, A. L., TOWERS, G. J., PILLAY, D. & 
PARRY, C. M. 2010. Full-length HIV-1 Gag determines protease inhibitor 
susceptibility within in-vitro assays. AIDS, 24, 1651-1655 
10.1097/QAD.0b013e3283398216. 
HEALTH, N. I. O. 2014. FDA-Approved HIV Medicines [Online]. Available: 
http://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-
medicines [Accessed 14 May 2014 2014]. 
LAMBERT-NICLOT, S., FLANDRE, P., MALET, I., CANESTRI, A., SOULIE, C., 
TUBIANA, R., BRUNET, C., WIRDEN, M., KATLAMA, C., CALVEZ, V. & 
MARCELIN, A. G. 2008. Impact of gag mutations on selection of darunavir 
resistance mutations in HIV-1 protease. J Antimicrob Chemother, 62, 905-8. 
LEVISON, J. H., ORRELL, C., GALLIEN, S., KURITZKES, D. R., FU, N., LOSINA, E., 
FREEDBERG, K. A. & WOOD, R. 2012. Virologic failure of protease inhibitor-
 180 
 
based second-line antiretroviral therapy without resistance in a large HIV treatment 
program in South Africa. PLoS One, 7, e32144. 
NDUNG'U, T., RENJIFO, B. & ESSEX, M. 2001. Construction and Analysis of an 
Infectious Human Immunodeficiency Virus Type 1 Subtype C Molecular Clone. 
Journal of Virology, 75, 4964-4972. 
NIJHUIS M, V. M. N., LASTERE S, SCHIPPER P, COAKLEY E 2007. A Novel Substrate-
Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Med, 4, e36. 
ORRELL, C., LEVISON, J., CIARANELLO, A., BEKKER, L. G., KURITZKES, D. R., 
FREEDBERG, K. A. & WOOD, R. 2013. Resistance in Pediatric Patients 
Experiencing Virologic Failure with First- and Second-Line Antiretroviral Therapy. 
The Pediatric Infectious Disease Journal. 
PARRY, C. M., KOHLI, A., BOINETT, C. J., TOWERS, G. J., MCCORMICK, A. L. & 
PILLAY, D. 2009. Gag determinants of fitness and drug susceptibility in protease 
inhibitor-resistant human immunodeficiency virus type 1. J Virol, 83, 9094-101. 
RABI, S. A., LAIRD, G. M., DURAND, C. M., LASKEY, S., SHAN, L., BAILEY, J. R., 
CHIOMA, S., MOORE, R. D. & SILICIANO, R. F. 2013. Multi-step inhibition 
explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest, 
123, 3848-60. 
RAVINDRA K. GUPTA, D. G., DEENAN PILLAY 2009. Management of paediatric HIV-1 
resistance. Curr Opin Infect Dis, 22, 256–263. 
REITZ, C., COOVADIA, A., KO, S., MEYERS, T., STREHLAU, R., SHERMAN, G., 
KUHN, L. & ABRAMS, E. J. 2010. Initial response to protease-inhibitor-based 
antiretroviral therapy among children less than 2 years of age in South Africa: effect 
of cotreatment for tuberculosis. J Infect Dis, 201, 1121-31. 
RHEE, S. Y., GONZALES, M. J., KANTOR, R., BETTS, B. J., RAVELA, J. & SHAFER, 
R. W. 2003. Human immunodeficiency virus reverse transcriptase and protease 
sequence database. Nucleic Acids Research, 31, 298-303. 
RHEE, S. Y., TAYLOR, J., FESSEL, W. J., KAUFMAN, D., TOWNER, W., TROIA, P., 
RUANE, P., HELLINGER, J., SHIRVANI, V., ZOLOPA, A. & SHAFER, R. W. 
2010. HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob 
Agents Chemother, 54, 4253-61. 
ROSENBLOOM, D. I., HILL, A. L., RABI, S. A., SILICIANO, R. F. & NOWAK, M. A. 
2012. Antiretroviral dynamics determines HIV evolution and predicts therapy 
outcome. Nat Med, 18, 1378-85. 
RSA, DEPARTMENT OF HEALTH. 2013. The South African Antiretroviral Treatment 
Guidelines. In: HEALTH, D. O. (ed.). South Africa. 
SHAFER, R. W. 2006. Rationale and uses of a public HIV drug-resistance database. J Infect 
Dis, 194 Suppl 1, S51-8. 
 181 
 
SILICIANO, J. D. & SILICIANO, R. F. 2013. Recent trends in HIV-1 drug resistance. Curr 
Opin Virol, 3, 487-94. 
SUTHERLAND, K. A., MBISA, J. L., CANE, P. A., PILLAY, D. & PARRY, C. M. 2013. 
Contribution of Gag and protease to variation in susceptibility to protease inhibitors 
between different strains of subtype B HIV-1. J Gen Virol. 
TAYLOR, B. S., HUNT, G., ABRAMS, E.J., COOVADIA, A., MEYERS, T., SHERMAN, 
G., STREHLAU, R., MORRIS, L., AND KUHN, L. 2011. Rapid Development of 
Antiretroviral Drug Resistance Mutations in HIV-Infected Children Less Than Two 
Years of Age Initiating Protease Inhibitor-Based Therapy in South Africa. AIDS 
Research and Human Retroviruses, 27, 945-956. 
VERHEYEN, J., LITAU, E., SING, T., DAUMER, M., BALDUIN, M., OETTE, M., 
FATKENHEUER, G., ROCKSTROH, J. K., SCHULDENZUCKER, U., 
HOFFMANN, D., PFISTER, H. & KAISER, R. 2006. Compensatory mutations at the 
HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced 
patients. Antivir Ther, 11, 879-87. 
ZANONI, B. C., SUNPATH, H. & FEENEY, M. E. 2012. Pediatric Response to Second-
Line Antiretroviral Therapy in South Africa. PLoS ONE, 7, e49591. 
ZYL, G. U., RABIE, H., NUTTALL, J. J. & COTTON, M. F. 2011. It is time to consider 
third-line options in antiretroviral-experienced paediatric patients? J Int AIDS Soc, 14, 
55. 
 
 
 
 
 
 
 
 
 
 
 182 
 
 
 
 
 
Chapter Four 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 183 
 
Paediatric HIV-1 infection remains of major concern with an estimated 700 children newly 
infected each day, globally (UNAIDS, 2013). In accordance with the WHO guidelines, there 
has been a shift to earlier initiation of paediatric treatment to maximise long-term growth, 
neurodevelopment and immunologic health (Penazzato et al., 2014). As more children are 
initiated on ART, the challenges and effects of long-term treatment need to be considered. 
Therapy of paediatric patients are complicated by high viral loads and the challenges 
experienced with accurate dosing (Gupta et al., 2009). Given the relatively few options 
available for subsequent treatment in paediatric patients failing PI-based therapy, there is an 
urgent need to make more drugs paediatric-friendly and easily accessible (Mofenson and 
Cotton, 2013). Studies evaluating more palatable sprinkles for LPV/r found that LPV/r 
exposure from sprinkles was comparable with syrup and that sprinkles were more acceptable 
than syrups for younger children (Musiime et al., 2014). Since HIV-1 paediatric patients are 
facing a chronic illness requiring life-long therapy (Pillay et al., 2014), it is important to 
improve and maintain adherence to these drugs to avoid development of drug resistance and 
unnecessary regimen switching. In addition, as children develop, ARV dosages need to be 
adjusted adequately to ensure optimal drug concentrations. Furthermore, with entry into 
adolescence, children are faced with many psychosocial factors that may affect their 
adherence to ART (Gupta et al., 2009). Some adults have been on ART for 15-20 years and 
are still doing well so this bodes well for long-term usage combined with good adherence. 
 
Diagnosis of HIV infection in infants is performed using HIV PCR at 6 weeks of age. A 
recent study in South Africa found that with a scale-up of PMTCT, there has been a 
remarkable decline in the vertical transmission rate from 23% in 2003 to 2.4% in 2012 
(Sherman et al., 2014). Following revision of the WHO guidelines for PMTCT in 2010, it 
was recommended to use one of two options, either Option A or Option B. Option A and 
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Option B start as early as 14 weeks gestation and  last up until one week after the cessation of 
breastfeeding (Thyssen et al., 2013). With Option A, HIV-1 positive pregnant women receive 
prophylaxis at antepartum (AZT), intrapartum (sdNVP+ first dose of AZT/3TC), postpartum 
(daily AZT/3TC for 7 days) and with Option B, HIV positive pregnant and breastfeeding 
women receive HAART (TDF+3TC (FTC) +EFV) intrapartum and through childbirth. In 
2013, a further recommendation was proposed by the WHO to offer all pregnant women 
lifelong ART (Option B+) irrespective of CD4 cell count. This is considered to be more 
beneficial since it could result in less HIV mother-to-child transmission (Thyssen et al., 
2013). The effectiveness of Option B+, if implemented successfully in South Africa gives 
promise for eliminating vertical transmissions as seen in developed countries. 
 
Current guidelines for the use of ARV agents in paediatric patients recommend that 
resistance testing should be considered in newly diagnosed infants <12 months of age prior to 
initiation of therapy (Rojas Sánchez and Holguín, 2014). It is necessary to perform 
surveillance of paediatric drug resistance in order to inform future paediatric treatment 
guidelines and improve health outcomes. A few studies which have been reported on HIV-1 
infected paediatric patients failing PI-based therapy in South Africa have shown a low 
frequency of protease resistance mutations (Wallis et al., 2011, van Zyl et al., 2009, Orrell et 
al., 2013, Levison et al., 2012, Pillay et al., 2014). Often, the absence of protease mutations 
in patients failing PI therapy is associated with poor adherence. However, some patients do 
present with mutations to other drug classes within their regimen suggesting drug exposure 
and hence the possibility of alternate routes of PI resistance. Regions outside of the protease 
gene have been shown to contribute to PI therapy failure and impact future PI options.  
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Interestingly, almost half of the children in our study did not have any major PI 
mutations despite failing a PI regimen. Those children who developed PI mutations had prior 
exposure to RTV. The gag region was investigated since it is the major substrate of the 
protease enzyme. Interestingly, changes were observed at both gag CS as well as non-CS. 
Although changes in gag CS have been well described in the literature, data on gag non-CS 
mutations are limited. It was found in three of the twenty patients that gag CS, in 
combination with protease mutations, contributed towards PI resistance. The selection of 
both protease and gag CS mutations in certain patients suggests co-evolution of the enzyme 
and substrate in the presence of PIs. A recent study described the co-evolution of the gag CS 
p1/p6Gag with NFV resistance mutations D30N/N88D (Kolli et al., 2014). This inter-
dependency between the substrate and enzyme demonstrated an improved fit of the substrate 
within the active site. The co-evolution of gag and protease may allow for sustained substrate 
recognition and cleavage in the presence of PI resistance mutations (Kolli et al., 2014). The 
compensatory role as well as contributing function of gag-CS mutations to PI resistance has 
also been described in other studies (Verheyen et al., 2006, Nijhuis M, 2007, Dam et al., 
2009).  
 
Although the PIs used for first-line treatment in paediatric patients varies, LPV/r remains the 
most widely used PI in resource-limited settings. Therefore it was important to determine the 
effects of other PIs in patients presenting with LPV/r selected mutations. Patient-derived 
viruses containing major LPV and RTV protease mutations showed cross-resistance mainly 
to ATV and APV. The least amount of resistance was seen with DRV implying that DRV 
may be a good option following failure on a PI-based therapy. Furthermore, one of these 
patients conferred cross-resistance to 4 PIs and contained a wild type protease with changes 
in both gag CS and non-CS. This suggests that gag may act as an alternate route to PI 
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resistance in this patient. It is important to note that the natural variation of the phenotypic 
assays is not well established and further tests are required to ascertain confidence intervals. 
Nevertheless, these findings highlight the shortfall of current genotypic resistance tests that 
exclude gag from predicted PI resistance scores. Under these circumstances, PI resistance 
would be under-estimated in some patients and could lead to the initiation on an ineffective 
PI.   
 
In addition to the development of signature LPV/r mutations upon sub-optimal 
adherence, the use of LPV/r has also been associated with long-term metabolic toxicity 
(Prendergast, 2013). A recent study compared the long-term metabolic effects of children 
maintained on a LPV/r-based regimen or switched to a NNRTI-based regimen (Arpadi et al., 
2012). It was found that although the children had undetectable viral loads and good immune 
reconstitution, those on LPV/r-based regimen had more lipid abnormalities compared to those 
on NNRTI-based regimen. The possibility of developing insulin resistance was also a cause 
for concern in this group of children due to their lifelong therapy. Although the benefits of 
ART outweigh these adverse effects, long-term toxicity needs to be addressed with the 
introduction of potent drugs, that have less severe adverse effects (Prendergast, 2013). 
However, the approval of new drugs is a lengthy process, especially in paediatric patients that 
require specialized formulations. In addition, delays are usually experienced in making new 
drugs available and accessible in resource-limited settings. The timeous switching of failing 
patients to drugs that are currently available should take preference over maintenance on an 
ineffective regimen. Although a PI-boosted first-line regimen is recommended for paediatric 
patients, studies have shown that the response to a NVP-based paediatric therapy is not 
affected when NNRTI mutations were present <25% and NVP therapy was preceded by a 
suppressive boosted PI-regimen (Moorthy et al., 2011, Hunt et al., 2011, Kuhn et al., 2012). 
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Therefore, the re-use of NVP in these patients will help preserve LPV/r for future treatment 
while minimising metabolic toxic effects (Kuhn et al., 2012). In this scenario, genotypic 
resistance testing of paediatric patients prior to treatment initiation would be essential as to 
identify NNRTI mutations. Furthermore, for the switch to remain effective, regular viral load 
testing would be necessary to monitor virologic outcomes (Kuhn et al., 2012). 
 
Apart from PI resistance, many paediatric patients also present with resistance mutations to 
RT inhibitors. NRTIs form the backbone of triple drug regimens in which PIs and NNRTIs 
are used. Treatment with NNRTIs (NVP) during PMTCT or in first-line therapy can lead to 
the rapid selection of Y181C mutation in paediatrics (Martinson et al., 2007). Treatment with 
a thymidine analogue usually leads to the development of thymidine analogue mutations 
(TAMs) which confer cross-resistance to other NRTI thymidine analogues compromising 
their efficacy in future regimens (Iyidogan and Anderson, 2014). Examples of TAM 
mutations include M41L, D67N, K70R, T210W, T215FY and K219QE (Rhee et al., 2003). 
D4T was commonly used in first-line therapy which selected for T69Ins and Q151M which 
causes cross-resistance among ABC, DDI, TDF, D4T and AZT. Most patients on 3TC 
develop the M184V mutation and although it renders the drug ineffective, it cripples the virus 
and subsequently decreases viral load. A study reported on the use of 3TC monotherapy in 
children as a holding strategy until effective ART becomes available (Lazarus et al., 2013). 
This study found that 3TC monotherapy helped maintain clinical and immunological status in 
majority of children. It was suggested that 3TC monotherapy could be used to preserve 
second and third-line regimens while addressing adherence issues (Lazarus et al., 2013). 
Treatment with NVP in an NNRTI-based regimen selects for many mutations such as L100I, 
K101P, K103NS, V106M, V108I, Y181C, Y188L and G190A, which also cause cross-
resistance to EFV. The use of EFV in children is only introduced in those ≥3 years of age due 
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to toxicity; therefore earlier exposure of NVP in first-line therapy may result in EFV being 
ineffective. New NNRTIs such as ETV and RVP show promise in patients with NVP/EFV 
resistance mutations however genotypic resistance testing would need to be done since 
K101P and Y181C also cause cross-resistance ETV and RVP (Rhee et al., 2003).  
 
Although ineffective by themselves in a majority of patients, gag CS and non-CS changes 
were found to contribute to cross-resistance to one or more PI. Larger studies are needed to 
confirm the role of gag in PI resistance. The development of algorithms that help to predict 
PI resistance in conjunction with gag mutations will be an important outcome of such studies. 
Going forward, it is also important to develop ARV drugs which are tolerable and accessible 
to paediatrics since maintenance on an ineffective regimen will only compromise their future 
treatment options. 
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Appendix I 
Preparation of Reagents 
 
0.7% Agarose Gel 
Dissolve 0.7 g agarose (Invitrogen, Spain) in 1X TBE (Tris/Acetic Acid/EDTA Buffer) 
buffer by heating in a microwave. Cool and add 2.5 μl Ethidium Bromide (10 mg/ml). Swirl 
to mix and pour into a gel casting tray. 
 
Agar Plates 
Dissolve 32.0 g LB Agar (Invitrogen, Carlsbad, CA) in 1L distilled water. Autoclave at 37˚C 
for 20 minutes. Allow to cool before adding 1ml Ampicillin (100mg/ml). Swirl to mix, pour 
onto plates and allow to set.  
 
LB Ampicillin 
Dissolve 25.0 g Luria Broth (Affymetrix, Ohio) in 1L distilled water. Autoclave at 37˚C for 
20 minutes. Allow to cool before adding 1ml Ampicillin (100mg/ml). Swirl to mix. 
 
Preparation of DMEM  
500 ml DMEM (Gibco, NY, USA) 
50 ml FBS (Gibco, NY, USA) 
12.5ml HEPES (Gibco, NY, USA) 
2.5 ml Gentamicin (Gibco, NY, USA) 
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To the DMEM, the FBS and antibiotics (HEPES and Gentamicin) are added. The DMEM 
was then swirled to ensure complete mixing of FBS and antibiotics in media. The DMEM 
was stored at 4 ˚C to preserve the antibiotics. 
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Appendix II 
Sequences of SDM primers 
 
SDM Primers (5’ → 3’) 
Protease Mutations 
M46I agtttgtcaggaaaatggaaaccaaaaataataggaggaattggag 
I47V tcaggaaaatggaaaccaaaaatggtaggaggaattggagg 
G48V ggaaaatggaaaccaaaaatgatagtaggaattggaggttttattaaag 
I54V tgataggaggaattggaggttttgttaaagtaagacagtatgatcaa 
V82A gtgttaataggacctactcctgccaacataattggaagaaatatgt 
I84V aataggacctactcctgtcaacgtaattggaagaaatatgttgac 
M46I+I54V ggaaaccaaaaataataggaggaattggaggttttatgaaagtaaga 
M46I+I47V gagtttgtcaggaaaatggaaaccaaaaatagtaggaggaattggagg 
  
Gag Mutations 
Q62K gaaggctgtaaacaaataatgaaacagcttcaaccagctctt 
Q62S acatcagaaggctgtaaacaaataatgtcacagcttcaaccagctct 
F79H ggaacagaggaacttagatcattacacaacacagtagcaactctctatt 
F79Y agacaggaacagaggaacttagatcattatataacacagtagcaactc 
P339Q ccattttaagagcattaggacaaggggctacattagaagaaat 
S373A ggcaatgagccaagcaaacgctacaagtatactgatgcag 
N374S aatgagccaagcaaacagttcaagtatactgatgcagag 
E428D aattagcctgcctatcagtacagtctttcatttggtgtc 
A431V agactgtactgagaggcaggttaattttttagggaaaatctg 
L449P gccagggaatttccctcagagcaggccag 
S451N tgttggctctggcctgttctgaaggaaattccc 
P453L ccttcagagcaggctagagccaacagccc 
L449P+P453L gccagggaatttccctcagagcaggcttcagagcaggc 
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